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Summary 
 
Lung cancer continues to have by far the highest cancer mortality in the UK.  Beyond 
stage of disease and the patient’s Performance Status there are no other robust clinical 
or  molecular  markers  of  prognosis  available  today.   One  major  reason for  the  high 
mortality rate of this disease is the significant proportion of patients who present with 
advanced incurable stage disease.  A second significant problem in the management of 
patients with lung cancer is chemotherapy resistance.  In patients with NSCLC (80% of 
cases) initial response rates to cisplatin-based chemotherapy are modest at best.  In the 
case of SCLC (20% of cases) the initial response rates to cisplatin-based chemotherapy 
are  high.    However  relapse,  often  with  chemotherapy  resistant  disease,  is  all  too 
common. 
 
There  is  a  significant  body  of  evidence  that  demonstrates  the  role  of  the  loss  of 
mismatch repair activity in the mechanism of chemotherapy resistance.  Studies to date 
have demonstrated that the loss of mismatch repair protein expression is a consequence 
of 2 main mechanisms: gene mutation and the epigenetic phenomenon of methylation of 
the  MLH1  (a  major  mismatch  repair  protein)  gene  promoter  region.    Studies  have 
shown  that  the  loss  of  MLH1  expression  is  associated  with  acquired  resistance  in 
ovarian and breast cancers.  Allelic imbalance (loss of heterozygosity) of chromosome 
3p is common in lung cancer samples and the MLH1 gene locus resides here.  This loss 
of heterozygosity (LOH) has been demonstrated to be a poor prognostic indicator in 
patients with primary adenocarcinoma of the lung.  In this translational research project 
the role of mismatch repair (MMR) and LOH in patients with lung cancer has been 
further investigated.   18 
In the first study using 2 separate cohorts of patients the potential role of mismatch 
repair proteins as a marker of prognosis in patients with NSCLC was investigated. 
 
The first cohort of patients had received either cisplatin based or non-cisplatin based 
chemotherapy for predominantly advanced (stage IIIb/IV) disease at Stobhill Hospital 
in Glasgow.  Pre-treatment paraffin-embedded bronchoscopic samples were collected 
retrospectively.  The aims of this study were to examine the level of expression of the 
MLH1, MSH2, p53 and Ki67 proteins in these small samples and assess whether these 
results correlated with any clinicopathological variables or with prognosis.  In addition 
differences in overall survival between the cisplatin and the non-cisplatin chemotherapy 
treated patients were assessed relative to the level of protein expression.  Despite the 
small size of the biopsies good inter-observer kappa scores were demonstrated between 
2 independent scorers for each protein immunohistochemistry score (IHC) (MLH1 - 
0.6062,  MSH2  –  0.4313,  p53  –  0.591).    Although  this  demonstrates  that  historic 
bronchoscopy samples can be used for such studies, the number of markers studied was 
limited due to small sample size and in this study there was insufficient tissue to assess 
expression levels of Ki67.  No significant correlations were demonstrated between IHC 
score and overall survival for any of the proteins studied, nor was there any difference 
between  the  different  chemotherapy  regimens.    Similarly  there  was  no  correlation 
between IHC score of the studied proteins and any clinicopathological variables. 
 
The  second  cohort  of  patients  all  had  resection  of  their  primary  NSCLC  tumour  at 
Aberdeen  Royal  Infirmary.    Of  these  50  patients,  10  had  received  pre-operative 
cisplatin-based chemotherapy.  Fresh frozen surgical samples collected at the time of 
surgery were analysed retrospectively. The aims of this study were to examine the level   19 
of expression of the MLH1, MSH2, p53 and Ki67 proteins in these samples and assess 
whether  these  results  correlated  with  any  clinicopathological  variables  or  prognosis.  
Whether any difference existed in these variables between the patients receiving pre-
operative chemotherapy and those that did not was also investigated.  This study failed 
to show any significant correlation between the level of protein expression and overall 
survival or any other clinicopathological variable.  Further there was no difference in 
the level of protein expression between those patients who had received pre-operative 
chemotherapy and those who had not.  However given that only a small number of 
patients  had  received  pre-operative  chemotherapy,  further  large  studies  would  be 
required to validate these results. 
 
In  the  second  study  we  investigated  the  status  of  CpG  island  methylation  (using 
methylation  specific  PCR)  and  its  role  as  a  marker  of  prognosis  in  patients  with 
NSCLC.  The samples were the same surgical samples as described above as well as 
normal adjacent lung tissue.  The markers studied were MLH1, p16, DAPK, TIMP 3, 
HIC  1,  MINT  25,  MINT  31  and  RASSF1A.    In  this  study  30  (60%)  of  samples 
exhibited methylation of at least one promoter site with 19 (38%) at 1 site, 5 (10%) at 2 
sites, 2 (4%) at 3 sites and 4 (8%) at 4 sites.  Twenty (40%) of the tumour samples 
exhibited no methylation at any promoter sites.  Methylation rates in normal adjacent 
lung  tissue  were  low.  There  was  no  significant  correlation  between  the  number  of 
methylated  sites  and  either  overall  survival  or  any  other  studied  clinicopathological 
variable.    The  investigation  of  methylation  at  individual  sites  demonstrated  an 
association  between  HIC  1  methylation  and  stage  of  disease  (p  =  0.020)  and 
methylation of MINT 31 was associated with a better overall survival (P = 0.030).  This 
remained  the  case  when  analysis  was  performed  excluding  those  patients  who  had   20 
received pre-operative chemotherapy.  This is the first report of MINT 31 methylation 
being studied in NSCLC and therefore further independent studies would be required to 
validate these results and confirm that the associations had not occurred by chance due 
to  multiple  testing.    No  significant  differences  in  any  of  the  studied  variables  were 
demonstrated when comparing patients who had received pre-operative chemotherapy 
with those who had not. 
 
A third study was performed to validate the findings of previous studies that loss of 
heterozygosity  (LOH)  of  chromosome  3p  is  a  common  occurrence  in  patients  with 
NSCLC (Mitsudomi et al., 1996).  This study also aimed to investigate any correlations 
between 3p LOH (D3S1289, D3S1300, D3S1304) or hMLH1 promoter methylation and 
level of MLH1 expression.  In addition this study attempted to correlate the presence of 
any molecular changes found in the serum DNA taken preoperatively from patients with 
those of their primary tumour samples.  For this study prospective collection of surgical 
tumour and normal adjacent lung tissue samples as well as a pre-operative whole blood 
sample was collected from patients undergoing resection of their primary disease at the 
Western Infirmary in Glasgow.  Numbers in this study were small thus making any 
attempt at statistical analysis inappropriate.  Observations demonstrated that 3p LOH 
was common in the primary tumour with 4/8 samples demonstrating LOH at D3S1289, 
5/6 at D3S1300 and 5/9 at D3S1304.  Corresponding changes were demonstrated in the 
preoperative serum samples in 2 of the 4 patients at D3S1289, 3/5 at D3S1300 and 2/5 
at D3S1304.  Loss of Heterozygosity at chromosome 3p did not appear to affect the 
level of MLH1 expression and hMLH1 methylation was not demonstrated in any of the 
studied tumour samples. 
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A final study, in collaboration with Dr J Plumb, was performed to investigate the role of 
the mismatch repair proteins in the chemotherapy sensitivity of a panel of small cell 
lung  cancer  cell  lines.    In  this  study  it  was  demonstrated  that  there  was  a  high 
correlation between cisplatin sensitivity and the mismatch repair proteins MLH1 (r
2 = 
0.83) and MSH2 (r
2 = 0.87) but not PMS2 (r
2 = 0.22).  Two of the cell lines originated 
from  metastatic  biopsies  from  the  same  patient,  one  pre-chemotherapy  treatment 
(LS274) and one post-chemotherapy (LS310).  It was shown that LS310 is 2.3 times 
more  resistant  to  cisplatin  and  shows  a  50%  reduction  in  MLH1  expression  when 
compared to LS274 (p < 0.001).  It was demonstrated that the hMLH1 promoter region 
of LS310 exhibited methylation whereas the LS274 promoter region did not.  Neither of 
these lines exhibited methylation of the p16, MINT 25 or DAPK loci suggesting that de 
novo methylation was not responsible for the methylation specific PCR results.  Further 
work demonstrated that treatment of the LS310 cell line with the demethylating agent 
decitabine increased its cisplatin sensitivity as well as increasing the level of MLH1 
expression of the cell line.  No such changes were demonstrated in the LS274 cell line 
after treatment with decitabine. 
 
In summary, this research project was limited by the availability of samples.  However 
it  has  demonstrated  that  collaborative  multidisciplinary  prospective  planned 
translational  research  can  be  done  and  emphasises  the  need  for  a  translational 
component to be an integral part of future lung cancer studies. 
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1.  Introduction 
 
1.1  Lung Cancer: the clinical problem 
Lung cancer remains the most common cancer in men in the United Kingdom. The 
incidence  of  lung  cancer  in  males  is  greater  than  the  next  two  most  common  male 
cancers (prostate and colon) taken together. The incidence of lung cancer in women 
continues to rise throughout the UK and in parts of the UK has overtaken the incidence 
of breast cancer (Gillis et al., 1992).  Figures from Cancer Research UK (CRUK) show 
that approximately ninety per cent of patients with lung cancer survive less than 12 
months and in 2003 33,436 deaths from lung cancer were reported in the UK (CRUK, 
2006).  
 
1.2  Pathogenesis and Classification 
For a cell to become malignant it has to acquire several key properties (Hanahan and 
Weinberg, 2000) and these are: 
1.  Loss of senescence and the acquisition of the ability to replicate indefinitely 
2.  Independence from normal growth signals 
3.  Lack of sensitivity to anti-growth signals 
4.  Evasion of apoptosis 
5.  Independent angiogenesis 
6.  Ability to invade and metastasise 
 
In the majority of cancers the initial insults are multi-factorial but in the case of lung 
cancer it has been unequivocally demonstrated that cigarette smoking is by far the most 
common causative factor in the development of lung cancer (Doll and Hill, 1950) and   23 
accounts for approximately 90% of cases (Szabo and Mulshine, 1993).  To date there 
are at least 60 known carcinogens within the 4000 known chemicals in cigarette smoke 
(Hecht, 2002), and these combine in susceptible individuals to cause the development of 
lung cancer.   
 
Approximately  95%  of  primary  lung  cancers  are  epithelial  in  origin  and  these  are 
categorised on the basis of histological appearance into Non-Small Cell Lung Cancer 
(NSCLC)  and  Small  Cell  Lung  Cancer  (SCLC).    NSCLC  diagnoses  are  then  sub 
classified into squamous cell carcinoma, adenocarcinoma, and large cell carcinoma as 
well as undifferentiated NSCLC.  There is no further histological sub-categorisation of 
SCLC (Wagenaar and Tazelaar, 1994).  Each of these cancers however appears, after 
initial insult, to have a different developmental pathway.  In squamous cell carcinoma 
there  is  a  relatively  well-understood  developmental  pathway  from  hyperplasia, 
dysplasia, carcinoma-in-situ through to invasive carcinoma (Hirsch et al., 2001).  The 
developmental pathway for primary lung adenocarcinoma is less well understood. There 
is evidence that areas of Atypical Adenomatous Hyperplasia (AAH) are the precursor 
for the development of adenocarcinoma (Westra, 2000), these areas being detectable in 
the lungs of up to 40% of patients with adenocarcinoma as compared to 11% of those 
with squamous cell carcinoma.  Further molecular evidence supports this hypothesis.  In 
up  to  39%  of  AAH  K-ras  mutations,  a  mutation  characteristic  in  primary  lung 
adenocarcinoma are found (Westra, 2000).   
 
Loss of Heterozygosity (LOH) of chromosome 3p is another example of a molecular 
alteration characteristic in primary lung adenocarcinoma and this has been demonstrated 
in up to 18% of AAH areas (Kitaguchi et al., 1998).  The difficulty in studying the   24 
natural progression of areas of AAH is that they are often overlooked on usual imaging 
modalities (CT scanning) as they simply appear as areas of ground glass opacification 
with no specific characteristic features (Westra, 2000). 
 
In  SCLC  there  has  been  no  characteristic  pre-neoplastic  sequence  or  morphological 
changes described however it has been demonstrated that there is a far higher rate of 
genetic  instability  (such  as  loss  of  heterozygosity  at  chromosome  3p)  in  SCLC 
compared  to  both  primary  squamous  cell  and  adenocarcinoma  of  the  lung  (Carney, 
1992). 
 
A recent review which examined the histology of all lung cancer diagnoses in Scotland 
in 1995, recorded through the national cancer registry, found that for those cases with 
positive  histology,  NSCLC  accounted  for  72.5%  with  38.7%  of  all  cases  being 
squamous cell, 19.5% adenocarcinoma and 14.3% classified as NSCLC only.  SCLC 
accounted for 23.7% of the cases with 3.7% of cases in the Scottish population being 
unclassifiable histologically (Gregor et al., 2001).   
 
Interestingly, this data differs somewhat from that reported in the United States where 
although  NSCLC  also  accounts  for  approximately  80%  of  all  Lung  Cancer, 
adenocarcinoma  is  the  predominant  NSCLC  accounting  for  45%  of  cases  with 
squamous only 20%.  These differences must be taken into account when comparing 
international studies of NSCLC, particularly those evaluating treatment modalities, as 
adenocarcinoma in particular has an increased propensity to metastasise and there is 
evidence  for  example  in  early  stage  disease  that  the  risk  of  relapse  is  higher  with 
adenocarcinoma and that this correlates with a poorer survival (Moldvay et al., 2000).   25 
1.3  Lung Cancer Staging 
The accurate staging of lung cancer gives both important prognostic information and 
enables the most appropriate treatment plan for an individual patient to be made.  The 
techniques  used  in  the  staging  of  lung  cancer  have  evolved rapidly in recent  years. 
Despite CT continuing to play a pivotal role in the process it has been shown to have 
both poor sensitivity and specificity when staging the mediastinum (sensitivity 57%, 
specificity  82%)  (Toloza  et  al.,  2003b).    Accurate  mediastinal  staging  is  essential 
prognostic information when planning the appropriate treatment for individual patients, 
as well as comparing staging data between studies. More recent non-invasive staging 
techniques have demonstrated better sensitivity and specificity relating to the staging of 
the  mediastinum  and  these  include  PET  (Positive  Emission  Tomography)  scanning 
(sensitivity 84%, specificity 89%) and CT-PET (where the CT and PET images are 
superimposed  on  one  another)  scanning  (sensitivity  78-93%,  specificity  82-95%) 
(Toloza et al., 2003b).  In addition to these techniques there is an increasing use of 
minimally  invasive  diagnostic/staging  techniques  employed  in  the  staging  of  the 
mediastinum.    Initially TBNA  (Trans-Bronchial  Needle  Aspiration)  of  lymph  nodes 
seen on previous CT scanning was introduced.  However this is a ‘blind’ technique and 
therefore has a sensitivity of only 76% although a better specificity of 96% (Toloza et 
al., 2003a).  
 
Newer  minimally  invasive  techniques  involve  the  use  of  TBNA  performed  under 
Ultrasound  guidance  EBUS-TBNA  (Endobronchial  Ultrasound-  TBNA)  and  EUS-
TBNA (Oesophageal Ultrasound-TBNA) with reported sensitivities of 85% and 81% 
respectively and specificities of 100% and 91% respectively (Toloza et al., 2003a) are 
being introduced into routine clinical practice.  However, the gold standard for staging   26 
of the mediastinum continues to be the invasive technique of mediastinoscopy with a 
sensitivity of 81% and specificity of 100% (Toloza et al., 2003a).  
 
Although  the  accurate  staging  of  the  mediastinum  is  essential  for  patients,  so  is 
evaluation of the possible presence of distant disease and non-invasive techniques used 
for this include U/S, CT, MRI, PET and CT-PET as well as invasive surgical techniques 
such as Video Assisted Thoracoscopy (VATS) and biopsy of possible metastatic lesions 
(e.g. adrenal, bone, skin and lung lesions). 
 
NSCLC  and  SCLC  are  staged  using  2  different  systems.    In  NSCLC,  the  revised 
International  Staging  System  (ISS)  is  used  and  details  the  anatomical  extent  of  the 
disease, examining tumour size and position (T) as well as regional nodal involvement 
(N) and the presence of any distant disease (M). Figures 1a and 1b (Mountain, 1986) 
summarise this staging system.  Approximately 65% of patients with NSCLC present 
with  locally  advanced,  stage  III  or  metastatic,  stage  IV  disease  and  as  such  have 
incurable disease (Spiro and Silvestri, 2005). 
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Table 1.1: The TNM (revised International Staging System) classification  
T  Extent of primary tumour 
Tis  Carcinoma in situ 
Tx  Positive cytology 
T1   ≤ 3cm 
T2 
> 3cm, main bronchus ≥ 2cm from carina, invades visceral pleura, partial 
atelectasis 
T3  Chest wall, diaphragm, pericardium, mediastinal pleura, main bronchus  
< 2cm from carina, total atelectasis 
T4  Mediastinum,  heart,  great  vessels,  carina,  oesophagus,  vertebra,  separate 
nodules in same lobe, malignant effusion 
 
N  Condition of regional nodes 
N0  No regional lymph nodes 
N1  Ipsilateral peribronchial, ipsilateral hilar 
N2  Ipsilateral mediastinal, subcarinal 
N3  Contralateral mediastinal or hilar, scalene or supraclavicular 
 
M  Presence or absence of distant metastases 
Mx  Distant metastasis cannot be assessed 
M0  No distant metastasis 
M1  Distant metastasis, includes separate nodules in different lobe 
 
Source:  UICC (International Union Against Cancer) TNM Classification of Malignant 
Tumours.  Fifth Edition.  Sobin LH, Wittekind Ch (editors).  New York: Wiley-Liss, 
1997 
 
Table 1.2: Stage I –IV Lung Cancer System 
Occult carcinoma  Tx  N0  M0 
Stage 0  Tis  N0  M0 
Stage IA  T1  N0  M0 
Stage IB  T2  N0  M0 
Stage IIA  T1  N1  M0 
Stage IIB  T2 
T3 
N1 
N0 
M0 
Stage IIIA  T1 
T2 
T3 
N2 
N2 
N1, N2 
M0 
Stage IIIB  Any T 
T4 
N3 
Any N 
M0 
Stage IV  Any T  Any N  M1 
 
Source:  UICC (International Union Against Cancer) TNM Classification of Malignant 
Tumours.  Fifth Edition.  Sobin LH, Wittekind Ch (editors).  New York: Wiley-Liss, 
1997 
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In SCLC staging assesses only the extent of the disease and categorises it as either 
limited, confined to a hemithorax and regional lymph nodes that can be encompassable 
into a reasonable radiation port, or extensive, which is defined as any disease that is not 
limited (Mountain, 1986).  Approximately two thirds of patients with SCLC will present 
with extensive disease. 
 
For  all  patients  presenting  with  lung  cancer  the  primary  question  that  needs  to  be 
answered is whether their disease is potentially curable?   This will depend on various 
prognostic markers but none more so than the stage of disease at presentation.  Other 
important  prognostic  factors  are  also  taken  into  account  when  planning  appropriate 
treatment options for the patient.  These various other prognostic markers, as well as 
disease stage, are now discussed. 
 
1.4  Non Small Cell Lung Cancer Management and Clinical Markers 
of Prognosis 
1.4.1  Stage I / II 
The  single  most  important  prognostic  marker  in  patients  with  NSCLC  is  stage  and 
whether the tumour is resectable or not, as to date surgery continues to be the treatment 
modality that offers the best potential of cure.  
 
However  accurate  staging  of  the  disease  does  not,  on  its  own,  predict  operability.   
Other factors need to be taken into account including assessment of the likelihood that 
the patient will survive the operation.  This will depend on the extent of the surgery 
required  to  achieve  the  best  chance  of  cure  and  prediction  of  post-operative  lung 
function.  In addition to these factors the patients other co-morbidities must be taken   29 
into account. It has been shown that Performance Status (PS) worse than 2 (figure 2) 
and  weight  loss  >10%  of  pre-morbid  body  weight  are  poor  prognostic  indices,  in 
patients being considered for resection (BTS Guidelines, 2001). 
 
Table 1.3: WHO/ECOG Performance Status 
0  Fully active.  Able to carry on all pre-disease performance without restriction 
 
1  Restricted in physically strenuous activities but ambulatory and able to carry 
out work of a light and sedentary nature 
2  Ambulatory and capable of all self-care but unable to carry out many work 
activities; up and about more than 50% waking hours 
3  Capable of only limited self-care; confined to bed or a chair for more than 
50% of waking hours 
4  Completely disabled; unable to carry out any self-care; totally confined to 
bed or chair 
 
 
In the United Kingdom resection rates of only 11% have been achieved compared to 
17% in the rest of Europe and 21% in North America (Fry et al., 1996).  Several factors 
may  account  for  this  including  the  significant  co-morbidities  in  patients  with  lung 
cancer in the United Kingdom as well as delays in patients seeking medical assessment.  
These  delays  are  thought  to  occur  predominantly  due  to  the  insidious  onset  of  the 
disease.  At present 65% of patients in the UK present with locally advanced stage III or 
metastatic stage IV disease (Spiro and Silvestri, 2005).   
 
Surgery offers the best chance of cure in an individual with NSCLC.  However, this 
only equates to five year survival figures of 67% for stage IA disease, 57% for stage IB, 
55% for stage IIA, 39% for stage IIB (T2N1) and 38% for stage IIB (T3N0) (Mountain, 
1997).    30 
A recent MRC study (MRC LU22) investigating induction chemotherapy followed by 
surgery in resectable patients has recently been reported.  This study of neo-adjuvant 
chemotherapy  recruited  519  patients  of  whom  258  received  pre-operative  platinum-
based chemotherapy and 261 who underwent surgery alone.  Although chemotherapy 
led to a good response rate and indeed downstaging in approximately 20% of patients 
there was no benefit in progression free survival (282 events, HR 0.98, 95% CI 0.81, 
1.23) or overall survival (232 deaths, HR 1.04, 95% CI 0.81, 1.35).  In addition there 
were more brain metastases reported in patients receiving pre-operative chemotherapy 
than those that underwent surgery alone (30 versus 11) (Nicolson et al., 2007).  
 
Several  host  factors  such  as  poor  lung  function  and  significant  comorbidity  may 
combine  to  make  a  patient  with  clinically  resectable  disease  medically  inoperable.  
These  patients  are  instead  considered  for  potentially  curative  treatment  with  radical 
radiotherapy.   
 
Although radical radiotherapy does offer the potential of cure there has been only one 
randomised  trial  comparing  radical  radiotherapy  with  surgery  (Wood  and  Morrison, 
1955).    This  study  consisted  of  58  patients  randomised  to  either  surgery  or  radical 
radiotherapy.  The results showed a 4-year survival of 23% in the surgical arm versus 
7% in the radiotherapy group.  These differences were not statistically significant due to 
the small numbers involved in the study.   
 
A  systematic  review  of radical  radiotherapy  studies  to  treat  early  stage  lung  cancer 
reports survival figures ranging from 50-93% at 1 year, 22-72% at 2 years, 17-55% at 3   31 
years and 0-42% at 5 years for patients with stage I/II disease (Rowell and Williams, 
2001).  
 
Therefore, current guidelines would suggest the use of radical radiotherapy for those 
patients  with  stage  I  or  II  disease  who  refuse  operation  or  are  deemed  medically 
inoperable (Management of Patients with Lung Cancer, SIGN 80 February 2005).   
 
A multi-centre randomised control study has demonstrated that the use of Continuous 
Hyperfractionated  Accelerated  RadioTherapy  (CHART)  in  patients  with  NSCLC  is 
associated with a 2 year survival of 30% compared to 21% in the control (conventional 
radical  radiotherapy)  arm,  translating  into  an  almost  50%  improvement  in  2  year-
survival  (Saunders  et  al.,  1997).  CHART  is  now  recommended  as  the  radical 
radiotherapy regime of choice.  
 
None  of  the  trials  referred  to  above  have  examined  the  potential  prognostic  role  of 
tumour specific molecular markers. 
 
1.4.2  Stage IIIa 
Two small trials showed encouraging results in terms of survival benefit with the use of 
neoadjuvant chemotherapy in patients with stage IIIa NSCLC (Rosell et al., 1994, Roth 
et al., 1994).  Patients with stage IIIa disease remain potentially operable although it is 
recommended that only patients with proven early N2 disease may be considered for 
resection  following  neoadjuvant  chemotherapy  if  there  has  been  CT  evidence  of 
response  (Management  of  patients  with  lung  cancer,  SIGN  80,  February  2005).  A 
recently published international multi-centre randomised control study has shown an   32 
absolute  survival  benefit  (4.1%)  with  cisplatin  based  chemotherapy  post  operatively 
with particular benefit for those patients with stage III disease (Arriagada et al., 2004). 
 
As regards clinical prognostic markers, other than stage, it remains the case that the 
most important factor in delivering high intensity treatment is performance status. 
 
1.4.3  Stage IIIb / IV 
The majority of studies have combined patients with both locally advanced stage IIIb  
(any  T4  or  any  N3)  and  metastatic  (any  M1)  disease  together  when  considering 
prognostic factors and management options.  A significant proportion of patients with 
stage IIIB disease will have a poor performance status or weight loss.  Recent advances 
in treatment options for this group suggest that the patients with a good performance 
status  should  be  identified  as  there  may  be  a  role  for  intensive  treatment  regimes 
incorporating more than 1 treatment modality (Jett et al., 2003).   
 
Several studies of treatment regimes which include induction chemotherapy followed 
by radical radiotherapy or surgery, and studies of concurrent chemoradiotherapy have 
demonstrated that good performance status patients benefit from combined modality 
therapy (Brundage et al., 2002).  
 
In  stage  IV  NSCLC,  traditional  management  has  been  Best  Supportive  Care  with 
radiotherapy for control of local symptoms. This approach does not impact on survival.  
In 1995, a meta-analysis
 was published evaluating the role of chemotherapy in NSCLC.  
This demonstrated that the use of cisplatin based chemotherapy results in a survival 
advantage  when  compared  with  the  traditional  treatment  modalities  alone,  even  in   33 
patients  with  stage  IV  NSCLC.   The  survival  benefit  achieved  with  the  addition  of 
cisplatin  based  chemotherapy  in  stage  IV  NSCLC  patients  is  an  absolute  survival 
benefit of 10% at 1 year, equating to a median survival improvement of six weeks, 
(Non-small cell lung cancer collaboration group, 1995).   
 
Studies have attempted to identify other host prognostic indicators in patients with stage 
IV disease and have shown that female patients under 70 years of age have a better 
prognosis  (Albain  et  al.,  1991,  Palomares  et  al.,  1996).    Clinical  measurements 
including haemoglobin, LDH and albumin have been shown to be useful predictors of 
survival (Albain et al., 1991, Sugiura et al., 1997).  However, throughout the published 
literature performance status, stage of disease and significant weight loss appear to be 
the  strongest  predictors  of  survival  in  patients  with  stage  IV  metastatic  NSCLC 
(Brundage et al., 2002). 
 
1.5  Small Cell Lung Cancer and Clinical Markers of Prognosis 
The  most  important  predictors  of  survival  in  Small  Cell  Lung  Cancer  (SCLC)  are 
disease extent and performance status (PS) of the patient at presentation (Rawson and 
Peto, 1990).  Patients presenting with limited stage disease have a median survival of 18 
months with chemotherapy as compared to those with extensive disease who have a 
median  survival  of  only  9  months.    Long-term  survival  for  patients  with  SCLC  is 
uncommon with a 2-year survival of 15-20% for those with limited disease and only 2% 
for those with extensive disease (Simon and Wagner, 2003). 
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Other host related prognostic factors have been evaluated in SCLC and various groups 
have attempted to combine these into scoring systems in order to try and further predict 
survival.  These include scoring systems from: 
 
1.  The Royal Marsden group using the variables of serum albumin, ALT levels and 
the ECOG/WHO performance status (Vincent et al., 1987). 
2.  The London Lung Cancer Group using the variables of serum albumin, sodium 
and alkaline phosphatase levels and the Karnofsky performance status (Souhami 
et al., 1988). 
3.  The  Manchester  score  using  the  variables  of  serum  LDH,  sodium,  alkaline 
phosphatase, bicarbonate in combination with the Karnofsky performance status 
and stage of disease (Cerny et al., 1987). 
 
Unlike NSCLC, surgery is not a standard treatment for patients with SCLC due to its 
high propensity to metastasise.  The treatment of choice for both limited and extensive 
disease is primarily chemotherapy, usually combined with radiotherapy, also having a 
role to play (Simon and Wagner, 2003). 
 
1.6  Chemotherapy in the Management of Lung Cancer 
Platinum  based  combination  chemotherapy  has a  central role in  the  management  of 
patients with SCLC and an ever-increasing role in the management of patients with 
NSCLC  from  early  stage  in  the  form  of  adjuvant  therapy  through  to  palliative 
chemotherapy in advanced disease.  
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‘Peyrones Chloride’ as it was originally known was first described in 1845 by Peyrone 
and  its  sterical  configuration  subsequently  described  in  1893  (Werner,  1893). 
Rosenberg observed the first reports of its anti-proliferative effects in 1965 (Rosenberg 
et  al.,  1965)  and  after  successfully  completing  animal  toxicology  studies  was  first 
administered to a human in 1971 (Hill JM, 1971). It was routinely available in general 
oncology practice by 1978.   
 
Over the subsequent 30 years of clinical use cisplatin has continued to be the mainstay 
of many chemotherapeutic regimens, although success rates vary between tumour types.  
For example there are high cure rates for people with testicular cancer using cisplatin 
(Jones and Vasey, 2003) whereas although response rates are evident against cancer of 
the ovary, bladder, cervix, head and neck as well as SCLC and NSCLC, relapse and 
subsequent  disease  chemo-resistance  are  common.    With  other  tumours  such  as 
colorectal and pancreatic cancer cisplatin based chemotherapy has been shown to have 
little impact on the disease (Haller, 2004, Lopes and Rocha Lima, 2005).   
 
These differences demonstrate that the presence or acquisition of resistance by cancer 
cells to cisplatin is a major clinical problem that undermines the potential curative use 
of this drug.  It is these issues, which are now addressed in relation to lung cancer. 
 
There are significant problems with platinum based chemotherapy in both SCLC and 
NSCLC. In the case of SCLC relapse is almost certain despite an initial response rate of 
up to 90% and complete response rates in limited disease of 50% (Simon and Wagner, 
2003). The relapse tumour is often resistant to further chemotherapy. In the case of 
NSCLC, despite the evidence that platinum based chemotherapy can lead to survival   36 
advantage, initial overall response rates are at best 50% when given in combination with 
another cytotoxic agent and only 21% when given as a single agent (Bunn, 1989).  
 
It  has  been  suggested  that  there  are  several  mechanisms  involved  with  platinum 
chemotherapy resistance within the lung cancer population. Clinically some tumours 
exhibit  intrinsic  resistance  whilst  others  appear  to  acquire  resistance  after  initially 
responding to chemotherapy.   
 
Several studies have been performed to try and identify the optimal treatment dose and 
scheduling  of  platinum  based  chemotherapy  in  order  to  try  and  maximise  clinical 
response and survival for patients with all forms of lung cancer.  The approaches most 
extensively studied have been conducted in patients with SCLC where the tumour is 
more chemosensitive than NSCLC and where chemotherapy plays an important role in 
the  management  of  limited  disease.      In  this  situation,  chemotherapy  is  given  with 
curative intent. 
 
In patients with SCLC these treatment approaches include the following: 
 
A:  Increasing the dose of chemotherapy.   
Two  reported  studies  have  looked  at  increasing  doses  of  cyclophosphamide  and 
doxorubicin within the standard 3 weekly regime of cyclophosphamide, doxorubicin 
and vincristine (CAV).  Despite demonstrating an increase in complete response rate 
from  22%  compared  to  12%  there  was  a  substantial  increase  in  toxicity  and  no 
demonstrable survival advantage (Figueredo et al., 1985, Johnson DH, 1987).   37 
A further study investigated increasing both the dose of cisplatin and etoposide for the 
first 2 cycles with standard doses for cycles 3 and 4.  Those exhibiting a complete 
response continued with cisplatin etoposide to a total of 8 cycles and the remainder 
were converted to CAV for cycles 5 – 8.  In this study there was no survival advantage 
for this dose intensified approach and there were problems with significant toxicities 
(Ihde et al., 1994). 
 
B:  Shortening  treatment  intervals  between  chemotherapy  cycles,  with  or 
without the addition of haematopoietic growth factors.   
Randomised  controlled  trials  (RCT)  have  been  reported  examining  the  impact  of 
shortening the interval (increased dose intensity) between chemotherapy treatments with 
or without haematopoietic support (G-CSF, granulocyte colony-stimulating factor) and 
the effect that this has on survival (Fukuoka et al., 1997, Steward et al., 1998, Thatcher 
et al., 2000, Woll et al., 1995).  These studies did report a median and 2-year survival 
benefit with the addition of the haematopoietic support. 
 
C:  Alternate regimes 
An  alternating  chemotherapy  regimen  has  been  evaluated  in  a  non-randomised  trial 
(Twelves  et  al.,  1991).    Twenty-three  patients  (16  limited  stage  disease)  received 
ifosfamide and vindesine or vincristine in weeks 0, 2 and 4 with cisplatin and etoposide 
weeks 6, 9, 12 and doxorubicin and methotrexate weeks 15 and 17.  This combination 
was well tolerated and demonstrated an overall response rate of 91% with a complete 
response rate of 43%.  The median survival was 54 weeks.  
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The above studies in patients with SCLC have concluded that in terms of platinum 
based  chemotherapy  the  optimum  dosing  schedule  is  3  weekly  and  that  the 
manipulation  of  chemotherapy  approaches  described  above  confer  no  significant 
survival advantage but add to patient toxicity. 
 
In patients with NSCLC, the majority of chemotherapy is given to patients with locally 
advanced and metastatic disease with palliative intent. NSCLC exhibits relatively low 
chemosensitivity  and  this  may  explain  the  relative  lack  of  studies  evaluating  dose 
intensification.  
 
A number of approaches have been performed in patients with NSCLC being treated 
with chemotherapy and these approaches are similar to those attempted/evaluated in 
patients with SCLC.  They include: 
 
A:  Giving the same total dose of cisplatin in different schedules. 
A study by Gandara (Gandara et al., 1993) gave the same total dose of cisplatin but in 
different schedules (50mg/m2 every 28 days for 8 cycles versus 100mg/m2 every 28 
days for 4 cycles).  This study demonstrated no difference in clinical outcome with 
median  survivals  of  6.9  and  5.3  months  respectively  (p=0.53).    However  increased 
ototoxicity, emesis, and myelosuppression were seen in the 100 mg/m
2 cisplatin arm 
although rates of renal toxicities and neuropathy were similar. 
 
Within this study there was a third arm where mitomycin was added to the high dose 
cisplatin  but  this  showed  no  benefit  in  terms  of  median  survival  compared  to  the 
cisplatin alone arms.   39 
At  present  there  is  a  prospective  randomised  trial  (BTOG-2)  recruiting  in  the  UK 
evaluating the optimum dose of cisplatin (50mg/m
2 versus 80mg/m
2, 3 weekly) when 
given in combination with gemcitabine as well as a third arm that investigates the effect 
of replacing the cisplatin with carboplatin (AUC 5).  The primary endpoint of this study 
is overall survival. 
 
B:  Shortening  treatment  intervals  between  chemotherapy  cycles,  with  or 
without the addition of haematopoietic growth factors. 
A study by Font (Font et al., 1999) evaluated the same doses of cisplatin and etoposide 
(35mg/m2 and 200mg/m2) given on days 1-3 every 4 weeks or every 3 weeks with 
recombinant  human  granulocyte  macrophage-colony  stimulating  factor  (GM-CSF) 
given on days 4-13.  This study showed no significant difference in terms of overall 
survival  with  the  medians  for  the  2  groups  being  7.2  and  9  months  respectively 
(p=0.07). 
 
What remains clear from all the previously published work is that, although cisplatin 
based chemotherapy can impact on patients with NSCLC as well as those with SCLC, a 
therapeutic plateau has been reached and in order to try and improve patient outcomes 
different  approaches  require  to  be  investigated.    One  approach  to  try  and  improve 
survival in patients with lung cancer requiring systemic therapy would be to try and 
overcome or modulate the clinical problem of cisplatin resistance. 
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1.6.1  Platinum resistance mechanisms 
The mechanism by which cisplatin enters the cell remains poorly understood but once 
inside the cell the active species is formed by aquation hydrolysis.  This product reacts 
with many potential intracellular targets including RNA, proteins and genomic DNA.  
Approximately 1% reacts with genomic DNA and it is this reaction with DNA that 
leads most commonly to GG intra-strand crosslinks, although a variety of intra- and 
interstrand crosslinks are formed.  There is good evidence to support that it is this DNA 
damage that is most relevant to the clinical cytotoxic effect of cisplatin (Siddik, 2003). 
A poor outcome has been shown where the level of DNA adducts is low and improved 
outcome where the level is high (Lawley and Phillips, 1996). 
 
However, there appears to be no single common pathway that adequately explains the 
phenomenon  of  cisplatin resistance.   Rather  there  is  a  complex  interaction  of  many 
mechanisms that combine to produce the phenomenon of clinical resistance seen in the 
clinic in different patients and in different tumour types. 
 
Examples of these mechanisms include: 
 
Blood flow and drug delivery to the tumour:   
A  study  by  Stewart  et  al  (Stewart  DJ,  1995)  demonstrated  differing  amounts  of 
detectable platinum in resected samples from patients with different tumour types, with 
most  drug  being  found  in  primary  brain  lymphoma  and  less  in  medulloblastomas, 
meningiomas, lung and head and neck cancers and the least in gliomas. 
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Drug uptake by the tumour:   
Studies have shown that many cisplatin resistant cell lines, including lung, have reduced 
cisplatin accumulation that may account for that resistance (Siddik, 2003).  There is 
evidence that this reduced drug uptake is not affected by drug dose but that it is affected 
by metabolic inhibitors without affecting drug efflux (Stewart DJ, 1995, Stewart DJ, 
1996). 
 
Drug efflux by the tumour:   
Resistance can be associated with either increased drug efflux from the cell (Chau and 
Stewart, 1999) or from the nucleus to the cytoplasm (Wang et al., 2004b).  Various 
cellular pumps have been implicated in these processes and include MRP2 (Peng et al., 
2004), MRP1 (Yeh et al., 2005), p-glycoprotein (Peng et al., 2004, Yeh et al., 2005) and 
MVP/LRP (Peng et al., 2004). 
 
Drug detoxification by the tumour:   
It  has  been  demonstrated  that  increased  levels  of  glutathione  can  achieve  this  by  a 
number of methods including the binding and inactivation of cisplatin, enhancing DNA 
repair or reducing cisplatin-induced oxidative stress (Siddik, 2003). 
 
DNA repair mechanisms:    
Cisplatin is highly effective against testicular cancers and it is known that these 
tumours have a very low capacity to repair platinum-induced DNA damage (Koberle et 
al.,  1997).    The  primary  mechanism  by  which  platinum-damage  is  repaired  is  the 
nucleotide  excision  repair  (NER)  system  (Reed,  1998).    The  ERCC1  gene  is  of 
significance in this regard as over-expression of the ERCC1 gene is associated with   42 
reduced platinum efficacy in ovarian cancer as well as NSCLC (Dabholkar et al., 1992, 
Rosell et al., 2003). 
 
Reduced apoptotic response:   
It is has been demonstrated that cells with p53 deletions or mutations are often resistant 
to cisplatin (Kandioler-Eckersberger et al., 1999).  Certain p53 missense mutations are 
associated with increased levels of p53 stability and therefore high protein levels (as 
measured using immunohistochemistry) of p53 and this is associated with poor outcome 
in platinum treated NSCLC (Kawasaki et al., 1998, Nakayama et al., 2003). 
 
DNA mismatch repair system (MMR):   
Cells  deficient  in  MMR  exhibit  increased  levels  of  cisplatin  resistance  and  reduced 
apoptosis  (Aebi  et  al.,  1996).   This  is  thought  to  be  an  important factor  in  clinical 
cisplatin resistance and will be reviewed in a later section. 
 
1.7   Novel Therapies in the Management of Lung Cancer NSCLC): 
Epidermal Growth Factor Receptor (EGFR) Inhibitors 
What is evident from the above examples of possible causes of cisplatin resistance is 
that, despite extensive research, the exact mechanisms involved and how these interact 
to  produce  the  clinical  problem  remains  unclear.   This  has  led  to  studies  exploring 
different approaches to the systemic based treatment of lung cancer.  One such approach 
has been the study and introduction to the clinical arena of the Epidermal Growth Factor 
Receptor (EGFR) Inhibitors and the development of one such EGFR inhibitor, Gefitinib 
(Iressa, Astra Zeneca®) is discussed.  Erlotinib (Tarceva, Roche®) is the only currently 
licensed EGFR inhibitor in use in the UK.     43 
The development of EGFR inhibitors, using ZD1839 (Gefitinib Iressa, Astra Zeneca ®), 
the first to be investigated in the clinical setting as an example, is reviewed to illustrate 
the potential use of such novel agents in the management of patients with lung cancer.   
 
The rationale for the clinical use of EGFR inhibitors is based on work reviewed by 
Salomon et al (Salomon et al., 1995) that showed the tyrosine kinase EGFR (TKEGFR) 
is over expressed in a wide variety of solid human cancers including NSCLC (as well as 
breast, head and neck, bladder and ovarian cancer). Moreover, in a number of studies, 
high levels of TKEGFR expression were associated with poor prognosis (Bartlett et al., 
1996, Bucci et al., 1997).  Tyrosine kinase appears to be an important component in 
signal  transduction  pathways,  with  mutated  or  over  expressed  tyrosine  kinases 
frequently associated with tumour growth.  EGFR has been shown not only to play a 
role in cell proliferation but also in processes important for tumour progression such as 
cell motility, cell adhesion, invasion, cell survival and angiogenesis.  Various research 
groups supported by pharmaceutical companies have developed molecules that inhibit 
EGFR by blocking tyrosine kinase activity. 
 
Gefitinib  (Iressa,  Astra  Zeneca®)  is  a  low  molecular  weight  synthetic  molecule 
(anilinoquinazoline).  Preclinical work has shown Gefitinib (Iressa, Astra Zeneca®) to 
potently inhibit EGFR tyrosine kinase activity in vitro and inhibit the growth of EGF 
stimulated KB oral carcinoma cells in culture (Barker et al., 2001). In addition Gefitinib 
(Iressa, Astra Zeneca®) has shown good oral bioavailability and antitumour activity in a 
range of human tumour xenografts in nude mice (A431 vulval, A549 NSCLC, DU145 
prostate, HX62 ovary as well as several colorectal tumours), treatment was tolerated for 
up to 3-4 months in these models and marked regression was seen in several tumour   44 
types (Fry, 1999).  These encouraging pre-clinical results took Gefitinib (Iressa, Astra 
Zeneca®) into clinical development.  
 
A  phase  I  study  enrolled  64  patients  at  8  dose  levels  of  Gefitinib  (Iressa,  Astra 
Zeneca®).    This  study  of  toxicity  included  a  pharmacokinetic  component  and 
demonstrated that Gefitinib (Iressa, Astra Zeneca®) was suitable for once daily oral 
administration.  It was found to be well tolerated with dose limiting toxicity observed at 
a  dose  well  above  that  at  which  antitumour  activity  had  been  demonstrated  in  the 
laboratory. Sixteen of the 64 patients enrolled into the phase I study had NSCLC. Four 
patients  demonstrated  a  partial  response  (as  defined  by  a  reduction  in  measurable 
disease of greater than or equal to 50%) and all the responses were seen in patients with 
NSCLC. Eight patients demonstrated stable disease of whom 3 had NSCLC (Ranson et 
al. 2240-50).  This study led directly on to the development of phase II and III studies in 
NSCLC.  Two large phase II (IDEAL 1 and 2) and phase III (INTACT 1 and 2) trials 
have now been completed and reported. 
 
IDEAL I and II (Fukuoka et al., 2003, Kris MG, 2002) were large, randomised, double 
blind, multicentre clinical trials.  Patients were randomised to receive either a 250mg or 
500mg  once  daily  dose  of  Gefitinib  (Iressa,  Astra  Zeneca®).    The  IDEAL  I  trial 
recruited 210 patients with stage IIIb (locally advanced) or stage IV disease who had 
recurrent or refractory disease following treatment with platinum based chemotherapy 
regimen.    The  IDEAL  II  trial  recruited  216  patients  with  performance  status  0-2.  
Eligible patients had stage IIIb or IV disease but in this trial had failed on two or more 
prior chemotherapy regimes containing platinum and docetaxel given separately or in   45 
combination.  All patients were of PS 0-2.  EGFR status was not an inclusion criterion 
for entry into the trials. 
 
Both trials assessed tumour response, symptom response and quality of life as well as 
toxicity/tolerability and survival.  The results are shown in table 1.4 and demonstrate no 
difference between the 2 studies. 
 
Table 1.4: Comparison of IDEAL I and II Results 
  IDEAL I  IDEAL II 
Endpoint  250mg/day 
(n=104) 
500mg/day 
(n=106) 
250mg/day 
(n=102) 
500mg/day 
(n=114) 
Tumour Response Rate  18.4%  19.0%  11.8%  8.8% 
Stable Disease  36.0%  32.4%  31%  27% 
Disease Control Rate  54.4%  51.4%  42.8%  35.8% 
Progression Free Survival  2.7 months  2.8 months  1.9 months  - 
Overall (median) Survival  7.6 months  8.0 months  7.0 months  6.0 months 
1 year Survival Rate  35.0%  29.0%  27.0%  24.0% 
 
Examination of the Quality of Life (QoL) data for evaluable patients in these trials 
demonstrated a trend toward better QoL in the 250mg dose arms of both studies. 
 
The toxicity data had previously shown Gefitinib to be well tolerated with the most 
common  side  effects  being  diarrhoea  and  skin  rashes.    The  phase  II  studies 
demonstrated that adverse events were less frequent and less severe at the 250mg/day 
dose of Gefitinib.   46 
These results encouraged the development of 2 large randomised, double blind, phase 
III trials (INTACT I and II) investigating the use of Gefitinib (Iressa, Astra Zeneca®) as 
first  line  treatment  for  patients  with  NSCLC  in  combination  with  chemotherapy 
(Giaccone  et  al.,  2004,  Herbst  et  al.,  2004).    There  were  3  arms  to  each  study: 
chemotherapy  plus  250mg/day  Iressa  versus  chemotherapy  plus  500mg/day  Iressa 
versus chemotherapy plus placebo.  In INTACT I the combination chemotherapy was 
cisplatin  plus  gemcitabine  and  in  INTACT  II  the  combination  chemotherapy  was 
carboplatin plus paclitaxel.  The primary endpoint in both studies was overall survival 
with secondary endpoints of progression free survival and time to worsening of disease 
related symptoms.  The results did not demonstrate any benefit in overall survival with 
Gefitinib (Iressa, Astra Zeneca®) when added to standard platinum based chemotherapy 
versus chemotherapy alone in advanced Non Small Cell Lung Cancer.  The authors of 
these papers have cited several reasons to explain these negative results including the 
fact that patients were neither recruited nor randomised on the basis of EGFR status. 
EGFR status was not known in either of the phase II trials above where encouraging 
response rates were demonstrated. The phase II study patients were different in that they 
had all been previously treated with chemotherapy and had either refractory or recurrent 
disease.  Thus despite initial promising results from this translational research approach, 
the  phase  III  studies  were  negative  and  Gefitinib  (Iressa,  Astra  Zeneca®)  has  been 
withdrawn from clinical use in the United Kingdom.  However, another EGFR Inhibitor 
Erlotinib (Tarceva, Roche®) has gone through the same development process and has 
been shown to prolong survival in phase III studies of the same patient population.  
Erlotinib (Tarceva, Roche®) is now used both alone and in combination with traditional 
chemotherapy (Shepherd et al., 2005). There is also currently a trial evaluating the role 
of Erlotinib as a first line monotherapy in locally advanced and metastatic NSCLC.   47 
In summary the EGFR tyrosine kinase inhibitors are a new class of drug that have been 
developed in a truly translational manner and one of these drugs, Erlotinib (Tarceva, 
Roche®) is now being used in clinical practice in the United Kingdom.   
 
There remain various unanswered questions in the chemotherapy of lung cancer and 
these  include,  how  to  predict  in  advance  which  patients  are  likely  to  benefit  from 
cytotoxic drugs, as well as how to determine the optimal combination of conventional 
cytotoxic agents. Future studies answering these questions could prove clinically useful 
in terms of improving patient survival. 
 
However it is likely that problems in relation to cytotoxic chemo-resistance will persist 
and as such new biological/molecular agents such as Erlotinib (Tarceva, Roche®) will 
need to be developed, based on a thorough understanding of the molecular biology of 
lung cancer. 
 
1.8  NSCLC and Tumour Related Molecular Prognostic Markers 
1.8.1  An overview of selected markers 
A review by Brundage et al in 2002 identified 887 published studies examining both 
patient  (host)  and  tumour  specific  prognostic  factors  that  were  predictive  of  patient 
survival (Brundage et al., 2002).  Within these studies 169 separate prognostic factors 
were identified as predictors of survival, although individual studies evaluated only a 
few of these.  The tumour markers studied have included: 
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Markers of proliferation such as Ki67:  
Conflicting evidence has been published as to any potential role Ki67 may have as a 
prognostic marker.  One small retrospective study of 61 surgically resected patients 
demonstrated a significant inverse association between patient survival and proliferation 
index  (Ki67  expression)  independent  of  any  clinicopathological  factor  (Pence  et  al., 
1993).  The results of this work were corroborated in a larger study of surgical patients 
where  a  high  Ki67  score  at  diagnosis  correlated  with  a  worse  disease  free  survival 
(p<0.03) (Scagliotti et al., 1993). However a further large retrospective study by Pujol et 
al failed to show any relationship between Ki67 expression and prognosis (Pujol et al., 
1996). 
 
p53 status:   
Alterations in the p53 – p21 pathway, controlling G1/S transition, are amongst the most 
commonly  observed  aberrations  in  NSCLC.    Studies  performed  have  used  both 
immunohistochemistry and direct sequencing to assess any effect these changes may 
have on prognosis and have given conflicting results.  Passlick et al (Passlick et al., 
1995)  reported  on  73  patients  using  immunohistochemistry  where  the  tumour  was 
deemed p53 positive if > 1% of the cells stained positive.  In this study 45% of cases 
were positive and this correlated with increased disease free survival in patients with 
early  stage  disease  (p=0.004)  and  in  men  (p=0.023).   However  no  significance  was 
identified in advanced stage of disease.  A further study by Lee reported on 156 patients 
(Lee et al., 1995).  In this study tumours were deemed to be p53 negative if <0.1% of 
them stained, low if 0.1 – 50% of cells stained and high if >50% stained p53 positive.  
The  authors  reported  that  patients  with  high  p53  positive  tumours  survived  longer 
(p=0.002) with this significance relating predominantly to non-squamous cell cancers   49 
(p=0.008)  but  not  squamous  cell  cancers  (p=0.17).    However,  the  studies  of  the 
prognostic significance of p53 have produced conflicting results.  A study by Quinal et 
al demonstrated that p53 positivity was associated with a worse prognosis (p<0.001) 
(Quinlan et al., 1992).  In this study of 114 patients with stage I/II disease tumours were 
scored positive on the basis of even a few cells staining positive for p53.  Likewise in a 
study of 85 patients with NSCLC, 64% of tumours stained positive for p53 (on this 
occasion positivity being those tumours where > 10% of cells stained) and these patients 
had a worse prognosis (borderline statistical significance) (Carbone et al., 1994).  The 
fact that these studies all use differing scoring systems to define p53 positivity may 
have produced conflicting results. 
 
Another method of evaluating the status of p53 is to assess gene mutation.  In the study 
by  Carbone  et  al.,  the  researchers  examined  the  mutational  status  as  well  as 
immunohistochemistry.  Interestingly the mutational status results differed within the 
study  population  compared  to  those  results  obtained  using  immunohistochemistry.  
Considering mutational status, 53% of the tumours exhibited DNA abnormalities but 
there  was  no  survival  difference  demonstrated  between  this  and  the  group  with  no 
demonstrable  mutation  (Carbone  et  al.,  1994).    However,  two  further  studies 
demonstrated p53 mutations were related with a poor overall survival (Horio et al., 
1993, Mitsudomi et al., 1993).  Horio et al. examined the tumours from 71 patients who 
had undergone potentially curative resection and identified a p53 mutation in 49% of 
these.  Furthermore  they  demonstrated  a  correlation  between  p53  mutation  and  poor 
overall survival (p=0.014). This correlation was also seen in those patients with stage 
I/II  disease  (p=0.016)  and  on  multivariate  analysis  p53  mutation  was  seen  to  be  an 
independent  adverse  prognostic  marker  (p=0.013).    Mitsudomi  et  al.  studied  120   50 
patients and demonstrated p53 mutations in 43% of their tumours.  Mutation did not 
correlate  with  age,  sex  or  stage  of  disease  but  did  appear  to  be  more  frequently 
associated with squamous cell differentiation, and on univariate analysis it was seen to 
be a poor prognostic marker (p=0.01).  In this study p53 mutation was a particularly 
poor marker for survival in stage III/IV disease (p=0.0091) but not stage I/II disease 
(p=0.2837).  On multivariate analysis p53 mutation was an independent poor marker of 
prognosis (p=0.018). 
 
K-ras mutation:   
The Ras proteins are pivotal regulators of cellular proliferation, differentiation, motility 
and apoptosis.  As in the case of p53 there are conflicting reports in the literature as to 
whether  mutations  of  K-ras  represent  a  negative  prognostic  marker  or  not.    Most 
recently  Camps  et  al.,  reported  on  the  presence  or  not  of  K-ras  mutations  in  the 
circulating DNA from patients with stage III/IV NSCLC (Camps et al., 2005).  Thirty 
percent  of  these  patients  exhibited  mutations  of  K-ras  but  there  was  no  difference 
statistically  in respect  of  patient  characteristics, response  rates  (p=0.37),  progression 
free  survival (p=0.23)  or  overall  survival  (p=0.28).   Schiller  et  al.,  reported  on  184 
patients that had undergone surgical resection of their primary tumour.  Of these, 24% 
had K-ras mutation and although the median survival in this group was shorter at 30 
versus  42  months  for  those  with  no  K-ras  mutation  this  did  not  reach  statistical 
significance (Schiller et al., 2001).  In this study there was no association between K-ras 
mutation and baseline patient characteristics.  However, Rosell et al., in a study of 112 
surgically resected patients reported the potential prognostic significance of the K-ras 
mutation (Rosell et al., 1995).  In this study the mutation rate was 27%.  When analysed 
by stage of disease those with stage I disease and no K-ras mutation had a median   51 
survival  of  46  months  compared  to  21  months  for  those  with  mutations  present.  
Interestingly  those  patients  with  stage  IIIA  disease  and  no  K-ras  mutation  had  a 
statistically similar survival to those with stage I disease at 16 months, whereas those 
with mutation had a median survival of only 7 months. 
 
Neuron Specific Enolase (NSE) expression:   
A study by Carles et al., looked at 97 NSCLC tumours immunohistochemically, 46% of 
them demonstrated NSE expression (Carles et al., 1993).  The NSE negative patients 
had  a  poorer  prognosis  than  those  who  expressed  NSE  and  this  correlated  well  on 
multivariate  analysis  along  with  Performance  Status  as  an  independent  marker  of 
prognosis.   Another  study  by  Diez  et  al.,  examined  NSE  levels in the  serum  of  84 
patients  with  NSCLC,  40  healthy  controls  and  20  patients  with  benign  pulmonary 
disease (Diez et al., 1993).  The level of NSE did not correlate with either the TNM 
stage  or  histological  subtype  of  the  tumour.    However  a  level  of  >15ng/ml  had  a 
significantly worse prognosis than those with a level < 15ng/ml a 24 months (p<0.05).  
 
ERCC1:   
The  excision  repair  cross  complementing  (ERCC)  genes  are  an  integral  part  of  the 
nucleotide excision repair pathway that repairs DNA damage. ERCC1, in particular, has 
a critical role in this pathway (Soria, 2007). In some recent studies it has been shown to 
be  an  important  marker  of  prognosis  in  patients  with  NSCLC  in  certain  clinical 
situations although the results are conflicting.   
 
In the surgical setting Simon et al., reported that tumour ERCC1 expression levels of 
more than 50 (Taqman quantitation) correlated statistically significantly with survival   52 
(Simon et al., 2005).   Those patients with ERCC1 <50 had a median survival of 35.5 
months compared to 94.6 months in those with ERCC1 >50 (p=0.01).   
 
However, in a study of patients who received adjuvant chemotherapy it was reported 
that loss of expression of ERCC1 correlates with both a better response to cisplatin 
based chemotherapy as well as improved median survival (Olaussen et al., 2006).  This 
study retrospectively evaluated 761 patients enrolled in the International Adjuvant Lung 
Cancer Trial (Arriagada et al., 2004) and using IHC; showed that 335 (44%) of samples 
were ERCC1 negative and 426 (56%) were ERCC1 positive. A benefit from cisplatin-
based chemotherapy was associated with ERCC1 negative status (test for interaction, 
p=0.009), with the study reporting that patients with ERCC1 negative tumours who 
received adjuvant chemotherapy had a significantly better survival than those in the 
observation arm (p=0.002) but no such survival advantage was found in those patients 
with ERCC1 positive tumours who received adjuvant chemotherapy compared to those 
in the observation arm (p=0.40) (Olaussen et al., 2006).  However, in keeping with the 
findings  of  Simon  et  al  it  was  shown  that  in  those  patients  who  did  not  receive 
chemotherapy that survival was better in those with ERCC1 positive tumours than those 
with ERCC1 negative tumours (p=0.009) (Simon et al., 2005).  
  
Despite  the  wealth  of  prognostic  studies  described  above,  there  remains  limited 
information regarding specific factors that would allow stratification of patients into 
different prognostic groups prior to receiving systemic chemotherapy.  These studies 
would be of significant benefit to the multi-disciplinary team when planning treatment 
options and could impact significantly on survival.  Specifically the current widespread   53 
use  of  chemotherapy,  including  adjuvant  chemotherapy,  could  be  rationalised  and 
targeted on an individual patient basis. 
 
1.8.2  DNA Mismatch Repair (MMR) and Lung Cancer 
Within the human genome there are hundreds of thousands of regions where a single 
nucleotide or short DNA sequences are repeated and these are termed microsatellites.  
They occur in both coding and non-coding regions of the gene and are of a constant 
length.    During  DNA  replication  there  is  often  misalignment  of  bases  within  these 
microsatellite regions.  This is due to slippage during replication of repetitive sequences 
or  during  strand  recombination  resulting  in  base-to-base  mismatch,  as  well  as 
insertion/deletion loops (ranging from one to ten or more bases) if they escape DNA 
polymerase  proofreading.  Within  the  normal  phenotype  this  does  not  represent  a 
significant problem as there is a DNA repair mechanism known as  DNA mismatch 
repair  (MMR)  first  described  in  1975  (Wildenberg  and  Meselson,  1975).  A  highly 
conserved post-replicative process MMR plays an integral role in maintaining genomic 
stability  following  DNA  damage  or  during  DNA  replication  by  recognising  newly 
synthesised daughter strands containing nucleotide sequencing errors and repairing it.  
DNA  MMR  is  present  not  only  in  mammalian DNA  but  also  in  that  of  yeasts  and 
bacteria (Prolla et al., 1994).  
 
In humans the mismatch repair system is known to be made up of at least 6 different 
proteins  (hMLH1,  hMSH2,  hPMS1,  hPMS2,  hMSH6  and  hMLH3)  (Bignami  et  al., 
2003).  The  initial  step  is  for  the  DNA  mismatch  to  be  recognised  by  heterodimers 
containing hMSH2: hMSH6 complexes and the subsequent repair step occurs when an 
hMLH1: hPMS2 complex interacts with this by some, as yet undefined, mechanism   54 
(Fishel, 1999), although it is known that DNA heliclases, nucleases and polymerases are 
involved in the process (Genschel et al., 2002). 
 
Some tumours however display alterations in the length of microsatellites and this leads 
to genetic instability more commonly termed Microsatellite Instability (MSI) or allelic 
imbalance/shift (Hoeijmakers, 2001, Katz and Kaestner, 2002, Loeb, 1994).  It has been 
demonstrated  that  Microsatellite  Instability  is  due  to  defects  in  the  mismatch  repair 
pathway (Karran, 1996) where replication errors within the microsatellite sequences are 
not repaired properly leading to the MSI.  Therefore the presence of MSI in tumours 
reflects an abnormality within the mismatch repair system. 
 
The significance of a defect in the mismatch repair mechanism is that it results in a 
spectacular increase in the DNA mutation rate - up to 100 times that observed in normal 
cells  (Herman  et  al.,  1998),  and  this  propagates  carcinogenesis.    There  are  well 
described  human  cancers,  in  particular  Hereditary  Non-Polyposis  Colonic  Cancer 
(HNPCC) where the hallmark of the tumour is microsatellite instability (Hemminki et 
al.,  1994).  HNPCC  (Lynch  Syndrome)  is  the  most  common  hereditary  (autosomal 
dominant) form of colorectal cancer and affects many generations at an early age (mean 
age  45  years).    It  has  preponderance  for  right-sided  colonic  tumours.  In  addition, 
patients with HNPCC display an increased incidence of certain extra-colonic cancers.  
These include endometrial, ovarian, stomach, small bowel, pancreas, hepatobiliary tract, 
brain  and  upper  uroepithelial  tract  cancers  (Lynch  et  al.,  2003).    The  germ-line 
mutations  of  DNA  mismatch  repair  proteins  responsible  for  HNPCC  have  been 
identified as predominantly hMLH1 (33%) and hMSH2 (31%) (Herman et al., 1998).  
The relevance of MMR deficiency in sporadic colorectal cancers is also of interest as   55 
Microsatellite  Instability  (MSI+)  has  been  observed  in  approximately  13%  of  these 
cancers. 
 
Because of the recognition that MSI plays an important role in the pathogenesis of 
colorectal cancers, criteria for the definition of MSI were agreed (Boland et al., 1998, 
Dietmaier et al., 1997).  The presence of high-frequency MSI has been defined as the 
presence of instability in 2 of a panel of 5 markers and low frequency of MSI if only 1 
marker  demonstrates instability.   The  markers  used  for  this in  colorectal  cancer  are 
D2S123, APC, p53 and mfd15CA.  This panel has been applied to other tumours when 
studying the presence of MSI.  With regard to HNPCC the panel has been recently 
updated, to include on occasion more than 5 markers to improve sensitivity (Umar et al., 
2004). 
 
 It has been shown that within this MSI+ population of colorectal cancers there is a 
significant  subset  where  no  mutation  of  MMR  genes  could  be  identified  within the 
cancer,  despite  a  decrease  in  expression  of  the  protein  (expression  assessed  by 
immunohistochemistry) (Aaltonen et al., 1993).  In a study by Herman et al samples of 
sporadic  colorectal  cancers  demonstrated  hypermethylation  of  hMLH1  in  84%  of 
cancers (Herman et al., 1998). This finding suggests that the transcriptional silencing of 
MMR genes might come about by more than one route. 
 
With respect to lung cancer a review article by Lawes et al., reported that MSI is not 
seen in SCLC but with rates varying between 0 – 68% in NSCLC (Lawes et al., 2003) 
and these differences are presumably due to the differing number of and loci of the 
microsatellite  markers  tested.    A  study  by  Adachi  et  al  demonstrated  a  statistically   56 
significant increase in MSI in stage III and IV tumours compared to early stage disease 
(p=0.0021) (Adachi et al., 1995).  Several studies have shown a worse prognosis for 
those with MSI+ tumours (Rosell et al., 1997, Zhou et al., 2000). 
 
The MMR gene hMLH1 resides on the short arm of chromosome 3p and it has been 
demonstrated in NSCLC that loss of heterozygosity at 3p is an independent adverse 
prognostic  marker  for  survival  in  adenocarcinoma  (p=0.052)  but  not  squamous  cell 
carcinoma (Mitsudomi et al., 1996).  There was however no association between loss of 
3p heterozygosity with gender, disease stage or grade of differentiation. 
 
Work  done  by  Xinarianos  et  al.  (Xinarianos  et  al.,  2000),  has  demonstrated  that 
expression of the Mismatch Repair (MMR) proteins MLH1 and MSH2 was reduced in 
primary lung cancer and that MLH1 was more frequently reduced in primary squamous 
cancer (p < 0.006) and MSH2 was more frequently reduced in primary adenocarcinoma 
of the lung (p < 0.003).  Previous work has already identified the potential prognostic 
role for the MLH1 protein in patients with breast cancer, where it was found that a 
correlation existed between reduced MLH1 expression after neo-adjuvant chemotherapy 
(compared to pre-chemotherapy levels of expression) and poorer survival (Mackay et 
al., 2000).  No such studies have been performed in patients with lung cancer. 
 
1.8.2.1 Loss of Mismatch Repair function and Platinum Resistance 
There  is  a  substantial  body  of  preclinical  and  clinical  evidence,  demonstrating  that 
alterations in mismatch repair proteins play a role in clinical cytotoxic chemotherapy 
resistance mechanisms.  How lack of MMR activity directly affects response to DNA 
damage as caused by cytotoxics drugs remains ill understood.    57 
Preclinical studies examining cell lines (HEC59) deficient in MMR proteins (MLH1 
and MSH2) and resistant to 6-thioguanine and N-methyl-N’-nitro-N-nitrosoguanidine, 
have demonstrated these lines have low level resistance to cisplatin, carboplatin and 
etoposide but are sensitive to mephalan, 5-fluorouracil, doxorubicin, perfosfamide or 
paclitaxel (Aebi et al., 1996).  
 
Further work on the HCT116 cell line, where chromosome 3, incorporating the hMLH1 
gene locus has been transfected into the cell line, demonstrates a resensitisation to the 
cytotoxic agents (Vikhanskaya et al., 1999) thus supporting that it is the loss of MMR 
activity that leads to this platinum resistance. 
 
In the ovarian cancer cell line A2780 it has been shown that in 9 of 10 cisplatin resistant 
derivatives that, although there is complete loss of MLH1 and PMS2 expression, there 
is no apparent loss of the hMLH1 gene (Brown et al., 1997).  A study by Durant et al 
reported  that  A2780/cp70  (an  in-vitro-derived  cisplatin  resistant  derivative  cell  line) 
demonstrated re-expression of the MLH1 protein when chromosome 3, containing a 
wild-type hMLH1 gene was re-inserted into the A2780/cp70 line and this correlated 
with a partial restoration of cisplatin sensitivity (Durant et al., 1999).  Further work has 
reported that ovarian samples taken at laparotomy from chemotherapy treated patients 
show  a  significant  increase  in  loss  of  MLH1  expression  (4/11,  36%)  compared  to 
samples  from  patients  who  had  not  had  chemotherapy  before  surgery  (4/39,  10%) 
(Brown et al., 1997).  This result was of borderline statistical significance (p=0.059, 
Fisher Exact test).  No statistically significant difference was demonstrated for MSH2, 
MSH6 or PMS2. 
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Mackay et al. reported a study in which samples were taken from 36 patients with breast 
cancer  undergoing  neoadjuvant  chemotherapy.    Paired  samples  before  and  after 
neoadjuvant chemotherapy were obtained from 28 patients and there was a significant 
reduction in the percentage of cells expressing MLH1 in the samples obtained after 
chemotherapy (p=0.001, n=28). Moreover a reduction in the intensity of staining for 
MLH1 within cells after chemotherapy was identified (p=0.068, n=28).  Cox regression 
analysis showed there was a highly significant correlation between low levels of MLH1 
expression  in  the  post-chemotherapy  samples  and  worse  disease  free  survival 
(p=0.0022,  n=28).    In  addition  there  was  a  difference  between  the  pre-  and  post-
chemotherapy  scores  of  MLH1  expression  that  correlated  with  a  poor  disease  free 
survival (p=0.0025, n=27) (Mackay et al., 2000).  
 
Further work on the A2780 ovarian cell line reported that the cisplatin sensitive parental 
cell line had methylation of only one hMLH1 allele whereas all 9 resistant cell lines 
derived from parental A2780 had methylation of both hMLH1 promoter regions and this 
resulted in a complete loss of MLH1 expression (Strathdee et al., 1999).   
 
These  studies  taken  together  further  support  the  hypothesis  that  mismatch  repair 
proteins play an important role in both intrinsic and acquired platinum resistance. 
 
1.8.3  DNA Methylation 
DNA methylation is a post-replicative enzyme-mediated chemical modification and is 
the only known naturally occurring DNA modification process.  Unlike MMR, there is 
little or no methylation in simple organisms such as yeasts and bacteria and this process 
is limited to mammals and humans (Bird, 1986).  DNA methylation is a very specific   59 
process  that  occurs  only  on  cytosines  that  are  followed  by  a  guanine  (CpG 
dinucleotides) in the DNA sequence (Herman and Baylin, 2003).  The function of this 
modification with particular reference to lung cancer as well as chemotherapy resistance 
is now described. 
 
1.8.3.1 DNA Methylation within the Normal Cell 
The CpG dinucleotide frequency within the human genome is lower than that which 
would be expected from mathematical models.  The majority of these (70-80%) are 
methylated (Bird, 1996).  The majority of this methylated DNA is found in the non-
coding regions of DNA (figure 1.1) and is associated with delayed transcription of these 
regions, which facilitates transcriptional silencing of these regions.  This, in itself, may 
play a protective role for the normal cell as it may prevent transcription of inserted viral 
sequences and transposons (DNA sequences that have moved from their usual location 
into  a  new  region  of  the  genome).    In  the  normal  cell,  specific  roles  of  DNA 
methylation  include  X-chromosome  inactivation,  control  of  imprinted  genes, 
suppression of testis specific genes as well as cell type specific repression (Jaenisch and 
Bird, 2003). 
 
However there is an exception to this and relates to the so-called CpG Island (Bird, 
1996).  CpG  islands  are  areas  of  300  –  3000  base  pairs,  which  in  total  make  up 
approximately 1% of the human genome.  Here the CpG frequency is of the order that 
would  be  expected  from  mathematical  modelling  and is  much  higher  than  the  CpG 
frequency throughout the remainder of the genome.  However, in comparison to the 
highly methylated CpG dinucleotide regions found in these non-coding regions, these 
CpG  islands  are  predominantly  methylation  free  thus  allowing  transcription  to  take   60 
place (Bird, 1996, Jones and Laird, 1999).  Further it is known that more than 60% of 
human  gene  promoters  are  located  within these  CpG  islands  (Bird,  1986,  Gardiner-
Garden and Frommer, 1987, Jones and Laird, 1999, Larsen et al., 1992, Strathdee et al., 
2001b). 
 
1.8.3.2 DNA Methylation within the Cancer Cell 
DNA  methylation  is  an  epigenetic  phenomenon  leading  to  an  alteration  in  gene 
expression without altering the nucleotide sequence.  The cancer cell differs from the 
normal cell as regards methylation profile.  There is a global hypomethylation of the 
genome but despite there being a loss of methylation of the CpG dinucleotides found 
within  the  non-coding  regions  of  the  DNA  in  cancer  cells,  there  is  a  gain  in  the 
methylation of the CpG dinucleotides found within the so-called CpG islands in cancer 
cells (Figure 1.1) (Esteller, 2000, Herman and Baylin, 2003, Toyota et al., 1999a).  Both 
of these mechanisms are thought to play a role in carcinogenesis. 
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Figure 1.1:  DNA methylation patterns in the normal and cancer cell 
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When a cancer cell loses methylation within the non-coding regions of DNA there is the 
possibility  of  loss  of  transcriptional  repression  of  normally  silent  genome  regions, 
which could cause potentially harmful expression of viral genes or normally silenced 
genes.  Alternatively loss of methylation may result in loss of functional stability of 
chromosomes in the cancer cell. 
 
Methylation of the CpG islands within the promoter regions of genes is associated with 
transcriptional silencing.  This is important in carcinogenesis, as it is a mechanism by 
which Tumour Suppressor Genes such as p16, APC, hMLH1, Rb and BRCA1, may be 
inactivated (Herman and Baylin, 2003).  Methylation can therefore be considered an 
epigenetic phenomenon that may be responsible for either the first or second hit in the 
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Knudson Hypothesis of transcriptional silencing of tumour suppressor genes (Knudson, 
2001).   What remains  unclear  is  the  timing  of DNA  methylation  in  carcinogenesis.   
Age  related  methylation  in  normal  tissues  is  well  recognised  and  this  increase  in 
methylation with age may partly explain the increased incidence of many tumours in 
older patients (Ahuja and Issa, 2000). 
 
It has been demonstrated that certain tumours exhibit a so-called CpG Island Methylator 
Phenotype (CIMP) where the tumour is characterised by a number of methylated genes 
(Strathdee et al., 2001a, Toyota et al., 1999a).  What again remains unclear in many 
cancers, including lung cancer, is whether the cancer possesses a CIMP and if they do is 
it the number/pattern of gene methylation or merely the loss of expression of a critical 
gene that leads to carcinogenesis? 
 
 
1.8.3.3 DNA Methylation, Mismatch Repair and Chemotherapy Resistance 
As described earlier Brown et al., (Brown et al., 1997) were able to demonstrate that 
selection for cisplatin resistance in the human ovarian cancer cell line A2780 resulted in 
the loss of mismatch repair protein MLH1 expression in 90% of the resultant cisplatin 
resistant cell lines and that re-introduction of the hMLH1 gene by direct chromosome 
transfer led to at least partial restoration of cisplatin sensitivity (Durant et al., 1999).  
This has also been reported to be the case in colorectal cancer cell lines (Fink et al., 
1998, Sammalkorpi et al., 2007). 
 
It has subsequently been shown in several tumour cell lines that this loss of MLH1, and 
subsequent  cisplatin  resistance,  often  relates  to  methylation  of  the  hMLH1  gene   63 
promoter.    The  study  by  Strathdee  et  al,  demonstrated  that  hMLH1  promoter 
hypermethylation was invariably associated with loss of MLH1 expression in the MMR 
deficient A2780/Cp70 ovarian cancer cell line and work by this group demonstrated that 
when  2  of  the  resistant  cell  lines  were  treated  with  5-azacytidine,  which  acts  as  a 
demethylating agent, there was also re-expression of the MLH1 protein (Strathdee et al., 
1999).   
  
It  has  been  demonstrated  also  that  the  demethylating  agent  2’-deoxy-5-azacytidine 
(DAC)  can  lead  to  resensitisation  of  MLH1  negative  (secondary  to  gene  promoter 
hypermethylation) MMR deficient drug resistant tumour (ovarian cell line A2780/cp70 
and  colon  SW48  xenografts  in  vivo  (Plumb  et  al.,  2000).    In  this  study,  MLH1 
expression was estimated using immunohistochemistry and the methylation status of the 
hMLH1  gene  promoter  assessed  by  Southern  blotting.    Re-expression  of  the  MLH1 
protein in vivo was achieved using DAC at doses that were non-toxic to the mice.  DAC 
at these doses had no effect on tumour xenograft size (even at the maximum tolerated 
dose 15mg/kg), which is an important finding in this study as DAC itself is a known 
cytotoxic agent. However when the mice bearing xenografts were treated with a lower 
dose  of  cisplatin  (6  mg/kg)  after  they  had  been  treated  with  DAC,  the  xenografts 
showed a clear growth delay, indicating a restoration of cisplatin sensitivity (Table 1.5). 
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Table 1.5: Analysis of the effects of DAC pre-treatment on the drug sensitivity of 
MMR-deficient A2780/cp70 and MMR-proficient A2780/cp70-ch3 xenografts 
Treatment  Time to double initial tumour volume (days) (mean 6 mice) 
  A2780/cp70  p-value  A2780/Cp70-chr3  p-value 
Control 
DAC 
2.4 ± 0.2 
2.5 ± 0.3 
NS  2.9 ± 0.2 
3.3 ± 0.4 
NS 
Carboplatin 
DAC+Carboplatin 
2.9 ± 0.2 
6.1 ± 0.5 
p < 0.001  5.4 ± 0.2 
5.6 ± 0.2 
NS 
Cisplatin 
DAC+Cisplatin 
2.9 ± 0.2 
6.0 ± 0.3 
p < 0.001  5.1 ± 0.2 
6.1 ± 0.2 
p < 0.05 
Temozolomide 
DAC+Temozolomide 
2.1 ± 0.2 
3.6 ± 0.2 
p < 0.001  4.7 ± 0.4 
4.6 ± 0.4 
NS 
Epirubicin 
DAC+Epirubicin 
4.3 ± 0.4 
6.0 ± 0.6 
p < 0.05  4.8 ± 0.5 
5.3 ± 0.7 
NS 
Taxol 
DAC+Taxol 
4.5 ± 0.2 
4.8 ± 0.6 
NS  5.2 ± 0.4 
5.2 ± 003 
NS 
Modified from Plumb et al (Plumb et al., 2000) 
 
This  finding  is  of  potential  clinical  significance  as  it  raises  the  possibility  that  a 
demethylating agent, such as decitabine (DAC) may be used to overcome methylation 
induced drug resistance in the clinical setting.   
 
Examples of tumours taken from cancer patients that have been studied and found to 
have  significant  levels  of  methylation  of  the  hMLH1  promoter  with  subsequent 
reduction in MLH1 expression are ovary, gastric and breast cancer (Mackay et al., 2000, 
Strathdee et al., 1999, Toyota et al., 1999a).  In ovarian cancer it is known that majority 
of  tumours  will  respond  to  platinum  based  chemotherapy  but  that  20-30%  will  be 
intrinsically  resistant  to  platinum  and  in  chemosensitive  tumours,  despite  initial   65 
response, relapse with platinum resistant disease is common (Kaye, 1996).  It may be 
that methylation of hMLH1 plays a significant role in the acquisition of this resistance 
as  it  has  been  demonstrated  that  there  is  a  loss  of  expression  of  MLH1  in  post-
chemotherapy tumour samples in comparison to pre-chemotherapy samples (Brown et 
al., 1997). 
 
1.8.3.4 DNA Methylation patterns in NSCLC 
The first report of gene promoter methylation in lung cancer was by Merlo et al in 1995 
(Merlo et al., 1995).  These authors demonstrated that the methylation of the p16 CpG 
Island was associated with transcriptional silencing of the gene and treatment of the 
monosomic cell lines with 5-deoxyazacytidine led to reversal of this genetic silencing.  
This is an important finding because these cell lines do not exhibit any mutations within 
the p16 gene and therefore gene silencing was attributable entirely to methylation.  This 
demonstrates that epigenetic silencing of genes by methylation is possible without the 
need for another genetic ‘hit’ (Merlo et al., 1995). 
 
Herman et al first described the technique of Methylation Specific PCR (MSP) (Herman 
et al., 1996a).  The technique differentiates between methylated and unmethylated DNA 
sequences and has allowed the study of specific genes or patterns of gene methylation in 
tumours and how these may relate to tumour behaviour.  The research into the role that 
methylation of specific genes may play in lung cancer, is highlighted in table 1.6.  The 
majority of these studies have examined methylation of specific genes in isolation and 
varied in sample number from 3 to 126 with a median of 35. 
   66 
One of the largest studies reported is that by Zochbauer-Muller at al, which examined 
abberant  methylation  of  8  gene  promoter  regions  in  107  primary  NSCLC  tumour 
samples (Zochbauer-Muller et al., 2001).  The promoter regions studied were RARB, 
TIMP-3, p16, DAPK, MGMT, ECAD, p14 and GSTP1 and correlation was made with 
some  clinicopathological  factors,  namely  gender,  age,  smoking  status,  TNM  stage, 
histology  and  overall  survival.    It  was  demonstrated  that  82%  of  tumours  had 
methylation of at least one of the studied gene promoters, with 37% one gene, 22% two 
genes, 13% three genes, 8% four genes and 2% five genes.  There was no correlation 
between the number of methylated genes and any of the clinicopathological variables.  
The  authors  demonstrated  that  methylation  of  ECAD  (19  of  107  [18%]  samples) 
correlated  with  a  better  overall  survival,  particularly  in  stage  I  disease  (p  =  0.005, 
Kaplan-Meier log rank test). In addition, it was reported that 41% of tumours exhibiting 
methylation of at least one promoter region had lymph node involvement whereas only 
11% of tumours exhibiting no methylation had lymph node involvement (p = 0.012). 
This study also reported that gene promoter methylation correlated significantly with 
loss  of  gene  expression  assessed  immunohistochemically  (p16  gene,  p  =  0.009) 
(Zochbauer-Muller et al., 2001). 
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Table 1.6:  MSP studies of gene promoter hypermethylation in lung cancer 
Gene  Reported methylation 
frequency (%) 
References 
 
ARF / p14  0 – 8  (Esteller et al., 2001, Kim et al., 2001b, 
Zochbauer-Muller et al., 2001) 
APC  0 – 46  (Esteller et al., 2001, Virmani et al., 2001) 
BRCA1  4  (Esteller et al., 2001) 
ECAD  18  (Zochbauer-Muller et al., 2001) 
HCAD  43 - 50  (Toyooka et al., 2001) 
p16  17 – 43  (Ahrendt et al., 1999, Esteller et al., 1999, 
Kashiwabara et al., 1998, Kim et al., 2001b, 
Ng et al., 2002, Sanchez-Cespedes et al., 
1999, Zochbauer-Muller et al., 2001) 
p15  0 – 5  (Esteller et al., 2001, Hamada et al., 1998, 
Herman et al., 1996b) 
p19  0  (Zhu et al., 2001) 
DAPK  16 – 23  (Esteller et al., 2001, Esteller et al., 1999, 
Zochbauer-Muller et al., 2001) 
FHIT  37 – 64  (Zochbauer-Muller et al., 2001) 
GSTP1  7 – 9  (Esteller et al., 2001, Esteller et al., 1999, 
Zochbauer-Muller et al., 2001) 
HOXB  75  (Flagiello et al., 1996) 
MGMT  21 – 29  (Esteller et al., 2001, Esteller et al., 1999, 
Palmisano et al., 2000, Wolf et al., 2001, 
Zochbauer-Muller et al., 2001) 
hMLH1  0 – 2  (Esteller et al., 2001, Virmani et al., 2002) 
RARB  40 – 76  (Virmani et al., 2000, Zochbauer-Muller et 
al., 2001) 
RASSF1A  30  (Burbee et al., 2001) 
S100A2  89  (Feng et al., 2001) 
TGFBR2  0 – 12  (Hougaard et al., 1999, Osada et al., 2001, 
Virmani et al., 2002) 
TIMP3  19 – 50  (Bachman et al., 1999, Esteller et al., 2001, 
Zochbauer-Muller et al., 2001) 
TP73  0  (Esteller et al., 2001) 
Table adapted from Tsou et al (Tsou et al., 2002)   68 
Only  4  genes  from  the  above  table  have  demonstrated  significant  correlation  with 
clinicopathological variables, DAPK (Death Associated Protein Kinase), p16, MGMT 
(O
6-Methylguanine-DNA-methyltransferase) and RASSF1A (Ras Association Domain 
Family 1).  DAPK is a positive mediator of apoptosis and methylation of this gene has 
been shown to be associated with advanced NSCLC stage (p = 0.003), increased tumour 
size (p = 0.009) and lymph node involvement (p = 0.04) and although stage I patients 
had  a  worse  overall  survival  this  did  not  reach  statistical  significance  (Kim  et  al., 
2001a).    As  discussed  in  section  1.8.4  below,  methylation  of  the  p16  (a  cyclin-
dependant kinase inhibitor) gene may be present in the sputum of high-risk individuals 
prior to their developing NSCLC.  More recently p16 methylation in patients with early 
stage (I/II) disease has been reported to be associated with a worse overall survival (p = 
0.002) (Wang et al., 2004a).   Methylation of the RASSF1A gene has been shown to be 
associated with a worse overall survival in stage IIIa disease (p < 0.0001) (Wang et al., 
2004a).  No  correlation  was  demonstrated  between  RASSF1A  gene  methylation  and 
overall survival by Toyooka et al (Toyooka et al., 2004). 
 
With regard to chemotherapy response, methylation of the HIC 1 and RASSF1A loci 
has been associated with chemotherapy resistance in male germ cell tumours (Koul et 
al., 2004).  This has not been demonstrated in patients with lung cancer. 
 
1.8.4  Prognostic markers in the serum DNA of lung cancer patients 
The presence of circulating tumour DNA in the serum of patients with cancer was first 
described  in  1977  (Leon  et  al.,  1977).  The  presence  of  tumour  DNA  out-with  the 
tumour sample in patients with lung cancer has been reported in sputum (Mao et al., 
1994, Miozzo et al., 1996) and more recent work has demonstrated methylation of lung   69 
cancer related genes such as p16 in the sputum of lung cancer patients (Palmisano et al., 
2000).    However  sputum  is  an  inconsistent  and  unreliable  source  of  material  from 
patients.  Not all patients with lung cancer produce sputum and sputum induction is an 
uncomfortable, sometimes unpleasant, experience for patients, as well as the resultant 
samples differing markedly in quality. 
 
The possibility of being able to isolate sufficient amounts of circulating tumour DNA in 
patients with cancer is attractive as it could allow the molecular profiling of a tumour 
without requiring a further tissue sample.  
 
At  present  there  are  no  clinical  examples  of  tumours  in  which  the  molecular  DNA 
profile  of  the  tumour  is reflected  in  the  serum of  the  cancer  patient  with  sufficient 
robustness that can be used to predict response to therapy or likely prognosis.  
 
1.8.4.1 Allelic imbalance in the serum of lung cancer patients 
The  detection  of  circulating  tumour  DNA  in  patients  with  lung  cancer  was  first 
described by Chen et al (Chen et al., 1996).  In this study at least one microsatellite 
alteration was detectable in 16 of 21 (76%) of SCLC samples and 15 of 21 (71%) of the 
corresponding serum samples.  One serum sample exhibited a microsatellite alteration 
when there was no microsatellite alteration in the primary tumour sample. 
 
Sozzi et al in 2001 in a series of 84 patients with NSCLC demonstrated that the mean 
concentration of DNA in serum was higher than that found in the serum of 43 control 
patients.  It was also reported in this study that 20 of 33 (61%) informative analysed 
patients displayed loss of heterozygosity at the 3p locus (6 markers studied) and that 9   70 
(45%) of these 20 informative samples demonstrated the same allelic imbalance as in 
the tumour (Sozzi et al., 2001).  This was one of the first studies of circulating DNA 
found in the serum of cancer patients to be confirmed as originating from the tumour, 
by virtue of it’s molecular profile. 
 
1.8.4.2 DNA methylation in serum of patients with lung cancer 
The feasibility of detecting tumour DNA methylation in the serum of NSCLC patients 
was  first  described  by  Esteller  et  al  (Esteller  et  al.,  1999).    Moreover  it  has  been 
demonstrated in ovarian cancer patients that detection of DNA methylation in the serum 
is predictive for poor overall survival (Gifford et al., 2004).   
 
p16 is one of the most studied genes in patients with NSCLC and it has been shown that 
methylation of p16 can be detected in the sputum of patients with lung cancer and that 
these  changes  may  predate  the  clinical  diagnosis  of  NSCLC  by  up  to  35  months 
(Kersting et al., 2000, Palmisano et al., 2000).  Two recent studies have demonstrated 
the presence of p16 methylation in the circulating serum DNA in patients with NSCLC 
using  methylation-specific  PCR.  Bearzatto  et  al  demonstrated  that  22    of  35 (63%) 
NSCLC  samples  demonstrated  p16  methylation  and  that  of  these  22,  12  (55%) 
demonstrated methylation of p16 in the corresponding serum sample (Bearzatto et al., 
2002).  A further study reported at the same time demonstrated the presence of p16 
methylation in 73 of 92 (79.3%) NSCLC samples, with corresponding p16 methylation 
in the serum of 64 (87.8%) of these patients (An et al., 2002).   
 
DAPK and GSTP1 methylation has also been detected in 4/5 and 1/2 serum samples 
from methylated tumours respectively (Esteller et al., 1999).   71 
Despite all of the work that has been performed to date lung cancer mortality remains 
high and in the majority of patients treatment intent is palliative.  In this situation the 
development of molecular markers that would allow the stratification of patients into 
tailored management pathways would be a major advance for this patient population. 
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1.9  Aims of the Study 
The results of studies of molecular markers in patients with lung cancer are conflicting 
and the relative importance of many molecular markers is still unclear.  In particular, 
there remains little evidence for molecular markers, other than possibly ERCC1, being 
useful in predicting which patients may benefit from systemic chemotherapy. Patients 
may require additional new approaches such as the enhancement of the response to 
cisplatin-based chemotherapy using demethylating agents.  This is already the case in 
other tumour types.  Alternatively molecular markers may predict sensitivity to novel 
biological  agents  such  as  EGFR  tyrosine  kinase  inhibitors,  either  alone  or  in 
combination with cytotoxic drugs. 
 
Several techniques now exist that will allow further evaluation of molecular markers as 
potential prognostic indicators, with the aim of providing tailored therapeutic strategies 
for patients with lung cancer. 
 
The purpose of this study is therefore to investigate the role of MMR proteins and other 
molecular markers as prognostic indicators in lung cancer, in relation to chemotherapy. 
 
The aims of this study, in 3 separate cohorts of patients, are as follows: 
 
1.  Investigate  the  role  of  mismatch  repair  proteins  as  a  possible  marker  of 
prognosis and predictor of chemotherapy response in patients with NSCLC. 
 
2.  Investigate CpG island methylation status and its role as a possible marker of 
prognosis in patients with NSCLC   73 
3.  Investigate the feasibility of examining the presence of allelic imbalance at a 
variety of loci both in tumour samples from and in the serum of patients with NSCLC 
and comparing this with the investigation of mismatch repair function in the tumour as 
well as the methylation profile in the tumour. 
 
The  first  cohort  of  patients  (Stobhill  Hospital,  Glasgow)  all  received  systemic 
chemotherapy, either cisplatin or non-platinum based, and from these patients historical 
paraffin-embedded tumour samples taken at the time of diagnostic bronchoscopy were 
available.  From these samples the immunohistochemical study of MLH1, MSH2 and 
p53 expression was undertaken.  The level of expression of these molecular markers 
was correlated with survival data as well as tumour stage and histology.  In addition any 
correlation  between  these  molecular  markers  and  survival  according  to  the  various 
chemotherapy regimes used was analysed. 
 
The  second  cohort  of  patients  (Aberdeen  Royal  Infirmary,  Aberdeen)  all  underwent 
surgical resection for their primary tumour and 20% (10) of these received preoperative 
cisplatin based chemotherapy.  From these patients banked, fresh, frozen tumour and 
normal adjacent lung was collected.  In addition to the fresh samples, corresponding 
paraffin embedded samples were also available.  From these paraffin embedded samples 
the expression of MLH1, MSH2, p53 and also Ki67 was studied.  These results were 
correlated with survival, stage and histology as well as comparing these results between 
those who had received preoperative chemotherapy and those who had not.  From the 
fresh tumour samples the presence of methylation at multiple loci and the existence of a 
CpG island methylator phenotype was investigated.  The results of this methylation 
profile  were  correlated  with  survival,  tumour  stage  and  histology  as  well  as   74 
investigating  any  potential  differences  between  the  results  from  those  patients  who 
received preoperative chemotherapy from those who had not. 
 
The third cohort of patients (Western Infirmary, Glasgow) underwent surgical resection 
of their primary NSCLC and in addition to tumour and normal adjacent samples being 
collected prospectively, a whole blood sample was collected prior to thoracotomy.  In 
this  study  the  protein  expression  of  MLH1,  MSH2  and  p53  was  measured  using 
immunohistochemistry as well as the study of the CpG island methylation profile. In 
addition the presence of allelic imbalance at a panel of loci was examined in the tumour 
sample as well as in the lymphocyte and serum samples. 
 
Finally, a cell line study was undertaken in SCLC cell lines to evaluate the role of the 
mismatch repair proteins and assess the significance of methylation of these in relation 
to  chemotherapy  sensitivity.    For  this  a  panel  of  small  cell  lung  cancer  lines  were 
examined for methylation of their hMLH1 promoter region and this was correlated with 
chemosensitivity. 
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2.   Materials and Methods 
 
2.1  Immunohistochemistry 
2.1.1  Materials 
2.1.1.1 Stable solutions for immunostaining 
These solutions were stable at 20°C. 
1.  Phosphate buffered saline (PBS) 
2.  Buffer for autostainer (PBS with 0.05% Tween: 0.5ml Tween in 1 litre PBS). 
3.  10-mmol/l  citrate  buffer  (5.88g  trisodium  citrate  in  2  litre  distilled  water, 
adjusted to pH 6.0 with concentrated hydrochloric acid). 
4.  0.1 % hydrogen peroxide: 1ml 100 vol. Hydrogen peroxide + 1 litre distilled 
water. 
5.  Antidote  to  diamminobenzidine  tetrahydrochloride  (DAB):  3g  potassium 
permanganate + 2 g sodium carbonate in 100 ml distilled water. 
 
2.1.1.2 Unstable solutions for immunostaining 
This quantity was made for 45 slides.  Solutions were made freshly and kept on wet 
ice.  The Vectastain Elite ABC Kit, Mouse IgG (Vector Laboratories) was used 
throughout. 
1.  Blocking  serum  (Vectastain  Yellow).   20 ml PBS  +  6  drops  yellow  block 
(300µl normal horse serum). 
2.  Biotinylated antibody (Vectastain Blue).  20 ml PBS + 6 drops yellow block + 
2 drops blue block (100µl biotinylated anti-mouse IgG). 
3.  ABC reagent (Vectastain Grey).  10 ml PBS + 4 drops reagent A (Avidin DH 
solution) + 4 drops Reagent B (biotinylated enzyme).   76 
4.  Diaminobenzidine tetrahydrochloride (DAB).  10 ml distilled water + 4 drops 
Vectastain buffer + 4 drops 0.1% hydrogen peroxide + 8 drops Vectastain 
DAB reagent. 
5.  DAB antidote (potassium permanganate solution) 
 
2.1.1.3 Primary Antibodies 
1.  Anti-hMLH1.  210 µl MLH1 antibody (500 µg/ml purified anti-human mouse 
monoclonal IgG, clone G168-15, Pharmingen) + 2079 µl PBS. 
2.  Anti-MSH2.  110 µl MSH2 antibody (100 µg/ml purified anti-human mouse 
monoclonal IgG, Ab-2 clone FE11, Calbiochem) + 2189 µl PBS. 
3.  Anti-p53.    22  µl  p53  antibody  (100  µg/ml  purified  anti-human  mouse 
monoclonal IgG, DO-1 clone FE11, Oncogene) + 2198 µl PBS. 
4.  Anti-Ki67.    111  µl  Ki67  antibody  (100  µg/ml  purified  anti-human  mouse 
monoclonal IgG, B56 clone, BD Pharmingen ®) + 2198 µl PBS 
 
2.1.1.4 Positive and negative controls 
Sectioned  paraffin-embedded  samples  of  cell  lines  with  known  positivity  for  each 
antibody  were  included  in  each  immunohistochemistry  run.    Cell  lines  used  are 
indicated in table 2.1.  Also included in each run was a negative control cell line slide to 
which primary antibody was not added.  This was to ensure no residual endogenous 
peroxidase  activity,  which  should  have  been  removed  during  the  0.1  %  hydrogen 
peroxidase step.  On completion of the immunostaining run, this slide should stain blue 
(negative).  If it did not, then the run was repeated.  With a new antibody, dilutions of 
the positive and negative controls were run to ensure the best antibody concentration 
was  used.    The  antibody  concentration  chosen  was  the  one,  which  gave  the  best   77 
definition  between  positive  (brown)  and  negative  (blue)  controls  but  minimal 
background staining. 
 
Table 2.1: Immunohistochemistry cell line controls 
  POSITIVE CONTROL  NEGATIVE CONTROL 
MLH1  A2780  A2780/cp70 
MSH2  A2780  LoVo 
P53  A2780/cp70  A2780 
Ki67  A2780  No negative 
 
2.1.1.5 Solutions for counterstaining 
1.  Haematoxylin; Harris formula filtered before use, Surgipath 
2.  100 % ethanol. 
3.  70 % ethanol. 
4.  Histo-clear, Fisher Scientific Ltd. 
5.  Scott’s Tap Water:  1 in 10 dilution in distilled water of Surgipath Scott’s Tap 
Water substitute. 
6.  Acid  alcohol:    10  ml  concentrated  HCl  (specific  gravity  1.16  g/ml  – 
approximately 33 %) + 990 ml ethanol. 
7.  Hystomount, Hughes and Hughes Ltd. 
 
2.1.2  Methodology for Immunohistochemistry 
The  department  developed  and  validated  the  use  of  an  automated 
immunohistochemistry  staining  technique  (DAKO  Autostainer)  and  this  technique 
was used for all the immunohistochemistry performed in this project.     78 
The  DAKO  Autostainer  protocol  was  developed  using  samples  with  known 
immunohistochemistry scores to ensure reliability and reproducibility of results.  
 
The  immunohistochemistry  technique  employed  in  this  project  involved  the  use  of 
streptavidin-biotin  coupled  to  peroxidase  activity  as  a  label,  which  utilises  the  high 
affinity of avidin for biotin.  Because this affinity is more than one million times that of 
an antibody to most antigens, the binding of avidin to biotin is fixed and irreversible.  
Furthermore,  avidin  has  four  binding  sites  for  biotin.    These  properties  mean  that 
macromolecular complexes can form between avidin and biotinylated enzymes. 
 
Initially, unlabelled primary antibody binds to the antigen of interest in the tissue.  This 
subsequently  binds  to  a  preformed  avidin  and  biotinylated  horseradish  peroxidase 
macromolecular complex.  The bound antibody complex turns brown after oxidation, 
which can be visualised using a light microscope.  Diamminobenzidine is added as the 
substrate for the bound antibody complex to produce the colour change.  If, however, no 
primary antibody is bound to the antigen of interest, there will be no peroxidase activity 
and  no  brown  colour  will  form.    Such  negative  samples  are  visualised  by 
counterstaining with haematoxylin, producing a blue colour.  Endogenous peroxidase 
activity, which would give a false positive result, is removed using hydrogen peroxide. 
 
In this study, microwaving was used to expose antigens to antibodies where the energy 
from heating in a microwave disrupts the protein-protein crosslinks that may occur in 
tissue sections fixed in formaldehyde and then embedded in paraffin and this increases 
their immunoreactivity.  The buffer used is important (Shi et al., 1995) and our group 
has found consistent results using microwave heating in citrate buffer at pH 6.  Before   79 
proceeding  with  an  immunohistochemistry  run,  the  optimum  antibody  concentration 
was determined by testing various antibody dilutions on samples of known positivity.  
In  this  way,  positive  staining  was  optimised  and  background  staining  reduced  to  a 
minimum. 
 
2.1.2.1 DAKO Autostainer protocol 
A. Dewaxing of slides (in a laminar flow hood) 
1.  Slides  were  placed  in  a  metal  rack  and  immersed  in  Histo-Clear  for  20 
minutes. 
2.  Slides were then rinsed in a bath of 100 % ethanol for 1 minute. 
3.  Slides were then rinsed in a bath of 70 % ethanol for 1 minute. 
4.  Slides were then rinsed in tap water for 1 minute. 
5.  Slides were then washed in a bath of PBS for 5 minutes. 
 
B.  Antigen retrieval 
1.  Slides were placed in a plastic rack and then into a microwave box with 750 ml 
citrate buffer.  The box was covered with cling film and the cling film then 
pierced. 
2.  The box was microwaved at 650-Watt power for 15 minutes. 
3.  The box was then left to cool for 20 minutes and the slides then transferred to 
PBS prior to loading onto the autostainer. 
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C.  Setting up the autostainer run and preparing reagents 
1.  The software instructions were followed to enter the number and identification 
of each slide.  This also calculated the volume of each reagent required. 
2.  The reagents were prepared as per the autostainer instructions and stored on ice 
until ready. 
3.  The  slides  were  loaded  in  order,  the  reagents  were  inserted  into  the  correct 
position and the autostainer run commenced. 
 
2.1.2.2 Counterstaining with haematoxylin (in a laminar flow hood) 
A.  Counterstaining 
1.  Slides were placed in a metal rack in tap water. 
2.  Slides were washed in haematoxylin for 1 minute and then rinsed in tap water. 
3.  Slides were then rinsed in acid alcohol for 5 seconds and then rinsed in tap 
water. 
4.  Slides were then washed in Scott’s Tap Water for 1 minute and then rinsed in 
tap water. 
5.  Slides were then washed in 70 % ethanol for 1 minute. 
6.  Slides were then washed in 100 % ethanol for 1 minute. 
7.  Finally, slides were washed in Histo-Clear for 5 minutes. 
 
B.  Mounting slides 
1.  Each slide was mounted using Hystomount and cover slips 
2.  Slides were left to set for at least 1 hour.  Care was taken to ensure all areas of 
the section were covered by Hystomount to prevent drying out. 
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2.1.2.3 Immunohistochemistry scoring 
Slides  were  scored  by  two  observers  independently  and  blinded  to  all  clinical 
information, thus allowing for variation between observers (inter-observer variability).  
The first observer, KK, is a Professor of Pathology with a particular interest in lung 
cancer  pathology  and  the  second  is  the  author  of  the  thesis,  who  received  specific 
training in lung cancer pathology and immunohistochemistry scoring.  To allow for 
variability  in  staining  two  slides  from  each  patient  were  stained  for  each  antibody.  
Relevant positive and negative controls (table 2.1) were checked for each run prior to 
scoring to try to minimise variability. 
 
Sections in this study were therefore scored using the multiplicative ‘quickscore’ and 
the scoring system below.  The overall immunohistochemistry score (IHC-score) was 
calculated by multiplication of the percentage score and the intensity score, giving a 
final score between 0 and 9.  When calculating the percentage score, a representative 
area of the section was chosen using light microscopy at low power and then counted at 
higher  power.   The  intensity  score  was  calculated  by  assessing  the  score  that  most 
accurately represented the majority of the cells counted. 
 
Table 2.2: Immunohistochemistry scoring system: Intensity staining 
Intensity Score (I-score)   
0  No stain 
1  Weakly positive 
2  Positive 
3  Strongly Positive 
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Table 2.3: Immunohistochemistry scoring: Percentage staining 
Percentage Score (%-score)   
0  0 – 4% of cells positive 
1  5 – 19% of cells positive 
2  20 – 79% of cells positive 
3  80 – 100% of cells positive 
 
2.1.2.4 Validation of immunohistochemistry 
Our group, to investigate variability during immunohistochemical staining and scoring, 
has undertaken extensive work, predominantly by Dr M Mackean (Centre for Oncology 
and Applied Pharmacology, University of Glasgow), and to validate the methods used 
in  our  group.    The  key  objective  of  using  immunohistochemistry  is  to  identify 
variability in staining due to differences in expression of the protein under investigation.  
However,  variation  in  results  may  occur  for  other  reasons  including  the  staining 
methodology used, inter-observer variability, intra-observer variability and the variation 
in protein expression within a heterogeneous tissue section. 
 
Dr Mackean investigated the variability of their immunohistochemistry scoring system 
used  in  our  group  by  calculating  kappa  scores.    The  kappa  score  is  a  method  that 
assesses the difference between scores by giving a weighting to the difference in the 
score.    The  kappa  statistic  is  the  observed  agreement,  corrected  for  a  chance,  as  a 
fraction of the maximum agreement between observers above that due to pure chance.  
When  analysed  by  Dr  Mackean  (unpublished  observations),  the  variability  in  the 
immunohistochemistry  ‘quickscore’  scoring  system  was  found  to  show  high 
reproducibility,   83 
2.2  DNA Extraction from blood and cultured cell lines  
2.2.1  Materials 
The QIAamp DNA Blood Mini Kit (QIAGEN) was used.  This kit is specifically 
designed to purify up to 6 µg of total DNA from 200 µl of whole blood.  Qiagen has not 
disclosed the exact constituents of the reagents supplied with this kit. 
 
Materials supplied with the QIAGEN DNA Blood Mini Kit: 
1.  QIAGEN protease stock solution (stored at 4°C). 
2.  Buffer  AL  (lysis  buffer).    This  contains  guanidine  hydrochloride  and  a 
chaotropic salt. 
3.  Buffer AW1 (wash buffer).  This contains guanidine hydrochloride and has high 
ethanol content. 
4.  Buffer AW2 (wash buffer).  This has high ethanol content. 
5.  Buffer AE (elution buffer).  This contains Tris-EDTA. 
6.  Spin columns and collection tubes. 
Materials not supplied: 
1.  Rnase A (20mg/ml) 
2.  Heating block 
3.  Centrifuge 
4.  100 % ethanol (added to buffers AW1 and AW2 as per kit instructions) 
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2.2.2  Methodology 
Whole  blood  samples  were  received  by  taxi  or  collected  in  person  from  Stobhill 
Hospital and collected in person from the Western Infirmary in Glasgow.  They were 
immediately centrifuged at 5000g for 10 minutes to separate the serum.  This was then 
removed with a pipette and placed in a separate sterile tube and labelled with the study 
number.  Samples were then stored at 4°C before performing DNA extraction. Samples 
were equilibrated to room temperature prior to proceeding with DNA extraction.   
 
Cultured cell lines were obtained from Dr J Plumb (Centre for Oncology and Applied 
Pharmacology, University of Glasgow) and DNA extraction methodology was the same 
as for the whole blood sample. 
 
All extractions were performed in a room designated for Category 2 work and in a 
laminar flow cupboard.  Precautions were taken to avoid cross-contamination between 
sample preparations, including the use of aerosol-barrier pipette tips, changing pipette 
tips between all liquid transfers and regular glove changes during the procedure.   85 
1.  Heating block prewarmed to 56°C. 
2.  Lysis and DNA Precipitation. 
  Blood/ 
Cell Cultures 
1.5ml eppendorf 
  Serum 
15ml falcon tube 
 
   
200 µl 
 
 
1 ml 
 
Rnase A 
(P20 pipette) 
 
 
4 µl 
 
20 µl 
 
Qiagen Protease 
(P200 pipette) 
 
 
25 µl 
 
 
125 µl 
 
Vortex 
 
 
Buffer AL 
(Lysis Buffer) 
 
   
200 µl 
   
1 ml 
 
Vortex 
 
 
Incubate on Heating Block @ 56°C for 10 minutes 
 
 
100% Ethanol 
(P1000 pipette) 
 
   
210 µl 
   
1050 µl 
 
Vortex 
 
 
Centrifuge Eppendorfs so contents are at base of tube 
 
3.  Spin columns were labelled for each sample. 
4.  635µl of each blood and serum was pipetted into the appropriate spin column 
and then placed into a collection tube. 
5.  Samples were then centrifuge at 8000 x g for 1 minute.   86 
6.  The elute was discarded and each spin column was placed into a fresh collecting 
tube. 
7.  Steps 4 - 6 was repeated a total of 5 times for each serum sample, due to the 
original volume of each serum sample. 
8.  500µl of buffer AW1 was added to each spin column without wetting the rim of 
the column. 
9.  The samples were then centrifuged at 8000 x g for 1 minute. 
10. The collection tubes were then discarded and each spin column placed in a fresh 
one.    500µl  of  buffer  AW2  was  then  added  into  each  spin  column,  without 
wetting the rim of the column. 
11. Samples were then centrifuged at 8000 x g for 3 minutes to ensure that all buffer 
AW2 was eluted through the spin column. 
12. The collection tubes containing the buffer AW2 were discarded and the spin 
columns placed into a clean 1.5 ml microcentrifuge tube.  200 µl buffer AE was 
added to each spin column and these were incubated at room temperature for 5 
minutes. 
13. The samples were centrifuged at 8000 x g for 1 minute.  Each elute was passed 
through the spin column again, incubated for 5 minutes and centrifuged at 8000 
x  g  for  1  minute  again.    In  total,  this  step  was  performed  twice for  serum-
depleted blood and 5 times for serum. 
14. The DNA concentration in the elute was quantified using a spectrophotometer.  
Three repeat samples were measured and the mean of these taken as the DNA 
quantity. 
15. Each sample was labelled and stored at -70°C 
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2.3  DNA Extraction from tissue 
2.3.1  Materials 
The  QIAGEN  Genomic  DNA  extraction  kit  was  used  throughout.    This  kit  is 
specifically designed to purify DNA from tissue. 
 
Materials supplied with the kit: 
1.  Buffer  G2  (lyses  nuclei  and  denatures  proteins).    This  contains  800mmol/l 
guanidine  hydrochloride;  30  mmol/l  tris-hydrochloride  (Tris-Cl),  pH  8.0;  30 
mmol/l EDTA, pH 8.0; 5 % Tween-20 and 0.5 % Triton X-100. 
2.  Buffer QF (high-salt elution buffer).  This contains 1.25 mol/l sodium chloride; 
50 mmol/l Tris-Cl, pH 8.5 and 15 % isopropranolol. 
3.  Buffer QBT (equilibration buffer).  This contains 750 mmol/l MOPS, pH 7.0; 15 
% isopropranolol and 0.15 % Triton X-100. 
4.  Buffer QC (medium-salt wash buffer).  This contains 1.0 mol/l sodium chloride; 
50 mmol/l MOPS, pH 7.0 and 15 % isopropranolol. 
5.  Qiagen genomic-tips. 
Materials not supplied with the kit: 
1.  Qiagen protease (1 × 125 mg protease in 6.25 ml distilled water). 
2.  Rnase A stock (100mg/ml) 
3.  100 % ethanol 
4.  70 % ethanol. 
5.  Liquid nitrogen. 
6.  Microdismembranation chamber 
7.  Heating block and centrifuge. 
8.  Isopropranolol.   88 
2.3.2  Methodology 
Fresh  tumour  and  normal  lung  tissue  was  identified  macroscopically  by  consultant 
pathologists and frozen at -70°C immediately after surgery.  Care was taken to remove 
normal  lung  tissue  from  as  far  from  the  tumour  as  possible  to  reduce  the  risk  of 
contamination of the normal tissue with tumour cells.  Once frozen at -70°C, samples 
were  batched  and  DNA  extracted  at  a  later  date.    The  samples  collected  from  the 
Western Infirmary in Glasgow were collected prospectively, whereas the samples from 
Aberdeen  Royal  Infirmary  were  collected  retrospectively  from  Dr  Keith  Kerr, 
consultant pathologist.  Both sample sites had collected and processed the samples as 
described above. 
 
All utensils were washed in 100 % ethanol prior to use and also in between each sample 
to  ensure  no  contamination.    All  utensils  were  cooled  with  liquid  nitrogen  prior  to 
handling each tissue sample in order to keep the samples as cold as possible and ensure 
maximum DNA extraction.  All extractions were performed in a laminar flow cupboard. 
 
1.  A pestle and mortar was used to break each tissue sample into small pieces, 
keeping the samples cold with liquid nitrogen.  The tissue sample was placed in 
the microdismembranation chamber on full amplitude for 5 seconds.  This was 
repeated twice more, ensuring that the sample remained cold in liquid nitrogen 
in between. 
2.  The resulting fine powder was added to 19 ml G2 buffer, 38 µl Rnase A and 1 
ml Qiagen protease (prepared earlier).  This was then vortexed and incubated at 
50°C overnight.   89 
3.  The lysate should be clear after incubation.  Any particulate matter was removed 
by centrifugation at 5000 × g for 10 minutes at 4°C. 
4.  The Qiagen Genomic-tips were equilibrated with 10 ml buffer QBT.  The buffer 
QF was incubated at 50°C. 
5.  The lysate was vortexed for 10 seconds and then poured through the equilibrated 
genomic-tip.    If  the  DNA  lysate  was  particularly  concentrated,  then  gentle 
positive pressure was applied to increase the flow rate through the genomic-tip. 
6.  The tip was washed with 15 ml buffer QC.  This was repeated one more time. 
7.  The DNA was eluted with 15 ml buffer QF into a clean Sorvall tube. 
8.  The DNA was precipitated with 10.5 ml isopropranonol and mixed. 
9.  The sample was centrifuged at 10 000 × g for 15 minutes at 4°C to precipitate 
the DNA. 
10. The supernatant was removed and the DNA pellet was washed with 500 µl of 
cold 70 % ethanol.  The sample was then vortexed. 
11. The  DNA  and  ethanol  were  then  pipetted  into  a  fresh  Eppendorf  tube  and 
centrifuged at 13 000 × g for 10 minutes. 
12. The  supernatant  was  removed  and  the  DNA  was  air-dried  at  37°C  for  30 
minutes.  The pellet was re-suspended in 200 µl distilled water and the DNA 
concentration was measured using a spectrophotometer. 
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2.4  Allelic imbalance analysis 
Fluorescently labelled primers were used in a PCR reaction, followed by analysis of the 
fluorescently  labelled  PCR  products  using  an  automated  DNA  sequencer  and 
appropriate  software.    In  this  study,  the  Applied  Biosystems  ABI  PRISM  DNA 
Sequencer was used throughout. 
 
2.4.1  Materials 
2.4.1.1 Polymerase chain reaction (PCR) 
1.  Taq DNA polymerase Amplitaq gold, 5 U/µl supplied with Geneamp 10 times 
PCR buffer II:  150 mmol/l KCl, pH 8.0 (applied Biosystems). 
2.  MgCl2 solution supplied at 25 mmol/l (Applied Biosystems). 
3.  dNTP  mixture  containing  dATP,  dCTP,  dGTP  and  dTTP,  10  mmol/l  each 
(Applied Biosystems). 
4.  Microsatellite primers fluorescently labelled with either 5’-FAM or HEX (Oswel 
DNA service, Southampton, UK). 
5.  DNA samples. 
6.  Sterile water. 
 
2.4.1.2 Sample preparation prior to polyacrylamide gel electrophoresis 
1.  100 % ethanol. 
2.  Glycogen (20mg/ml), molecular biology grade (Roche). 
 
2.4.1.3 Polyacrylamide gel electrophoresis 
1.  Sequagel 6 monomer solution supplied with Sequagel Complete Buffer solution 
(Flowgen).   91 
2.  10  %  ammonium  persulphate  freshly  made  with  distilled  water  as  required 
(Fisher). 
3.  Deionised formamide sample loading buffer: 1 ml deionised formamide, 200 µl 
dextran blue, 50 mmol/l EDTA pH 8.0. 
4.  Genescan  DNA  internal  lane  size  standard  GS500XL  ROX  (Applied 
Biosystems). 
5.  TBE: 21.6 g Tris, 11 g boric acid, 1.69 g EDTA in 2 litres distilled water. 
6.  Glass  plates  for  Applied  Biosystems  ABI  PRISM  373  DNA  Sequencer, 
appropriate  spacers  (0.3  mm),  bulldog  clips,  duck-billed  pipette  tips  and  a 
sharkstooth comb. 
 
2.4.2  Methodology 
2.4.2.1 PCR 
1.  All  PCR  was  performed  under  conditions  designed  to  prevent  cross 
contamination.  Separate areas were designated for pre- and post- PCR and all 
PCR preparation was carried out in PCR hoods with UV sterilisation facilities.  
Equipment  was  kept  separate from  that  used  for  other  techniques  within  the 
laboratory. 
2.  The quantity and recipe for the mastermix required depended on the primer used 
and  the  number  of  samples.    For  each  PCR  run,  the  quantity  (number  of 
samples) + (negative control) + 1 was made.  
3.  The  DNA  samples  and  reagents  were  thawed  at  room  temperature  and 
transferred to wet ice.  The mastermix was made up as above and then vortexed 
briefly in a benchtop centrifuge.  The mastermix was stored on wet ice until use.  
2 µl of each DNA sample was added to the base of a well in a 96 well plate.  The   92 
appropriate amount of mastermix was added to each well and the plate was then 
covered with an adhesive plate sealer.  The plate was centrifuged briefly. 
4.  The  PCR  reactions  were  performed  using  the  protocol:  95°C,  10  minutes,  1 
cycle; 95°C, 45 seconds, Tm, 45 seconds, 72°C, 45 seconds, for a total of 30 
cycles; 72°C, 5 minutes, 1 cycle; 4°C hold.  The annealing temperature (Tm) was 
adjusted  dependant  upon  the  locus  being  amplified  (table  2.4).    The  PCR 
products were stored at -20°C until required. 
 
Table 2.4: Allelic imbalance / shift PCR primer conditions 
Primer 
(chromosome) 
Primer sequence (5’ – 3’)  Tm 
(°C) 
Size 
(bp) 
 
APC 
(5q) 
 
 
ACTCACTCTAGTGATAAATCG 
AGCAGATAAGACAGTATTACTAGTT 
 
55 
 
96-
122 
 
D2S123 
(2p) 
 
 
AAACAGGATGCCTGCCTTTA 
GGACTTTCCACCTATGGGAC 
 
60 
 
197-
227 
 
p53 
(17p) 
 
 
GAATCCGGGAGGAGGAGGTTG 
AACAGCTCCTTTAATGGCAGCGGGAGGAGGTTG 
 
55 
 
140-
175 
 
MfD15CA 
(17q) 
 
 
GGAAGAATCAAATAGACAAT 
GCTGGCATATATATATTTAAACC 
 
52 
 
150 
 
D3S1289 
(3p) 
 
 
AAAGCAACTTGTAAGAGAGCA 
CTCCTAGATATAATCACTGGCA 
 
51 
 
197-
215 
 
D3S1300 
(3p) 
 
 
AGCTCACATTCTAGTCAGCCT 
GCCAATTCCCCAGATG 
 
48 
 
217-
241 
 
D3S1304 
(3p) 
 
TTCGCTCTTTGATAGGC 
ATTTCATTTGTAATTTACTAGCAG 
 
 
47 
 
253-
269 
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2.4.2.2 PCR product preparation 
1.  1 µl of each PCR sample was transferred to another 96 well plate and 0.5 µl 
glycogen, molecular biology grade and 3 µl 100 % ethanol was added to each 
well.  The plate was covered with adhesive film, centrifuged briefly and stored 
at -20°C overnight. 
2.  The following day, the plate was centrifuged at 1500 × g for 10 minutes, then 
the adhesive cover was removed and the samples air-dried for several hours until 
all the ethanol had evaporated. 
3.  Once  dry,  1  µl  deionised  formamide  running  dye  and  0.5  µl  Genescan  size 
standard GS500XL were added to each sample to resuspend the DNA.  The size 
standard is an internal lane marker added to account for lane-to-lane differences 
across  the  gel  during  electrophoresis.    Following  this,  the  samples  were 
denatured at 95°C for 5 minutes and then placed on wet ice prior to gel loading. 
 
2.4.2.3 Polyacrylamide gel electrophoresis 
1.  The glass plates were cleaned so that they were free from dust and the cleaned 
plate  surfaces  were  not  touched.    To  assemble  the  plates,  two  notched  gel 
spacers  were  positioned  on  the  plate  at  each  edge  and  the  second  plate  was 
aligned, ensuring that the edges were flush.  The plates were clamped together 
with bulldog clips. 
2.  40 ml Sequagel 6 monomer solution, 10 ml Sequagel complete buffer and 400 µl 
fresh ammonium persulphate solution were mixed and the gel was cast using a 
50 ml syringe.  The plates were tapped at the same time to ensure no air bubbles 
were trapped between the plates.  A sharkstooth comb was inserted between the 
plates to form a well for loading.  The gel was allowed to set for 2 hours.   94 
3.  All 1.5 µl of the resuspended PCR product (see sections 2.2 and 2.3) was loaded 
into each well using duck-billed pipette tips and electrophoresis was commenced 
for 12 hours at 2500 V. 
4.  The virtual gel produced was analysed using software to compare the size of the 
product bands with known sizes of bands in the internal lane size standard.  The 
electropherograms produced displayed the height of each peak, this being the 
relative amount of each allele present. 
5.  Results were calculated by comparing alleles in tumour/serum DNA with the 
corresponding  alleles  in  lymphocyte  DNA.    The  formula  (n1)(t2)/(n2)(t1)  was 
used  to  calculate  results  for  heterozygous  alleles,  where  n1  =  lymphocyte 
samples  larger  allele,  t2  =  tumour  (serum)  samples  smaller  allele,  n2  = 
lymphocyte samples smaller allele, t1 = tumour (serum) samples larger allele.  In 
this study, allelic imbalance was defined as an imbalance of allele intensities > 
30%, i.e. < 0.7. 
 
Where this calculation could not be performed, for example when the sample 
was homozygous at the locus investigated in the lymphocyte DNA then the PCR 
result was termed as non-informative. 
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2.5  Methylation specific PCR  
Methylation  specific  PCR  is  dependent  upon  modification  of  the  DNA  samples  by 
sodium bisulphite. The purpose of this modification is to deaminate all unmethylated 
cytosines such that they are converted to uracil, whilst the 5-methylcytosines remain 
unchanged, leading to a sequence change between the methylated and unmethylated 
DNA  and  this  is  shown  in  figure  2.1.    This  sequence  change  then  allows  the 
development of specifically designed PCR primers for the different sequences between 
the  originally  methylated  and  unmethylated  DNA.    This  methodology  was  first 
described by Herman (Herman et al., 1996) and is termed methylation specific PCR 
(MSP).  Subsequent PCR products can be further analysed either on an agarose gel or 
by DNA sequencing. 
 
Figure 2.1:  DNA bisulphite modification 
Unmethylated DNA      Methylated DNA 
ggg gcg gac cac g      ggg gc
mg gac
m c
mgc
m g 
             
       bisulphite modification 
 
ggg gug gau ugu c      ggg gc
mg gac
m c
mgc
m g 
 
2.5.1  Materials 
2.5.1.1 DNA Modification 
In this study all modifications performed were done so using the Intergen CpGenome
TM 
DNA Modification kit (Intergen) and is done over 2 days. The exact constituents of the 
reagents supplied with the kit have not been disclosed by Intergen.   96 
The methodology of the modification will be discussed in detail, but in essence day 1 
consists of reagent preparation and commencement of the modification process with 
completion  of  the  modification-taking  place  on day  2.   The  DNA  samples  are then 
stored at -20°C ready for Methylation Specific PCR, the modified samples being stable 
for up 1-month post modification. 
 
Materials supplied with the kit: 
1.  DNA Modification Reagent I:  this contains a sodium salt of the bisulphite ion 
which  causes  unmethylated  cytosines  to  be  sulfonated  and  hydrolytically 
deaminated, yielding a uracil sulfonate intermediate. 
2.  DNA  Modification  Reagent  II:    This  contains  another  salt,  which  acts  with 
Reagent III to bind DNA. 
3.  DNA Modification Reagent III:  This contains a micro-particulate carrier, which 
binds the DNA in the presence of Reagent II. 
4.  DNA Modification Reagent IV:  This improves the yield if the starting sample 
contains less than 1 µg DNA. 
Reagents I, II and IV were stored at -20°C and reagent III at 4°C 
 
Materials not supplied with the kit: 
1.  Water bath incubator set at 37°C and 50°C as appropriate. 
2.  Microcentrifuge. 
3.  PH indicator paper. 
4.  Screwcap centrifuge tubes. 
5.  NaOH pellets. 
6.  70 %, 90 % and 100 % EtOH   97 
7.  β-mercaptoethanol. 
8.  TE Buffer (10mmol/l Tris-HCl; 0.1mmol/l EDTA, pH 7.5). 
 
2.5.1.2 Methylation-Specific PCR 
1.  Taq DNA polymerase FastStart Taq (Roche Diagnostics). 
2.  FastStart Taq buffer (no MgCl2 added) (Roche Diagnostics). 
3.  MgCl2 solution supplied at 25 mmol/l (Applied Biosystems). 
4.  dNTP  mixture  containing  dATP,  dCTP,  dGTP,  10  mmol/l  each  (Applied 
Biosystems). 
5.  Microsatellite primers. 
6.  Template DNA sequences. 
7.  Sterile water. 
8.  In vitro methylated DNA (IVM) (Intergen). 
9.  Genomic human DNA. 
10. Mineral oil. 
 
2.5.1.3 Agarose gel electrophoresis 
1.  Ethidium bromide (10 mg/ml). 
2.  Agarose. 
3.  TBE: 21.6 g Tris, 11 g boric acid, 1.69 g EDTA in 2 litres distilled water. 
4.  123bp DNA ladder (Life Technologies). 
 
2.5.2  Methodology 
The  environment  in  which  modification  and  subsequent  DNA  amplification  is 
performed  is  critical to  achieving  accurate,  reliable  results.    All  modifications  were   98 
therefore carried out in CAT 1 (pre-PCR DNA) facilities. This area is separate from 
both the PCR and post-amplification areas.  All materials such as pipettes, pipette tips 
etc. were separated from other laboratory equipment and all reagents were made freshly 
for each modification procedure.  1 µg of DNA was used for each modification.  If less 
than 1 µg of DNA was available, as near to 1 µg as possible was used and Reagent IV 
added.  The DNA concentration was quantified using a spectrophotometer, with the 
mean of three repeat samples being taken.  Control samples were modified together 
with the samples of interest.  In vitro methylated DNA and distilled water were included 
in each batch of samples to be modified as positive and negative controls respectively.   
 
2.5.2.1 Reagent Preparation 
All reagents were made freshly for each modification procedure. 
1.  DNA Modification Reagent II: 1 µl of B-Mercaptoethanol was added to 20 ml of 
deionised water.  750 µl of this solution and 30 µl of 3mM NaOH was added to 
1.35 g of DNA Modification Reagent II for each sample to be modified.  This 
mixture was then shaken well to ensure complete dissolution. 
2.  3 M NaOH Stock: 1g of NaOH pellets was dissolved in 8.3 ml of water. 
3.  20  mM  NaOH/90% EtOH:  To  prepare  1ml  of this  solution  900  µl  of  100% 
EtOH was combined with 93.4 µl of H2O and 6.6 µl of 3 mM NaOH. 
4.  DNA Modification Reagent I: 571 µl of water was added to 227 mg of DNA 
Modification reagent I for each sample to be modified.  The pH was adjusted to 
5.0 with 30 µl mol/l NaOH. 
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2.5.2.2 DNA Modification Procedure 
In microcentrifuge tubes 
1.  2  µl  of  DNA  Modification  Reagent  IV  was  added  to  each  DNA  sample 
containing less than 1 µg DNA. the total volume was brought up to 100 µl with 
sterile water.  
2.  7.0 µl 3M NaOH was added and mixed. 
3.  Samples were incubated at 37°C for 10 minutes in a waterbath. 
4.  550 µl of freshly prepared DNA Modification Reagent I was then added and 
each sample vortexed. 
5.  Samples were then incubated at 50°C for 16 to 20 hours in a waterbath. 
 
2.5.2.3 Completion of Chemical Modification and DNA Clean-up 
1.  DNA Modification Reagent III was re-suspended by vigorous vortexing. 
2.  5 µl of DNA Modification Reagent III (well-suspended) was added to the DNA 
solutions in each tube. 
3.  750 µl of DNA Modification Reagent II was added to each tube and mixed 
briefly. 
4.  Samples were incubated at room temperature for 10 minutes. 
5.  Samples were then spun at 5000×g to pellet DNA Reagent III.  The supernatant 
was discarded. 
6.  800 µl of 70% EtOH was added to each sample, vortexed and centrifuged at 
5000  ×  g  for  10  seconds.    The  supernatant  was  discarded.    This  step  was 
performed 3 times in total. 
7.  The tubes were then centrifuged at 12000×g for 3 minutes and the remaining 
supernatant removed with a pipette.   100 
8.  50µl 20 mM NaOH/90% EtOH was added to each of the samples. 
9.  The  pellets  were  then  resuspended  by  vortexing  and  the  samples  were  then 
incubated at room temperature for 5 minutes. 
10. The samples were then spun at 5000 × g for 10 seconds to pellet the sample.  
The pellets were then washed by adding 800µl of 90% EtOH and vortexing.  
The samples were spun again at 5000 × g and supernatant removed.  This step 
was repeated once. 
11. After the supernatant from the second wash was removed, the samples were 
centrifuged at 12000×g for 5 minutes. 
12. All  the  remaining  supernatant  was  removed  with  a  pipette  and  40  µl  of  TE 
(10mmol/l Tris/EDTA, pH 7.5) added.  The pellet was resuspended by vortexing 
again. 
13. The samples were incubated for 15 minutes at 55°C in order to elute the DNA. 
14. The  samples  were  then  centrifuged  at  12000  ×  g  for  3  minutes  and  the 
supernatant (modified DNA) transferred to a new-labelled tube prior to PCR. 
15. Samples  then  stored  at  -20°C  for  up  to  2  months  and  used  for  Methylation 
Specific PCR 
 
2.5.2.4 Methylation Specific PCR (MSP) 
1.  Methylation-specific PCR was performed in a similar manner to conventional 
PCR  with  standard  precautions  taken  to  prevent  contamination.    PCR  was 
performed  in  dedicated  hoods  with  dedicated  pipettes,  pipette  tips  and  PCR 
tubes.   101 
2.  The quantity and recipe for the PCR mastermix required depended upon the 
primer being used and the number of samples.  The quantity made for each PCR 
run was (number of samples) + (negative control) + 1. 
3.  Initially, optimal PCR conditions for each primer were determined using in vitro 
methylated bisulphite modified DNA (IVM) as a positive control and genomic 
(lymphocyte)  DNA  as  a  negative  control.    The  annealing  temperature  and 
magnesium concentrations were varied using a gradient block cycler until the 
optimal conditions were obtained.  Optimal conditions were then tested on a 
panel  of  positive  and  negative  samples,  together  with  IVM  DNA,  genomic 
DNA,  unmodified  DNA  and  distilled  water  as  controls.    Once  the  optimal 
conditions  were  confirmed,  the  same  PCR  block  was  used  for  all  the  PCR 
reactions performed with that primer. 
4.  Initially, the success of a modification was confirmed by a PCR reaction using a 
primer specific for unmethylated DNA, such as GAPDH.  With such a primer, 
all  modified  samples  should  give  a  positive  band  using  agarose  gel 
electrophoresis but unmodified samples should be negative.  Subsequently, the 
samples were amplified using primers specific for methylated DNA at the loci 
being analysed. 
5.  The  DNA  samples  and  reagents  were  thawed  at  room  temperature  and  then 
transferred to wet ice.  The recipe for each PCR reaction was a 25 µl reaction 
volume containing 1 µl modified template DNA, 1 × PCR buffer, 0.1 mmol/l 
dNTPs,  0.5  µl  each  forward  and  reverse  primer,  1  U  FastStart  Taq  DNA 
polymerase and varying magnesium concentrations for each primer, as shown in 
table 2.5, each sample was overlaid with 1 drop of mineral oil.   102 
6.  PCR reactions were performed using the protocol: 95°6 minutes, I cycle; 95°C, 
30 seconds, Tm 30 seconds, for a total of 35 cycles; 72°C, 5 minutes, 1 cycle; 
4°C, hold.  Specific PCR conditions for each primer are given in table 2.5. 
 
2.5.2.5 Agarose gel electrophoresis 
1.  Following methylation-specific PCR, products were separated on a standard 2 % 
agarose  gel.    2  g  agarose  was  added  to  100  ml  1  %  TBE  and  this  was 
microwaved  on  high  power  for  1  minute.    To  visualise  the  products,  30  µl 
ethidium bromide (10mg/ml) was added before pouring the gel. 
2.  1 µl loading dye was added to 5 µl PCR product and this was then loaded into 
each well.  Appropriate size DNA ladders were used to determine the product 
size. 
3.  PCR products were visualised using the Bio-Rad Gel Documentation system.  
IVM  DNA  showing  a  positive  signal.    Modified  and  unmodified  human 
(lymphocyte)  DNA  and  water  should  show  a  negative  or  a  very  low  signal.  
Samples were scored positive if the PCR signal was approximately equivalent to 
IVM (score 3), intermediate if equal to IVM 1:5 dilution (score 2), weak if equal 
to IVM 1:25 dilution (score 1) and negative if no signal or equivalent to human 
(lymphocyte) DNA (score 0).  Samples were deemed positive if score 2 or 3 was 
obtained in two separate PCR reactions. 
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Table 2.5: Methylation-specific PCR primer conditions 
Primer  Primer sequence 
5’ 3’ 
F: 
R: 
Tm 
(°C) 
Magnesium 
Conc. 
(mmol/l) 
Product 
size  
(bp) 
 
hMLH1 
 
ACGTAGACGTTTTATTAGGGTCGC 
CCTCATCGTAACTACCCGCG 
 
 
64 
 
2 
 
115 
 
P16 
 
TTATTAGAGGGTGGGGCGGATCGC 
CCACCTAAATCGACCTCCGACCG 
 
 
65 
 
 
2 
 
234 
 
DAPK 
 
GGATAGTCGGATCGAGTTAACGTC 
CCCTCCCAAACGCCGA 
 
 
64 
 
 
2 
 
98 
 
TIMP-3 
 
CGTTTCGTTATTTTTTGTTTTCGGTTTC 
CCGAAAACCCCGCCTCG 
 
 
59 
 
3 
 
116 
 
HIC-1 
 
TTCGGGTTAGGGTCGTAGTC 
CTAACCGAAAACTATCAACCCTCG 
 
 
57 
 
2.5 
 
243 
 
MINT 25 
 
GCGAAAGCGAAAGTCGTT 
CCCAACGCACATAACGAACC 
 
 
57 
 
3 
 
213 
 
MINT 31 
 
AGGGTAATTAGGGAGACGAC 
AAAACGCTTACGCCACTACG 
 
 
58 
 
2 
 
252 
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3.  The role of MMR proteins as a marker of prognosis in 
patients with NSCLC 
 
3.1    Introduction 
In the UK, approximately 80% of patients with NSCLC present in the UK with locally 
advanced or incurable metastatic disease. Moreover approximately 50% of patients with 
surgically  resected  disease  will  develop  tumour  recurrence.    There  is  a  clearly 
established role for chemotherapy in all stages of NSCLC (Non-small cell lung cancer 
collaboration group, 1995, Arriagada et al., 2004).  Other than the recently reported 
studies  of  ERCC1  (Simon  et  al.,  2005,  Olaussen  et  al.,  2006)  there  is  limited 
information on potential molecular markers of response to chemotherapy and survival in 
patients with NSCLC.  The markers studied were the mismatch repair proteins MLH1 
and MSH2 as well as p53 and the marker of proliferation Ki67. 
 
The objectives of this study in 2 distinct cohorts of patients were therefore to address 
the following questions: 
 
•  Does  the  level  of  expression  of  a  panel  of  molecular  markers  correlate  with 
prognosis in patients with NSCLC? 
•  Does  the  level  of  expression  of  these  markers  correlate  with  other 
clinicopathological variables? 
•  Can small diagnostic bronchial biopsies be used to study this panel of molecular 
markers?   105 
•  Does  neoadjuvant  chemotherapy  alter  expression  levels  of  the  molecular 
markers and has this any affect on overall survival? 
•  Can these molecular markers help to predict in advance treatment response to 
platinum versus non-platinum containing chemotherapy? 
 
3.2    Patients 
Patient samples within this study came from 2 distinct groups: 
 
Group 1: 
Archived paraffin blocks of tissue taken at the time of diagnostic bronchoscopy in 67 
patients were obtained.  All of these patients had received chemotherapy as first line 
treatment for their NSCLC between 1995 and 2000 at Stobhill Hospital in Glasgow. 
Clinical  data  including  histology  and  stage  was  available  for  all  these  patients  and 
thirty-six were male.  Mean age for all patients was 65.9 years (range 44 – 78 years).  A 
summary of patient characteristics and clinicopathological data obtained from a review 
of the patient case notes as well as the pathology reports taken from the time of the 
diagnostic bronchoscopy is given in table 3.1. 
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Table 3.1:  Patient characteristics – The Stobhill Bronchoscopy Population 
Patient characteristics  Cisplatin based 
chemotherapy (n = 45) 
Non-Cisplatin based 
chemotherapy (n = 22) 
Sex 
Male 
Female 
 
27 
18 
 
9 
13 
Age 
Range 
Mean 
 
44 – 83 
64.3 
 
56 – 78 
65.9 
Performance Status 
0 
1 
2 
Not documented 
 
1 
34 
7 
3 
 
0 
12 
10 
0 
Histology 
Squamous 
Adenocarcinoma 
NSCLC – not specified 
Large cell 
Undifferentiated 
 
19 
6 
16 
3 
1 
 
11 
3 
6 
1 
1 
Stage 
I/II 
III 
IV 
Not documented 
 
5 
22 
12 
6 
 
2 
12 
4 
4 
Chemotherapy regimes   
MVP (35) 
gemcitabine/cisplatin (10) 
 
ifosfamide (15) 
gemcitabine (7) 
Survival 
median (months) 
range 
 
9 
0.5 - 38 
 
 
10 
2 - 28 
 
 
Group 2: 
Archived paraffin embedded tumour samples were collected retrospectively from 50 
patients who had undergone surgical resection of their tumour between 1996 and 2000.  
All patients were treated at Aberdeen Royal Infirmary and of this group 10 had received 
neo-adjuvant  cisplatin  based  chemotherapy  (prior  to  surgery).    In  addition  to  the 
paraffin embedded samples, fresh frozen tumour and normal lung samples were also 
collected  from  this  cohort  of  50  patients  at  time  of  surgery  and  frozen  for  future   107 
analysis. Thirty-eight were male and the mean age for all patients was 65 years (range 
46  –  80  years).  A  summary  of  patient  characteristics  is  given  in  table  3.2.    Again 
clinicopathological data was collected from a review of the patient case notes as well as 
the pathology reports taken from the time of the surgery. 
 
Table 3.2:  Patient characteristics – The ARI Surgical Cohort 
Patient characteristics  Surgery alone (n = 40)  Neoadjuvant  cisplatin 
chemotherapy + surgery 
(n = 10) 
Sex 
Male 
Female 
 
33 
7 
 
5 
5 
Age 
Range 
Mean 
 
49 – 79 
65.5 
 
43 – 73 
59.7 
Histology 
Squamous 
Adenocarcinoma 
NSCLC – not specified 
Large cell 
Undifferentiated 
 
32 
0 
8 
0 
0 
 
5 
3 
2 
0 
0 
Stage 
I 
II 
III 
IV 
Not documented 
 
15 
16 
7 
1 
1 
 
2 
3 
3 
0 
2 
Survival 
Median (months) 
Range 
 
 
42 
1 - 63 
 
23 
1 - 58 
 
 
3.3    Methods 
Ethical approval for this study was obtained through local Ethics committees in both 
Glasgow and Aberdeen.  Immunohistochemical studies were performed as described in 
detail in chapter 2.1.  Two individuals as described in chapter 2.1.2.3 scored sections   108 
from the bronchoscopy cohort independently.  Statistical analysis was performed using 
Statistical Package for the Social Sciences (SPSS).  
 
3.4  Results 
3.4.1  Inter-observer variability 
Table  3.3  shows  inter-observer  Kappa  scores  for  the  proteins  analysed  in  group  1 
patients.    This  confirms  good  correlation  between  the  2  observers  for 
immunohistochemistry  scoring  with  only  1  comparative  result  less  than  0.4.   These 
results confirm a close correlation between the 2 observers. 
 
Table 3.3:  Inter-observer Kappa scores for proteins analysed 
Protein  Kappa score  Standard Error  Number of valid samples 
MLH1 
Intensity 
Percentage 
IHC score 
 
0.5233 
0.6386 
0.6062 
 
0.0694 
0.0658 
0.059 
 
61 
MSH2 
Intensity 
Percentage 
IHC score 
 
0.4242 
0.3852 
0.4313 
 
0.0748 
0.0908 
0.0718 
 
57 
pP53 
Intensity 
Percentage 
IHC score 
 
0.5966 
0.4942 
0.591 
 
0.0703 
0.0781 
0.0679 
 
60 
 
 
3.4.2  Correlation of protein expression with overall survival 
Possible  correlation  between  IHC  score  and  overall  survival  was  evaluated  in  both 
cohorts of patient.  The univariate examination of this association was made using Cox 
regression analysis.  Table 3.4 shows a summary of these results for group 1 patients. 
No  correlation  between  the  IHC  score from  any  of  the  proteins  studied  and  overall 
survival was demonstrated in this cohort of patients.      109 
Possible correlation between IHC score and overall survival between those patients in 
group  1  who  had  cisplatin  based  chemotherapy  versus  those  that  had  non-cisplatin 
based chemotherapy were also evaluated and these results are tabulated in table 3.5.  No 
correlation between the IHC score and overall survival was demonstrated in either the 
group that had platinum based chemotherapy or the group that received non-platinum 
based chemotherapy. 
 
Table 3.4:  Correlation  between  IHC  scores  and  overall  survival  in 
bronchoscopic  samples (Group 1) 
Protein  p-value  Standard Error  Number of valid samples 
MLH1  0.554  0.04  67 
MSH2  0.121  0.044  67 
p53  0.121  0.039  66 
 
 
Table 3.5:  Correlation between IHC score, chemotherapy regime and overall 
survival in bronchoscopic samples (Group 1) 
Protein  p-value  Standard Error  Number of valid samples 
MLH1 
Cisplatin 
Non-cisplatin 
 
0.539 
0.913 
 
0.056 
0.081 
 
43 
22 
MSH2 
Cisplatin 
Non-Cisplatin 
 
0.183 
0.913 
 
0.057 
0.076 
 
43 
22 
p53 
Cisplatin 
Non-cisplatin 
 
0.576 
0.062 
 
0.046 
0.078 
 
42 
22 
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Table 3.6 shows a summary of these results for the group 2 patients. No correlation 
between  the  IHC  score  from  any  of  the  proteins  studied  and  overall  survival  was 
demonstrated in this cohort of patients.    
Possible correlation between IHC score and overall survival between those patients in 
group 2 who had cisplatin based chemotherapy preoperatively versus those that had 
surgery  alone  were  also  evaluated  and  these  results  are  tabulated  in  table  3.7.    No 
correlation between the IHC score and overall survival was demonstrated in either the 
group that had platinum based chemotherapy preoperatively or the group that underwent 
surgery alone. 
 
Table 3.6:  Correlation  between  IHC  scores  and  survival  in  surgical  samples 
(Group 2) 
Protein  p-value  Standard Error  Number of valid samples 
MLH1  0.308  0.052  50 
MSH2  0.154  0.065  50 
p53  0.497  0.046  50 
Ki67  0.968  0.070  50 
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Table 3.7:  Correlation between IHC score, chemotherapy regime and overall 
survival in surgical samples (Group 2) 
Protein  p-value  Standard Error  Number of valid samples 
MLH1 
no chemotherapy 
chemotherapy 
 
0.428 
0.632 
 
0.054 
0.187 
 
40 
10 
MSH2 
no chemotherapy 
chemotherapy 
 
0.161 
0.986 
 
0.073 
0.143 
 
40 
10 
p53 
no chemotherapy 
chemotherapy 
 
0.553 
0.886 
 
0.052 
0.107 
 
40 
10 
Ki67 
No chemotherapy 
chemotherapy 
 
0.935 
0.661 
 
0.080 
0.260 
 
40 
10 
   
 
3.4.3  Correlation of protein expression with tumour histology and stage  
Possible  correlation  between  protein  expression  and  either  histological  subtype  or 
tumour stage in both bronchoscopic and surgical samples was investigated by Kruskal-
Wallis test. This failed to demonstrate any relationship between IHC score for any of 
the  proteins  examined  and  histological  subtype  or  tumour  stage  in  both  cohorts  of 
patients. 
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3.5    Discussion 
Group 1: 
Sixty-seven archived paraffin embedded samples were obtained from 67 patients who 
received chemotherapy for NSCLC at Stobhill Hospital, Glasgow between 1995 and 
2000. This represents 60.9% (67/110) of all patients who received chemotherapy for 
NSCLC over the same time period.  Difficulties in obtaining bronchoscopic samples 
from all of these 110 patients related to the fact that the local pathology department was 
in  the  process  of  relocating  making  tracing  of  the  samples  difficult.    Moreover  the 
storage facilities for some of the older archived samples had been affected by damp and 
subsequent  mould,  rendering  the  samples  unsuitable  for  analysis.    Despite  these 
difficulties 67 of 110 samples were obtained, processed and analysed. 
 
The pathology reports indicated a diagnosis of NSCLC in 22 of 67 (32.8%) of these 
samples  with  no  further  subclassification  possible.  This  is  unfortunate  as  there  are 
separate pathways for tumour initiation and progression for squamous cell carcinoma 
and adenocarcinoma.  These two histological subtypes account for the vast majority of 
NSCLC and without accurate histological diagnosis potentially significant differences 
in molecular markers between these two sub-types may be masked. 
 
A broad range of chemotherapeutic agents and regimens were used in this cohort of 
patients.  This relates to the fact that during the study time period (1995 – 2000) the use 
of chemotherapy in NSCLC was growing and the significant role of cisplatin as an 
important cytotoxic drug in NSCLC was being established (Non-small cell lung cancer 
collaboration group, 1995).  Moreover new drugs were being introduced over the time   113 
period (e.g. gemcitabine).   In this study 22.4% (15/67) patients received single agent 
ifosfamide as part of a clinical study ongoing at the time of their treatment. 
 
In  retrospective  studies  it  is  often  difficult  to  collect  accurate  data  on  the  patient 
population, which is dependant on the quality of the records kept for the patients in 
relation to disease extent, stage, detailed pathology and treatment.  This was the case in 
this patient cohort where stage was documented for only 57 of 67 (85.1%) patients in 
the study population. Moreover 7 patients (10.4%) were documented as having stage 1 
or 2 disease and patients with such early stage disease would usually be regarded as 
potentially radically treatable by means of either surgery or radical radiotherapy. Ten 
patients (14.9%) had no stage documented.  
 
Within  the  sample  population  the  majority  of  patients  had  Performance  Status  (PS) 
documented and the majority were of PS 0 – 2.  This finding demonstrates that patients 
who need to be fit enough for chemotherapy to treat their NSCLC had this important 
prognostic indicator considered when planning their treatment.  Only 3 patients had no 
record of their PS documented.  
 
Group 2: 
The number of patients undergoing resection for NSCLC in Scotland remains low with 
an average resection rate of 10.7% (Gregor et al., 2001).  
 
At  the  time  that  this  research  project  was  carried  out  there  were  national  concerns 
pertaining to the ownership of tissue samples as well as retained organs in pathology 
departments and this severely limited our ability to obtain fresh tissue prospectively.  In   114 
the past it had not been felt necessary to ask patients or relatives for their consent for 
research  to  be  carried  out  on  tissue  removed  as  part  of  their  surgical  procedure.  
National guidelines regarding consent and use of tissue and organs for research have 
now been published (Human Tissue Act, 2004). 
 
On account of the insurmountable problems (logistical as well as ethical) in relation to 
obtaining fresh tumour prospectively, we studied previously collected and banked fresh 
frozen surgical samples. We obtained samples retrospectively from patients who had 
lung cancer resection surgery in Aberdeen Royal Infirmary.  The local ethics committee 
approved the collection and use of these samples without requiring the patients or the 
relatives of the patients to be informed as it was felt that the research would have no 
bearing on the future health or treatment options of these individuals.  All patients were 
deceased at the time of this study-taking place. 
 
 The Pathology department in Aberdeen at the time had a particular interest in studying 
primary adenocarcinoma of the lung.  Thus the primary adenocarcinoma samples had 
already been studied in other research projects and as a consequence the tissue collected 
for this study was predominantly primary squamous cell carcinoma of the lung (n=37, 
74%). 
 
Within this group there were patients that were pathologically staged as having stage III 
disease (10 patients, 20%) and stage IV in 1 patient (2%).  Three of the stage III patients 
had preoperative chemotherapy whilst 7 (14%) of these patients had no neoadjuvant 
chemotherapy and there is no record of adjuvant therapy having been given.  These 7   115 
patients  were  presumably  clinically  under-staged  as  currently  in  the  UK  operative 
therapy for stage III disease is limited to the context of a clinical trial. 
 
Within this cohort the PS of the patient was not documented but it is assumed that the 
majority if not all the patients will have had a PS less than 2 to be considered medically 
fit for thoracotomy. 
 
With regard to immunohistochemical scoring several methods of scoring both intensity 
(I-score) and percentage of cells scored (%-score) have been described and the area 
remains  controversial  with  different  authors  using  various  methods  to  calculate  the 
overall score.  Some authors use the ‘H-score’ (McClelland et al., 1990), which gives a 
result  between  0  and  300  using  a  complicated  calculation;  (%  of  cells  stained  at 
intensity 1 × 1) + (% of cells stained at intensity 2 × 2) + (% of cell stained at intensity 3 
× 3), where the intensity score is defined as in table 2.2. 
 
However, it has been demonstrated that more simple calculations produce comparable 
results.  In one study (Detre et al., 1995), it was found that similar results could be 
obtained  with  either  an  additive  (I  +  %)  ‘quickscore’  or  a  multiplicative  (I  x  %) 
‘quickscore’, where the I-score and the %-score are defined as in tables 2.2 and 2.3 
respectively.  Importantly scoring took one quarter of the time when compared with the 
H-score technique.  
 
The use of an immunohistochemistry ‘quickscore’ for calculating both intensity and 
percentage of cells stained is well established (Kinsel et al., 1989) and Dr. M. Mackean 
(Centre  for  Oncology  and  Applied  Pharmacology,  University  of  Glasgow)  has   116 
previously validated the multiplicative ‘quickscore’ technique.  Using this technique, 
Dr. Mackean has also shown that it is possible to achieve a high level of correlation in 
inter-observer, intra-observer and intra-slide scores and therefore this scoring method 
was used in the current study.  
 
There remains a paucity of data regarding possible correlations between the level of 
mismatch  repair  expression  and  clinicopathological  variables  in  patients  with  lung 
cancer.   Moreover the studies that have been performed in lung cancer also used the 
different  scoring  techniques  described  above,  and  this  makes  interpretation  and 
comparison of study results difficult.    
 
A  study  by  Xinarianos  et  al  demonstrated  a  correlation  between  reduced  MLH1 
expression levels and the presence of nodal metastases in surgically resected primary 
squamous  cell  carcinoma  of  lung  but  not  adenocarcinoma  (Xinarianos  et  al.,  2000). 
Brooks et al reported that reduced expression of MSH2 correlated with a poor overall 
survival  in  a  cohort  of  patients  where  the  nodal  tissue  examined  was  obtained  at 
mediastinoscopy (Brooks et al., 2003).  This study also demonstrated that an intense 
level  of  p53  expression  correlated  with  a  poor  overall  survival.    In  this  study 
immunohistochemistry was measured using a semiquantative scale where it was the 
percentage  of  cells  staining  rather  than  the  intensity  that  constituted  the  positive  or 
negative  score  for  protein  expression.  A  study  by  Skarda  et  al  demonstrated  no 
correlation between mismatch repair protein expression (MLH1 and MSH2) and either 
disease free or overall survival in a cohort of patients where the study samples were 
taken at time of surgery (Skarda et al., 2006). 
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Nonetheless all of the studies described above demonstrate the potential importance of 
examining  molecular  markers  and  were  all  carried  out  on  either  surgically  resected 
samples or samples taken at mediastinoscopy.  It would be of significant advantage to 
have prognostic information obtained from examination of the diagnostic sample. In the 
majority  of  patients  this  means  examining  diagnostic  tissue  taken  at  time  of 
bronchoscopy. Thus it is important to validate studies in bronchoscopic specimens and 
this is what we attempted to do in Group 1 patients.  The bronchoscopy samples used in 
this study were truly representative of the tissue available for study by the pathologists 
having been used to obtain the initial diagnosis of lung cancer.   
 
The  principle  question  in  these  2  cohorts  of  patients  was  does  a  correlation  exist 
between a panel of molecular markers and prognosis in patients with NSCLC?  
  
In  our  study  of  samples  taken  at  both  the  time  of  diagnostic  bronchoscopy  (patient 
group 1) and at surgery (patient group 2) there was no correlation demonstrated between 
MMR protein expression and survival (tables 3.4 and 3.6) in keeping with the study 
performed by Skarda (Skarda et al., 2006).  However our results conflict those reported 
by Brooks (Brooks et al., 2003).  
 
An obvious criticism of using bronchoscopic samples is the relatively small size of the 
tissue sample, often with only a few cells present, and an example of this is that we 
were unable to study the expression of Ki67 in these bronchoscopic samples due to lack 
of tissue.   Despite small sample size good correlation between independent observers 
was  demonstrated  (table  3.1)  when  scoring  the  immunohistochemistry  samples.  
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counting the percentage of cells is integral to the IHC score and there is the potential for 
bias dependant on the number of cells present in any given sample.  In an attempt to 
confirm our findings in relation to immunohistochemistry in the bronchoscopic cohort 
of patients (group 1) we repeated the study, in the cohort of patients (group 2) where 
surgical samples were studied. In this latter study the expression levels of a panel of 
molecular markers and lack of correlation with clinicopathological variables were found 
to  be  the  same.   Figure  3.1  shows  staining  for each  protein  demonstrating  the  size 
difference between bronchoscopy and surgical obtained samples.   
 
This does not confirm that there was no bias present in the bronchoscopy study. In a 
study  by  Taillade  et  al  comparison  was  made  between  the  immunohistochemical 
expression  of  5  markers  (EGFR,  Ki67,  ERCC1,  phospho-Akt  and  hTERT)  in  both 
bronchoscopy samples and resected surgical samples from the same patient (Taillade et 
al., 2007). In the case of Ki67, ERCC1 and hTERT there was significant correlation 
between the bronchial biopsies and corresponding surgical sample (0.64 [p < 0.0001], 
0.83 [p < 0.0001] and 0.55 [p < 0.001] respectively) but poor correlation for the markers 
EGFR  and  phospho-Akt  (0.24  [p  =  0.17]  and  0.29  [p  =  0.09]  respectively), 
demonstrating that for certain previously validated markers the use of the bronchoscopy 
samples is a valid and important study method, when the number of patients undergoing 
resection for NSCLC in Scotland remains low with an average resection rate of 10.7% 
(Gregor et al., 2001). 
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Figure  3.1:  IHC  staining  for  individual  proteins;  bronchoscopy  and  surgical 
samples 
MLH1 
       
bronchoscopy           surgical 
 
MSH2 
       
bronchoscopy           surgical 
 
p53 
       
bronchoscopy           surgical 
All sections photographed at low power.   120 
At  the  time  of  this  research  project  the  role  of  neoadjuvant  chemotherapy  was  the 
subject of intense interest in patients with NSCLC.  In this study we also examined if 
there was any difference between MLH1 expression levels in those samples obtained 
from patients treated with chemotherapy pre-operatively and those samples obtained 
from patients that had surgery alone and if these were predictive of any differences seen 
in relation to overall survival.  Previously published work by Mackay et al in breast 
cancer demonstrated a reduction in MLH1 expression in tumour samples obtained from 
patients who had been treated with preoperative chemotherapy.   This reduced MLH1 
expression correlated with a poor disease free survival (Mackay et al., 2000).   
 
We demonstrated in the surgical cohort of patients (group 2) no difference in expression 
level of MLH1 (IHC score) and no survival difference between those patients that had 
preoperative chemotherapy versus those that underwent surgery alone.   This was also 
the case for MSH2 and p53.  These findings are similar to those reported in a recent 
study by Skarda et al which also described no difference in expression levels of MLH1 
or  MSH2  and  survival,  irrespective  of  treatment  with  preoperative  platinum  based 
chemotherapy or not (Skarda et al., 2006).   
 
A further objective of this study was to evaluate the role of the mismatch repair proteins 
(MLH1  and  MSH2)  as  well  as  p53  in  treatment  naive  patients  diagnosed  at 
bronchoscopy who proceeded to have either platinum based or non-platinum containing 
chemotherapy  (Group  1).      The  hypothesis  being  is  there  reduced  level  of  MMR 
expression (IHC score) pre-treatment and if so does this reduced expression level allow 
you to predict chemotherapy response to chemotherapy and overall survival.  If this is   121 
the case it opens the possibility in the future to tailor chemotherapy regimes dependant 
on molecular markers. 
 
In our study we demonstrated no difference in survival rates when correlated with level 
of protein expression and chemotherapy regime (table 3.5, group 1).  
 
The only other published study that has examined protein expression in chemonaive 
patients before going on to receive chemotherapy was the study by Brooks et al.  In this 
study there were 2 distinct treatment groups. The first received single agent vinorelbine 
chemotherapy  plus  concurrent  radiotherapy.  The  second  group  were  treated  with 
vinorelbine plus carboplatin and concurrent radiotherapy.  In this study patients with a 
reduced expression of the mismatch repair protein MSH2 had a significantly reduce 
response to therapy and a worse cancer-free and overall survival (Brooks et al., 2003).  
However it is not clear whether the significantly reduced response to therapy relates to 
chemotherapy or radiotherapy or both. 
 
In summary the results of this study do not support the findings from other studies that 
demonstrate the potential role of a panel of molecular markers in predicting response to 
treatments  as  well  as  important  prognostic  information.    However  it  is  clear  when 
comparing  all  these  studies  that  there  is  no  well  defined  mechanism  for  scoring  in 
immunohistochemistry studies making direct comparison often difficult in addition to 
all of the studies evaluation samples taken form different sites at differing points in their 
cancer management journey.   
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Future studies should centre on the collection and prospective study of a large panel of 
molecular  markers  using  diagnostic  samples  collected  pre-treatment.  These  results 
should be correlated with a variety of clinicopathological variables, including response 
to chemotherapy, the majority of which will still be platinum based in the UK and most 
importantly survival.   
 
In addition a large prospective study where the primary objective is to correlate the 
findings in small samples such as bronchoscopy biopsies with larger surgical samples to 
confirm the study by Taillade et al is required (Taillade et al., 2007).   
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4.  A study into CpG Island methylation status and its role 
as a marker of prognosis in patients with NSCLC 
 
4.1    Introduction 
Methylation  is  known  to  be  an  important  epigenetic  mechanism  leading  to  gene 
suppression (Jones and Laird, 1999).  Studies indicate that there may be concordant 
patterns  of  methylation  present  in  certain  tumour  types  including  ovarian  cancer 
(Strathdee et al., 2001a), prostate cancer (Jeronimo et al., 2004), gastric cancer (Toyota 
et al., 1999a) and gallbladder cancer (Roa et al., 2006).  In each of these studies the 
number of loci examined and the endpoints assessed have varied, from early molecular 
detection in prostate cancer to survival in the study of gallbladder cancer.  A recent 
paper by Park et al has demonstrated distinct methylation patterns (13 loci studied) in 9 
common cancers (lung, breast, prostate, larynx, liver, colon, stomach and cervix) but 
did not report any significant correlations with clinicopathological data and methylation 
profile (Park et al., 2007). 
 
In  the  case  of  lung  cancer  there  have  been  a  number  of  studies  investigating  the 
methylation profiles of both NSCLC and SCLC (Safar et al., 2005, Toyooka et al., 
2001), but the clinical relevance of these methylation profiles remains unclear. This 
includes possible use of methylation profiles to predict response to specific cytotoxics 
drugs.  
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The objectives of this study were therefore to try and answer the following questions: 
 
•  Does the methylation profile in NSCLC correlate with overall survival? 
•  Does  the  methylation  profile  correlate  with  any  other  clinicopathological 
variables? 
•  Is there any difference in survival between patients who have had neoadjuvant 
chemotherapy plus surgery versus patients who had surgery alone in relation to 
the methylation profile of the tumour sample? 
 
4.2    Methods 
Ethical  approval  for  this  study  was  obtained  from  the  local  Ethics  committee  in 
Aberdeen. The patient population was the same as that described in chapter 3, group 2 
and their clinicopathological data is shown in table 3.2.  Methylation Specific PCR 
(MSP) was performed as described in detail, chapter 2.5 with DNA extracted from the 
cancer and normal lung sample as per the protocol described in chapter 2.3. Statistical 
analysis was performed using SPSS.  
 
The  methylation  profile  of  these  50  tumours  was  analysed  using  8  gene  promoter 
regions.    Using  methylation-specific  PCR  the  primers  analysed  were  MLH1,  p16, 
DAPK, TIMP3, HIC1, MINT 25, MINT 31 and RASSF1A (the MSP for RASSF1A 
gene promoter region was carried out by another student in the lab). 
 
The  methylation  status  of  the  same  8  gene  promoter  loci  were  analysed  in  normal 
adjacent lung removed at the time of the cancer resection. 
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4.3  Results 
Of these 50 samples the mean DNA concentration from the tumour samples was 145.8 
µg/ml (range 23 – 673) and for normal lung 88.1 µg/ml (range 0 – 242).  MSP was 
successfully performed on all.  All patients had died at the time of analysis and so 
definitive survival data is available for all patients.  Results for the MSP carried out on 
the tumour samples are shown in table 4.1.  The results of MSP in adjacent normal lung 
are shown in table 4.2.  In tables 4.1 and 4.2 the presence of methylation is indicated by 
an X and no evidence of methylation with a 0. Table 4.3 summarises the methylation at 
each locus in both tumour and normal tissue. 
 
Table 4.1:  Methylation status of lung cancer samples at eight loci 
Primer  hMLH1  p16  DAPK  TIMP3  HIC1  MINT25  MINT31  RASSF1A 
1  0  0  0  0  0  0  0  X 
2  0  X  0  0  0  0  0  0 
3  0  0  0  0  X  0  X  0 
4  0  0  0  0  0  0  0  X 
5  0  0  0  0  0  0  X  0 
6  0  0  0  0  0  0  0  0 
7  0  0  0  0  0  0  0  0 
8  0  0  0  0  0  0  X  0 
9  0  0  0  0  0  0  0  0 
10  0  0  0  0  0  0  0  X 
11  0  X  0  0  0  0  0  0 
12  0  0  0  0  0  0  0  0 
13  0  0  0  0  X  0  0  0 
14  0  0  0  0  0  0  0  X 
15  0  X  X  0  0  0  X  X 
16  0  0  0  0  0  0  0  0 
17  0  0  0  0  0  0  0  X 
18  X  0  0  0  0  X  X  X 
19  0  0  0  0  0  0  0  0 
20  0  X  0  0  0  0  0  0 
21  0  0  0  0  0  0  0  0 
22  0  0  0  0  0  0  0  X 
23  0  0  0  0  0  0  0  0 
24  0  0  0  0  0  0  0  0 
25  0  X  X  0  0  0  X  X   126 
26  0  X  0  0  X  0  X  X 
27  0  X  0  0  X  X  0  0 
28  0  X  X  0  0  0  0  0 
29  0  X  0  0  0  0  0  0 
30  0  0  0  0  0  0  0  0 
31  0  0  0  0  0  0  X  0 
32  0  X  0  0  0  0  0  X 
33  0  X  0  0  0  0  0  0 
34  0  0  X  0  0  0  0  0 
35  0  0  0  0  0  0  0  0 
36  0  X  0  0  0  0  0  0 
37  0  0  0  0  0  0  0  0 
38  0  X  0  0  0  0  X  X 
39  0  X  X  0  0  0  0  0 
40  0  0  0  0  0  0  0  0 
41  0  0  0  0  X  0  0  0 
42  0  0  0  0  0  0  0  0 
43  0  0  0  0  0  0  0  0 
44  0  0  0  0  0  0  0  0 
45  0  0  0  0  0  0  0  0 
46  0  0  0  0  0  0  0  0 
47  0  0  0  0  0  0  X  0 
48  0  0  0  0  0  0  0  0 
49  0  0  0  0  0  0  0  0 
50  0  0  X  0  0  0  0  X 
 
 
Table 4.2:  Methylated and unmethylated normal lung samples at eight loci 
Primer  hMLH1  p16  DAPK  TIMP3  HIC1  MINT25  MINT31  RASSF1A 
1  0  0  0  0  0  0  0  0 
2  0  0  0  0  0  0  0  0 
3  0  0  0  0  X  0  0  0 
4  0  0  0  0  0  0  0  0 
5  0  0  0  0  0  0  0  X 
6  0  0  0  0  0  0  0  0 
7  0  0  0  0  0  0  0  0 
8  0  0  0  0  0  0  0  0 
9  0  0  0  0  0  0  0  0 
10  0  0  0  0  0  0  0  0 
11  0  0  0  0  0  0  0  0 
12  0  0  0  0  0  0  0  0 
13  0  0  0  0  0  0  0  0 
14  0  0  0  0  0  0  0  0 
15  0  0  0  0  0  0  0  0 
16  0  0  0  0  0  0  0  0   127 
17  0  0  0  0  0  0  0  0 
18  0  0  0  0  0  0  0  0 
19  0  0  0  0  0  0  0  0 
20  0  0  0  0  0  0  0  0 
21  0  X  0  0  0  0  0  0 
22  0  0  0  0  0  0  0  0 
23  0  X  0  0  0  0  0  0 
24  0  0  0  0  0  0  0  0 
25  0  X  0  0  0  0  0  0 
26  0  0  0  0  0  0  0  0 
27  0  X  0  0  0  0  0  0 
28  0  0  0  0  0  0  0  0 
29  0  0  0  0  0  0  0  0 
30  0  0  0  0  0  0  0  0 
31  0  0  0  0  0  0  0  0 
32  0  0  0  0  0  0  0  0 
33  0  0  0  0  0  0  0  0 
34  0  0  0  0  0  0  0  0 
35  0  0  0  0  0  0  0  0 
36  0  0  0  0  0  0  0  0 
37  0  0  0  0  0  0  0  0 
38  0  X  0  0  0  0  0  0 
39  0  0  0  0  0  0  0  0 
40  0  0  0  0  0  0  0  0 
41  0  0  0  0  0  0  0  0 
42  0  0  0  0  0  0  0  0 
43  0  0  0  0  0  0  0  0 
44  0  0  0  0  0  0  0  0 
45  0  0  0  0  0  0  0  0 
46  0  0  0  0  0  0  0  0 
47  0  0  0  0  0  0  0  0 
48  0  0  0  0  0  0  0  0 
49  0  0  0  0  0  0  0  0 
50  0  0  0  0  0  0  0  0 
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Table 4.3  Summary of tumour and normal tissue methylation at each locus 
Primer  Tumour (n)  Tumour (%)  Normal (n)  Normal (%) 
hMLH1  1  2  0  0 
p16  14  28  5  10 
DAPK  6  12  0  0 
TIMP3  0  0  0  0 
HIC 1  5  10  1  2 
MINT 25  2  4  0  0 
MINT 31  9  18  0  0 
RASSF1A  13  26  2  4 
 
In total 60% (30) of the tumours demonstrated methylation of at least one primer site 
whilst  40%  (20)  of  the  tumours  demonstrated  no  methylation  at  any  primer  site. 
Looking  at  number  of  methylated  primers  per  tumour  38%  (19)  demonstrated 
methylation at 1 site, 10% (5) at 2 sites, 4% (2) at 3 sites and 8% (4) at 4 sites.  This is 
illustrated graphically in figure 4.1.  Examples of MSP gels demonstrating successful 
bisulfite modification and  methylation at the MINT31 locus are shown in figures 4.2 
and 4.3 respectively. 
 
Figure 4.1:    Number of methylated loci per cancer sample 
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Figure 4.2: GAPDH primer to analyse DNA modification; 2% agarose gel 
          
Ladder      1    2    3    4    5    6    7     8   9   10         A   B   C 
 
123 bp ladder 
Lanes 1 – 10:    tumour  (top) and normal adjacent lung samples (bottom) 
Lane A:    ivm DNA (top) and lymphocyte DNA (bottom) 
Lane B:    ivm DNA, 1 in 5 dilution (top) and no sample (bottom) 
Lane C:    ivm DNA, 1 in 25 dilution (top) and distilled H20 (bottom) 
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Figure 4.3: MSP MINT31 primer; Samples 31 - 40; 2% agarose gel 
 
    Ladder       1    2    3    4    5    6    7     8   9   10        A   B   C 
 
123 bp ladder 
Lanes 1 – 10:    tumour  (top) and normal adjacent lung samples (bottom) 
        Positive results are seen in lanes 1 and 8, 
(tumour samples 31 and 38) 
Lane A:    ivm DNA (top) and lymphocyte DNA (bottom) 
Lane B:    ivm DNA, 1 in 5 dilution (top) and no sample (bottom) 
Lane C:    ivm DNA, 1 in 25 dilution (top) and distilled H20 (bottom)   131 
4.3.1  Correlation between methylation at individual sites and overall survival 
Univariate  analysis  of  any  association  between  methylation  at  individual  sites  and 
overall  survival  was  performed  using  Cox  regression  analysis.    Univariate  analysis 
demonstrated a significant association between the methylation of the MINT 31 gene 
promoter  region  and  improved  overall  survival  (p=0.03)  but  no  other  statistically 
significant  associations  with  the  primers  studied  was  seen,  table  4.4.    This  is 
demonstrated in the Kaplan-Meier survival curve shown in figure 4.4. 
 
Table 4.4:  Correlation between methylation at individual sites and overall 
 survival 
  Number (%) of samples  
Primer  p-value  Methylated  Non-methylated 
hMLH1  0.196  1  48 
p16  0.323  14  35 
DAPK  0.924  6  43 
TIMP3  NA  0  49 
HIC1  0.475  5  44 
MINT25  0.171  2  47 
MINT31  0.030  9  40 
RASSF1A  0.06  13  36 
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Figure 4.4:  Kaplan-Meier  survival  curve  (months);  methylated  versus  non-
methylated MINT 31: all patients 
 
 
4.3.2  Correlation of methylation at multiple sites and overall survival 
Univariate  analysis  of  any  association  between  overall  survival  and  methylation  at 
multiple sites was examined using Cox regression analysis.  Samples demonstrating the 
presence of 2 or more methylated sites were considered to be ‘multiple’ compared to 
those with methylation at only 1 site.  There was no significant correlation demonstrated 
with overall survival dependant on the number of sites demonstrating methylation of the 
primers examined (p=0.252, n=29). 
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4.3.3  Correlation  of  methylation  at  both  individual  and  multiple  sites  and 
clinicopathological variables 
Assessment of any potential correlations between the methylation at individual sites and 
the clinicopathological variables of stage and histology was performed using Kruskal-
Wallis statistics.  A statistically significant relationship between methylation of the HIC 
1  primer  with  stage  was  identified  (p=0.02,  table  4.5).  All  the  samples  exhibiting 
methylation of this primer were obtained from patients with stage IIb disease. 
 
Analysis of whether there was a correlation between the presence of methylation at 
multiple  sites  and  stage  or  histology  was  performed  using  Cox  regression  analysis.  
Multiple methylated sites were defined as the presence of methylation at 2 or more sites.  
There was no statistically significant correlation between the number of methylated sites 
with either stage or histology (data not shown). 
 
Table 4.5:  Correlation between methylation at individual sites with stage and 
histology 
  Clinicopathological Variable (p value) 
Primer  Stage  Histology 
hMLH1  0.426  0.893 
p16  0.446  0.544 
DAPK  0.893  0.772 
TIMP 3  1.000  1.000 
HIC 1  0.020  0.382 
MINT 25  0.750  0.699 
MINT 31  0.503  0.672 
RASSF1A  0.527  0.477 
   134 
4.3.4  Correlation between methylation status and survival between those patients 
undergoing chemotherapy and surgery with those having surgery alone 
To perform this analysis Cox regression analysis was used and the cohorts of patients 
receiving chemotherapy preoperatively were examined independently from those that 
underwent surgery alone. The number of patients receiving neoadjuvant chemotherapy 
was small and failed to show any statistically significant survival data in relation to 
methylated primers, (table 4.6). 
 
Table 4.6: Correlation between methylation at individual sites and overall 
survival; neoadjuvant chemotherapy patient samples 
  Number (%) of samples 
Primer  p-value  Methylated  Non-methylated 
hMLH1  NA  0  10 
p16  0.437  1  9 
DAPK  NA  0  10 
TIMP3  NA  0  10 
HIC1  0.994  2  8 
MINT25  NA  0  10 
MINT31  NA  0  10 
RASSF1A  0.963  2  8 
 
 
Performing the same analysis on those patients receiving no preoperative chemotherapy 
again  demonstrated  a  statistically  significant  relationship  between  the  presence  of 
methylation at the MINT 31 primer and overall survival, table 4.7 and figure 4.5. 
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Table 4.7: Correlation between methylation at individual sites and overall 
survival; no chemotherapy patient samples 
  Number (%) of samples 
Primer  p-value  Methylated  Non-methylated 
hMLH1  0.207  1  38 
p16  0.761  13  26 
DAPK  0.920  6  33 
TIMP3  NA  0  39 
HIC1  0.591  3  36 
MINT25  0.187  2  37 
MINT31  0.035  9  30 
RASSF1A  0.071  11  28 
 
 
Figure 4.5:  Kaplan-Meier  survival  curve  (months);  methylated  versus  non-
methylated MINT 31: no chemotherapy 
   136 
4.4  Discussion 
Methylation-specific PCR (MSP) is a now well-established technique for evaluating the 
presence of methylation in tumours as well as other clinical samples.  It is a 2-step 
procedure that relies firstly on successful (bisulphite) modification of the study DNA 
before the PCR amplification stage. 
 
It has now become apparent that the technique can on occasion be associated with false 
positive results and a review of these issues and how they may relate to this study in 
particular follows because false positive results could lead to an overestimate of the 
DNA methylation frequency. 
 
Two reviews highlight the potential of false positives when using MSP and relate to the 
bisulphite  modification  of  the  DNA  as  well  as  the  annealing  temperature  and  the 
number of cycles within the PCR amplification step (Derks et al., 2004, Rand et al., 
2002).  Modification must be complete as the design of the primers often ends with a 
cytosine  of  a  CpG  site  at  the  3’  site  and  this  in  itself  can  lead  to  amplification  of 
unconverted sequences.  In this study modification was checked by a PCR reaction 
using  a  primer  specific  for  unmethylated  DNA,  such  as  glyceraldehide-3-phosphate 
dehydrogenase (GAPDH).  With this primer, all modified samples give a positive band 
(2% agarose gel electrophoresis) but unmodified samples are negative. 
 
Both the annealing temperature and the number of cycles within the PCR reaction are 
important steps as it has been shown that a low annealing temperature and the use of an 
excessive number of PCR cycles can lead to mismatching within the reaction that then 
manifests as a false positive result and within this study no more than 35 cycles per   137 
primer reaction was used and the annealing temperature for each primer is detailed in 
table 2.5, page 103. 
 
Rand et al (Rand et al., 2002) has also suggested further controls are required to confirm 
MSP  results  and  one  such  technique  is  COBRA  (Combined  Bisulphite  Restriction 
Analysis)  whereby  restriction  digests  determine  DNA  methylation,  a  technique  first 
described by Xiong et al. (Xiong and Laird, 1997).  Whilst the use of COBRA was not 
available during this research study subsequent work by others on the study samples 
with  a  HIC1  primer  have  confirmed  the  MSP  results  for  that  primer,  (personal 
communication). 
 
In this study we have demonstrated methylation of at least 1 gene promoter region in 
60% (n=30) of the cancer samples.  This is less than in the published literature where 
the  percentage  appears  to  be  higher  (approximately  80%)  (Kim  et  al.,  2001a, 
Zochbauer-Muller  et  al.,  2001).   Both  of  these  studies  used  MSP  and  analysed  the 
methylation  status  of  8  promoter  loci.  In  both  of  these  studies  there  was  a  higher 
proportion of adenocarcinoma than in this study.  In the paper by Kim et al there is 
evidence of a higher percentage of methylation of RASSF1A in the adenocarcinoma 
samples compared to the squamous (47% versus 36%), and their findings would thus be 
consistent with the findings in this study. 
 
Individual genes were methylated in varying amounts in this study with p16 the highest, 
which  demonstrated  methylation  in  28%  of  the  samples  through  to  TIMP3,  which 
showed no evidence of methylation in any of the studied tumour samples.  A review of 
lung cancer methylation studies by Tsou et al published after the completion of our   138 
MSP  study  shows  our  data  to  be  similar  to  that  in  the  published  literature  when 
comparison is made only with studies involving clinical tumour samples assessed by 
MSP for the gene promoters hMLH1 (2% observed versus 0% published), p16 (28% 
versus 17-43%), DAPK (12% versus 16-44%) and RASSF1A (26% versus 30%) (Tsou 
et  al.,  2002).    The  only  locus  studied  that  differs  significantly  from  the  published 
literature is TIMP3 where we found no evidence of methylation in the cancer samples 
studied.  This  compares  with  results  in  the  published  literature  where  the  rates  of 
methylation varied between 19 – 26%.  In relation to the other loci studied there are no 
published studies of MSP for HIC1 or MINT sequences using clinical tumour samples.  
 
When comparing the lung cancer tissue with normal adjacent lung resected at the time 
of surgery there was very little evidence of methylation within the normal lung other 
than in the case of p16 where 10% (n=5) of the normal lung demonstrated methylation 
of the p16 promoter.  Interestingly 2 of these patients did not demonstrate methylation 
of the p16 promoter in the corresponding cancer sample.  A possible explanation for this 
would be experimental contamination.  However, if this were the case, then one would 
expect similar results across all of the studied loci and this is not the case.  However p16 
is one of the most commonly studied genes in lung cancer methylation changes and it 
may be the case that the methylation represents field change perhaps secondary to the 
effects of cigarette smoking.  In that regard it is worthy of note that methylation of p16 
has been studied in the sputum of high risk smoking individuals and also in patients 
with  lung  cancer  and  2  separate  studies  have  demonstrated  the  presence  of  p16 
methylation in the sputum of individuals with no evidence of active cancer at the time 
(Kersting et al., 2000, Palmisano et al., 2000).  In one of these studies p16 methylation   139 
was found in the sputum of patients 34 and 35 months prior to the diagnosis of lung 
cancer being made. 
 
The  primary  objective  of  this  study  was  to  investigate  any  correlation  between 
methylation of the panel of genes with overall survival.  In 7 of the 8 studied genes 
there was no statistically significant correlation.  This is not in agreement with a study 
of DAPK which reported poor overall survival in those patients with stage I disease 
who had methylation of the DAPK promoter (p=0.007) (Tang et al., 2000).  However, 
there was no such correlation between DAPK promoter methylation and survival in 
another  published  study  despite  them  demonstrating  an  association  between  DAPK 
methylation  and  larger  tumour  size  (p=0.009)  as  well  as  more  advanced  stage  
(p=0.003) (Kim et al., 2001a).  In the study by Tang et al the reported rate of DAPK 
methylation was 44% and in the Kim paper the rate of DAPK methylation was 24%.  
This is more in keeping with the results of the present study.  
 
The  significance  of  the  MINT  sequences  has  not  previously  been  reported  in  lung 
cancer.  It has been shown in this study that methylation of the MINT 31 promoter is 
associated significantly with overall improved survival (p=0.03).  This was the case on 
univariate analysis for all patients and this remained the case when the patients who 
received preoperative chemotherapy were removed from the analysis (p=0.035).  The 
methylation  status  of  the  MINT  sequences  has  not  previously  been  studied  in  lung 
cancer and their function remains unknown.   
 
MINT 31 is situated on chromosome 17q21 where recently a t-type calcium channel 
gene was identified (CACNA1G).  It has been proposed that this t-type channel could   140 
be  involved  in  cancer  development  by  modulating  calcium  signalling,  potentially 
affecting cell proliferation and apoptosis (Toyota et al., 1999b).  However a paper by 
Ogi et al did not show a significant correlation between the methylation of these 2 gene 
promoter regions and it will require further study to elucidate the role of the genes 
controlled by the MINT 31 and the other MINT sequences (Ogi et al., 2002). 
 
Other studies have reported that methylation of the MINT31 locus is associated with 
better prognosis in other solid tumour types, for example gastric cancer (p=0.04) (An et 
al., 2005).  Others have reported it to be associated with a poorer prognosis, for example 
oral squamous cell carcinoma (p=0.041) (Ogi et al., 2002).  
 
With the small numbers involved in the current study it is difficult to comment further 
on the potential prognostic role of methylation of these promoters in NSCLC.  Similarly 
it is difficult to determine the effect that the methylation of any one single gene has on 
clinical  behaviour.   The  current findings  require  further  study  in  a  larger  cohort  of 
patients. 
 
Within this study cohort of patients the methylation of the HIC1 gene was the only 
individual gene to show a correlation with stage of disease.  In this study methylation of 
HIC 1 was present only in those patients with stage IIb squamous cell lung cancer and 
more  specifically  those  tumours  that  were  more  than  3cm  in  size  and  had  cancer 
positive  hilar  lymphadenopathy.    However  there  was  no  evidence  that  survival  was 
affected by the methylation of this gene making it unlikely that the methylation of this 
gene could relate to the clinical aggressiveness of the tumour.  There is little published 
evidence  pertaining  to  the  methylation  status  of  HIC  1  in  NSCLC.    Eguchi  et  al   141 
published  a  paper  in  2001  (Eguchi  et  al.,  1997),  which  reported  the  presence  of 
methylation at multiple sites in 22% of patients with lung cancer.  Similar to our results 
this was evident more in patients with squamous cell cancer than adenocarcinoma and 
in  those  samples  obtained  from  patients  with  tumours  greater  than  3cm  and  with 
evidence of lymph node involvement. However, these results did not reach statistical 
significance  (p  value  not  given).    Further  large-scale  clinical  trials  are  required  to 
evaluate further the potential clinical relevance of this finding. Interestingly it has been 
recently suggested that methylation of HIC 1 in germ cell cancer cell lines may indicate 
cisplatin  resistance  and  this  would  have  potential  significance  as  regards  the 
chemotherapy treatment for patients with NSCLC.  It is worth noting that treatment of 
these cell lines with the demethylating agent 2-deoxy-5-azacytidine did not improve 
chemotherapy sensitivity in all of the resistant lines (Koul et al., 2004). 
 
In  this  study  the  presence  of  multiple  methylated  sites  did  not  correlate  with  either 
overall  survival,  stage  of  disease  or  histological  subtype.    This  would  suggest  that 
assessing the methylation status of multiple gene promoter sites in patients with NSCLC 
does not offer any advantage over the prognostic factors that are currently in use today 
(performance status and stage of disease).  However, this study suffers from several 
limitations, not least of which is sample size with a total population of only 50 patients. 
Of these only 11 patients demonstrated methylation at multiple sites.  This makes it 
impossible to draw any definite conclusions.   
 
There  are  a  number  of  published  studies,  which  have  investigated  the  presence  of 
multiple  methylated  loci  in  patients  with  lung  cancer.    Zochbauer-Muller  in  2001 
reported the methylation profile across a panel of 8 genes and concluded those tumours,   142 
which  exhibited  multiple  sites  of  methylation,  might  represent  a  subgroup  of  lung 
cancers  with  a  unique  pathogenesis.  However,  they  failed  to  show  any  correlation 
between the methylation profile and clinicopathological variables (Zochbauer-Muller et 
al., 2001).   
 
Toyooka  et  al  reported  that  there  were  differences  in  methylation  profiles  between 
NSCLC and SCLC tumour samples but within these groups there was no association 
reported between the methylation profile and survival (Toyooka et al., 2001).  Two 
more recent papers have also studied methylation at multiple sites and both used a panel 
consisting of 8 genes.  In the first of these by Safar et al it has been reported that by 
using the technique of recursive partitioning, precise patterns of gene methylation with 
prognostic significance can be identified. Moreover these remain significant when other 
recognised prognostic factors are included in a multivariate analysis.  The genes found 
to have prognostic significance within this study using recursive partitioning were APC, 
ATM and RASSF1A, (figure 4.6).   However, MLH1, DAPK, p16, MGMT nor ECAD 
did  not  have  any  bearing  on  this  model.   In  this  study  it  was  observed that,  if  the 
methylation status of RASSF1A was considered in isolation, Cox regression analysis 
demonstrated no association with overall survival. 
 
 
 
 
 
 
   143 
Figure 4.6: Illustration of recursive partitioning in NSCLC (data, Safar et al) 
APC methylated
52% 2-yr survival
RASSF1A methylated
16.7% 2-yr survival
ATM methylated
51% 2-yr survival
ATM not methylated
29% 2-yr survival
RASSF1A not methylated
APC not methylated
 
 
 
One further article in press at present again examined the methylation status of a panel 
of 8 genes and again failed to show any statistically significant correlation between the 
number  of  genes  methylated  and  either  tumour  subtype  (adenocarcinoma  versus 
squamous cell) or tumour stage (Kim et al., 2007).  
 
In summary the presence of and clinical relevance of the methylation status in NSCLC 
is potentially great with many studies including our own highlighting this.  However the 
studies to date are relatively small with the majority looking at samples from less than 
100 patients.  The next step must therefore be for a consensus to be reached as a result 
of  these  studies  on  which  genes  are  important  and  how  many  of  these  should  be 
included in future studies.   144 
5.  A study into the expression of the mismatch repair 
proteins  in  a  cohort  of  surgically  resected  patients  with 
NSCLC 
 
5.1  Introduction 
Microsatellite  Instability  has  a  reported  frequency  in  NSCLC  of  between  0  –  67% 
(Lawes et al., 2003) and Loss of Heterozygosity (LOH) at chromosome 3p has been 
shown  to  be  an  independent  adverse  prognostic  marker  for  survival  in  primary 
adenocarcinoma of lung (p = 0.052) (Mitsudomi et al., 1996). These studies did not 
compare  LOH  at  chromosome  3p  with  MLH1  protein  expression  (chromosome  3p 
locus).  A more recent paper has demonstrated a correlation between MLH1 expression 
and allelic imbalance at chromosome 3p (Xinarianos et al., 2000).  It is now recognised 
that circulating DNA in the serum of lung cancer patients originating from tumour cells 
can  be  isolated  and  often  demonstrates  the  same  allelic  imbalances  as  those  of  the 
primary tumour (Sozzi et al., 2001). 
 
To further investigate the above a study was designed to prospectively collect surgically 
resected  tumour  and  normal  adjacent  lung  samples  from  patients  with  lung  cancer 
undergoing surgical resection of their tumours.  In addition a preoperative (and where 
available a postoperative) whole blood sample was also obtained.  
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The objectives of this study were: 
•  To examine for the presence of allelic imbalance in fresh frozen lung cancer 
samples  and  compare  the  findings  with  those  in  normal  adjacent  lung  and 
lymphocyte DNA obtained from circulating blood. 
•  To establish if any allelic imbalance identified in fresh tumour were present in 
the pre-operative serum sample taken from the same patient. 
•  To assess where possible if any allelic imbalance identified in the serum DNA of 
patients pre-operatively persisted in a post-operative serum sample. 
•  To evaluate if allelic imbalance at chromosome 3p or methylation of the hMLH1 
promoter (if identified) correlated with loss of expression of MLH1 as measured 
by immunohistochemistry.  
 
5.2  Methods 
Ethical  approval  for  this  study  was  obtained  through  the  local  Ethics  committee  in 
North  Glasgow.    Samples  were  collected  from  10  patients  undergoing  resection  of 
NSCLC at the Western Infirmary in Glasgow. This involved obtaining consent from the 
patient the night prior to operation and then personal attendance during the patient’s 
thoracotomy.  The author then took the surgical sample immediately to the Pathology 
department where a consultant pathologist localised and resected two tumour samples 
(in such a way as to not affect the pathological staging of the tumour) for the study.  In 
addition 2 macroscopically normal adjacent lung samples were also collected.  A single 
tumour and normal adjacent lung sample were then immediately frozen to -70°C and 
stored for DNA extraction at a later date. The second tumour and normal samples were 
paraffin embedded and slides cut from these by Dr Colin Nixon (University of Glasgow 
Veterinary School, Department of Pathology).  Formal pathology reports were collected   146 
at  a  later  date.    For  each  patient  there  was  a  whole  blood  sample  collected  pre-
operatively and the serum immediately separated from this by centrifuge at 5000 × g for 
10 minutes.  The samples were then stored at 4°C prior to DNA extraction.  Where 
possible a second blood sample was collected and processed (as described for the pre-
operative sample) by myself from the patient approximately 3 months post surgery. The 
patient demographics are shown in table 5.1. 
 
Table 5.1:  Patient demographics 
Patient characteristics  Surgery (n = 10) 
Sex 
Male 
Female 
 
4 
6 
Age 
Range 
Mean 
 
49 – 75 
59.4 
Histology 
Squamous 
Adenocarcinoma 
Large cell 
Bronchoalveolar 
NSCLC unspecified 
 
6 
1 
1 
1 
1 
Stage 
IA 
IB 
IIA 
 
4 
4 
2 
 
 
Immunohistochemical  studies  were  carried  out  as  per  the  methodology  described  in 
chapter 2.1.  DNA extraction from whole blood and serum was performed using the 
protocols  detailed  in  chapter  2.2  and  from  tissue  in  chapter  2.3.  Allelic  imbalance 
studies  were  performed  following  the  protocol  described  in  chapter  2.4.  The  loci 
examined in this prospective observational study were, mfd15CA, APC, p53, D2S123, 
D3S1289,  D3S1300  and  D3S1304.    The  MSP  studies  were  performed  as  per  the 
methodology described in chapter 2.5. The promoter regions analysed were MLH1, p16,   147 
DAPK, TIMP 3, HIC 1, MINT 25 and MINT 31.  Due to the small number of samples 
available statistical analyses have not been performed but observations made. 
 
5.3  Results 
5.3.1  Allelic Imbalance in NSCLC 
Table 5.2 demonstrates the proportion of homozygous (non-informative) alleles for each 
locus  studied  in  the  tumour  samples.    Of  the  remaining  heterozygous  (informative) 
tumour  samples  table  5.3  demonstrates  the  number  of  tumours  exhibiting  Loss  of 
Heterozygosity (LOH) for each studied locus with results ranging from 25% (1/4, p53) 
to 83% (5/6, D3S1300).  Figures 5.1 – 5.7 illustrate the distribution of allelic imbalance 
ratio results for the lung cancer tumour samples. 
 
Table 5.3 illustrates those serum samples that demonstrated LOH when compared with 
the corresponding tumour, with Figure 5.8 showing an example of LOH.  A range of 
results was again demonstrated from 0% (both p53 and D2S123) to 67% (2/3, APC). 
 
Table 5.2:  Proportion of homozygous, heterozygous and non-informative alleles 
for each locus 
Primer  Number of 
homozygous 
alleles 
% of 
homozygous 
alleles 
Number of 
heterozygous 
alleles 
% of 
heterozygous 
alleles 
Unsuccessful 
PCR 
Mfd15CA  2  20  8  80  - 
APC  2  25  6  75  2 
D2S123  1  17  5  83  4 
p53  6  60  4  40  - 
D3S1289  0  0  8  100  2 
D3S1300  3  33  6  67  1 
D3S1304  0  0  9  100  1   148 
Figure 5.1:  Frequency of allelic imbalance ratio in tumour DNA: mfd15CA 
 
Figure 5.2  Frequency of allelic imbalance ratio in tumour DNA: APC 
 
Figure 5.3  Frequency of allelic imbalance ratio in tumour DNA: D2S123 
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Figure 5.4:  Frequency of allelic imbalance ratio in tumour DNA: p53 
 
Figure 5.5:  Frequency of allelic imbalance ratio in tumour DNA: D3S1289 
 
Figure 5.6:  Frequency of allelic imbalance ratio in tumour DNA: D3S1300 
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Figure 5.7:  Frequency of allelic imbalance ratio in tumour DNA: D3S1304  
 
Table 5.3:  Summary of the frequency of allelic imbalance in tumour and serum 
DNA at each locus 
Primer  Number of 
tumour 
samples 
with allelic 
imbalance 
% of 
tumours 
with allelic 
imbalance 
Number of 
corresponding 
serum 
samples with 
allelic 
imbalance 
% of 
corresponding 
serum 
samples with  
allelic 
imbalance 
Mfd15CA  5/8  62  3/5  60 
APC  3/6  50  2/3  67 
D2S123  2/5  40  0/2  0 
p53  1/4  25  0/1  0 
D3S1289  4/8  50  2/4  50 
D3S1300  5/6  83  3/5  60 
D3S1304  5/9  56  2/5  40 
 
Post-operative  serum  samples  were  available  for  only  3  of  the  10  patients.    One 
patient’s  postoperative  serum  sample  continued  to  demonstrate  LOH  in  2  of  the  4 
markers demonstrating LOH in their pre-operative serum sample.  The other 2 patients 
post-operative serum samples demonstrated novel LOH at 1 and 2 markers respectively 
compared  to  the  pre-operative  serum  samples  whilst  the  pre-operative  LOH  was  no 
longer evident. 
   151 
Figure 5.8:  LOH at D3S104 loci: Virtual fluorescent polyacrylamide gel analysis 
 
Horizontal axis:  Allele size in base pairs as measured against a size standard 
Vertical axis:    Allele peak heights as measure against a size standard 
 
Fig 5.8 demonstrates LOH of the DNA at loci D3S1304 in both the tumour and serum 
DNA taken from the same patient.  No LOH is demonstrated in the normal adjacent 
lung tissue sample 
 
5.3.2  Methylation profile in early stage (I/IIa) NSCLC and normal adjacent lung 
samples 
Of these 10 samples studied MSP was successfully performed on all. Results for the 
MSP carried out on the tumour samples are shown in table 5.4.  The results of MSP in 
adjacent normal lung are shown in table 5.5.  In these tables the presence of methylation 
is indicated by an X and no evidence of methylation with a 0.  
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Table 5.4:  Methylation status of lung cancer samples at seven loci 
  Primer 
Sample  hMLH1  p16  DAPK  TIMP 3  HIC 1  MINT 25  MINT 31 
1  0  X  0  0  0  0  0 
2  0  0  0  0  0  0  0 
3  0  0  X  0  0  0  0 
4  0  0  0  0  0  0  0 
5  0  0  X  0  0  0  0 
6  0  0  0  0  0  0  X 
7  0  0  0  0  0  0  0 
8  0  0  0  0  0  0  X 
9  0  0  0  0  0  0  0 
10  0  X  0  0  0  0  0 
 
In total 60% (6/10) of the tumours demonstrated methylation of one primer site whilst 
40% (4/10) of the tumours demonstrated no methylation at any primer site.  
 
Table 5.5:  Methylation status of normal adjacent lung samples at seven loci 
  Primer 
Sample  hMLH1  p16  DAPK  TIMP 3  HIC 1  MINT 25  MINT 31 
1  0  0  0  0  0  0  0 
2  0  0  0  0  X  0  0 
3  X  0  0  0  0  0  0 
4  0  0  0  0  0  0  0 
5  0  0  0  0  0  0  0 
6  0  0  0  0  0  0  0 
7  0  0  0  0  0  0  X 
8  0  0  0  0  0  0  0 
9  0  0  0  0  0  0  0 
10  0  0  0  0  0  0  0 
   153 
The  majority  of  normal  lung  samples  (7/10)  showed  no  methylation  at  any  of  the 
studied primer sites whilst three demonstrated methylation at one primer site, these were 
hMLH1, HIC 1 and MINT 31.  Interestingly adjacent normal lung samples 2 and 7 did 
not demonstrate methylation of any primer site in the corresponding primary tumour 
sample.   In  adjacent  normal  lung  sample  3,  which  demonstrated  methylation  of  the 
hMLH1 promoter site, the corresponding tumour did not demonstrate methylation of 
this site.  However tumour sample 3 did show methylation of the DAPK locus. 
 
5.3.3  Protein expression in early stage (I/IIa) NSCLC and normal adjacent lung 
samples 
Of  the  10  patient  samples  immunohistochemistry  for  MLH1,  MSH2  and  p53  was 
successfully performed on all of the tumour and normal adjacent lung samples.  The 
results are summarised in table 5.6.   154 
Table 5.6  Protein  expression  levels  in  early  stage  (I/IIa)  lung  cancer  and 
normal adjacent lung samples  
  MLH1  MSH2  p53 
Sample  % 
T/N 
I 
T/N 
IHC 
T/N 
% 
T/N 
I 
T/N 
IHC 
T/N 
% 
T/N 
I 
T/N 
IHC 
T/N 
1  0/3  0/2  0/6  0/3  0/2  0/6  0/3  0/2  0/6 
2  0/1  0/1  0/0  1/2  1/1  1/2  0/2  0/2  0/4 
3  2/2  1/1  2/2  1/1  1/1  1/1  0/0  0/0  0/0 
4  2/2  1/1  2/2  2/0  1/0  2/0  0/0  0/0  0/0 
5  2/2  1/1  2/2  0/1  0/1  0/1  0/0  0/0  0/0 
6  3/2  2/1  6/2  3/0  2/0  6/0  3/1  2/1  6/1 
7  2/2  1/1  2/2  1/1  1/1  1/1  0/1  0/1  0/1 
8  2/1  1/1  2/1  2/0  1/0  2/0  3/0  2/0  6/0 
9  1/1  1/1  1/1  2/0  2/0  4/0  3/0  3/0  9/0 
10  2/1  1/1  2/1  1/0  1/0  1/0  2/0  2/0  4/0 
% = percentage score of cells staining; I = Intensity score for cell stain 
T = tumour sample; N = normal adjacent lung sample 
 
Nine of the 10 samples studied demonstrated LOH at least one chromosome 3p locus 
(D3S1289,  D3S1300,  D3S1304).    No  correlation  between  IHC  score  and  LOH  at 
chromosome 3p was identified.  Likewise no tumour samples exhibited methylation of 
the hMLH1 gene promoter and therefore no correlation could be recognised between 
methylation of this locus and MLH1 protein expression. 
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5.4  Discussion 
As previously discussed this research project was carried out at a time when there were 
national  concerns  pertaining  to  the  ownership  of  tissue  samples  as  well  as  retained 
organs in pathology departments and this severely limited our ability to obtain fresh 
tissue prospectively.  As a direct consequence the number of samples collected and 
studied in this chapter is significantly less than had been originally calculated during the 
planning  of  the  project.    Despite  this  it  has  been  clearly  demonstrated  that  the 
prospective collection of tissue and blood is possible by integrated multidisciplinary 
cooperation with the cardiothoracic team and the Pathology Departments at the Western 
Infirmary in Glasgow as well as the Pathology Department at the University of Glasgow 
Veterinary School. By the end of the research period a further 10 samples had been 
collected and stored for future analysis. Due to the small numbers statistical analyses 
were not performed but useful observations were made. 
 
The  ratio  of  heterozygous  alleles  in  normal  tissue  DNA  (normal  adjacent  lung, 
lymphocytes) should be equal to 1.0, although slight variation is common.  In respect to 
the  allelic  imbalance  studies  the  allelic  ratio  of  the  DNA  from  the  heterozygous 
(informative)  samples  from  all  sources  was  compared  with  the  allelic  ratio  in 
lymphocyte DNA.  The equation used for the calculation of LOH is given in chapter 
2.4.2.3.  Lymphocyte DNA was used as the normal control as it is understood that 
macroscopically  and  indeed  microscopically  normal  lung  may  be  affected  by  either 
contamination with cancer cells or genetic field change due to exposure to the inhaled 
smoke carcinogens (Hittelman et al., 1996).  A ratio of 0.7 was used to define LOH in 
this study.  One of the difficulties in comparing studies of LOH is that the definition of 
LOH as well as the study technique varies significantly in the literature between tumour   156 
types as well as between studies looking at the same tumour types.  Examples of this in 
lung  cancer  include  the  study  by  Liloglou  et  al  where  a  ratio  of  0.77  was  used  in 
comparison to the study by Wong et al where LOH was defined as ‘a relative reduction 
in one allele in the tumour sample’ (Liloglou et al., 2000, Wong et al., 2002).  A more 
recent  study  by  Woenckhaus  et  al  using  tumour  DNA  from  pleural  fluid  has 
demonstrated that using a ratio of 0.7 and comparing this with a ratio of 0.5 in the same 
samples leads to an increase in the sensitivity of the test but a decrease in specificity 
(Woenckhaus et al., 2005).  This decrease in specificity would be of concern if taking 
such  a  molecular  assay  into  the  clinical  setting.    These  differences  will  only  be 
overcome if there is an internationally agreed definition for LOH.  Figures 5.1 to 5.7 
illustrate the spectrum of results that could be obtained depending on the definitions 
used to define LOH.  
 
Although it was not possible to make statistical comparisons and draw firm conclusions 
in  our  study  due  to  the  small  numbers  it  has  been  clearly  demonstrated  that  allelic 
imbalance is a common occurrence in patients with NSCLC, however microsatellite 
instability was not evident in the studied samples.   
 
Although  similar  allelic  imbalance  was  demonstrable  in  the  serum  DNA  when 
compared  with  the  corresponding  tumour  sample  this  was  not  a  consistent  finding.  
Again the small numbers involved in the study limit any firm conclusions been drawn, 
but a study by Sozzi et al has demonstrated a similar incidence of allelic imbalance at 
chromosome 3p in primary tumour DNA and the corresponding serum DNA sample 
(Sozzi et al., 2001).   157 
It  is  the  case  however  that  if  serum  DNA  were  to  be  a  reliable  substitute  tool  for 
analysing  molecular  changes  in  the  primary  tumour  then  the  results  would  require 
significantly more consistency between the 2 DNA sources.  
 
In  this  study  no  correlation  between  the  changes  demonstrable  in  the  pre-operative 
sample with the post-operative sample were identified.  This may simply be a reflection 
of the small study numbers but the analysis may be compounded by the serum DNA 
reflecting changes in putatively ‘normal’ tissue affected by field change.  Unless a large 
clinical  trial  was  to  show  significant  results  it  might  unfortunately  be  the  case  that 
serum DNA is not a reliable tool for the analysis of tumour molecular DNA changes. 
 
Due to difficulties in tissue collection described above and the resultant time constraints 
of the research project analysis of the gene promoter regions in the serum DNA with 
correlation with the corresponding changes in the primary tumour was not possible.  
However 10 further samples (tumour, normal, serum, lymphocyte) have been collected 
and added to the original 10 samples and it is envisaged that this resource will be made 
use of and studied by others in the group, in particular the study of DNA methylation 
changes in serum DNA. 
 
With the number of samples available no statistical correlation with clinicopathological 
variables was made but in the samples tested there was no observational correlation 
between allelic imbalance at chromosome 3p, or methylation of the hMLH1 promoter 
region with the expression level of MLH1 measured by immunohistochemistry.     158 
Until a large clinical trial has been undertaken to identify if serum DNA is a reliable 
tool for the analysis of DNA changes demonstrated in the primary tumour, the results of 
this work suggest that this is not the case. 
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6.  A study into the role of the mismatch repair proteins in 
the chemotherapy sensitivity of a panel of SCLC cell lines 
 
6.1  Introduction 
Unlike NSCLC, Small Cell Lung Cancer (SCLC) is a highly chemo-sensitive cancer 
with platinum based chemotherapy in patients with limited stage disease given with 
curative intent.  In patients with extensive disease overall response rates of 60 - 70% are 
seen with complete responses achieved in 20 - 30% of patients (Simon and Wagner, 
2003).    However,  despite  these  initial  high  response  rates,  relapse  is  common  and 
indicates a uniformly poor prognosis with the median survival for those patients with 
limited disease only 12 - 18 months and for extensive stage disease only 6 - 9 months, 
table 6.1. 
 
Table 6.1  Chemotherapy response rates and survival in SCLC 
  Limited Disease  Extensive Disease 
Complete response  50%  20 – 30% 
Partial response  40%  30 – 40% 
Overall response  90%  60% 
Median survival  12 – 18 months  6 months 
 
 
Published studies have investigated the potential role of mismatch repair mechanisms in 
SCLC as measured by microsatellite instability (MSI).  In these studies differing results 
were obtained with reported MSI rates of 0 – 76% (Chen et al., 1996, Mao et al., 1994, 
Merlo et al., 1994, Pylkkanen et al., 1997).   
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Only the study by Merlo et al examined any correlation that may exist between MSI and 
clinicopathological  factors.    Tumour  samples  were  collected  from  archived  paraffin 
embedded tissue derived from autopsy studies.  No differences were identified in the 
rate of MSI and either stage of disease or between patients who received chemotherapy 
and those who did not (Merlo et al., 1994).    
 
There has to date been only one study published which investigated the methylation 
profile of SCLC.  Moreover this study did not examine the methylation status of the 
hMLH1 promoter (Toyooka et al., 2001). 
 
The objectives of this study were in a panel of small cell lung cancer cell lines were to: 
•  Examine  if  there  was  any  correlation  between  the  level  of  mismatch  repair 
protein expression and level of chemotherapy sensitivity. 
•  Evaluate  the  possible  role  of  methylation  of  hMLH1  in  relation  to 
chemosensitivity 
 
6.2  Methods 
Cell  lines  established  by  Dr  R  Milroy  in  the  Centre  for  Oncology  and  Applied 
Pharmacology, University of Glasgow were used in this study and the source of each 
cell line is detailed in table 6.2.  Cell lines LS274 and LS310 were derived from the 
same patient pre and post chemotherapy respectively.  Both the original biopsies were 
taken from sites of metastasis.   161 
Table 6.2  Source of biopsy and treatment history of the cell line panel 
Cell Line  Source  History 
LCPH3  Mouse xenograft  Post-therapy relapse 
LS106  Bronchial biopsy  Pre-therapy 
LS111  Neck node  Pre-therapy 
LS112  Skin metastasis  Pre-therapy 
LS274  Skin nodule  Pre-therapy 
LS277  Skin nodule  Pre-therapy 
LS310  Axillary node  Post-therapy 
 
Drug sensitivity studies were performed by Dr J Plumb using methodology previously 
published (Plumb et al., 1994). Methylation Specific PCR (MSP) was performed as 
described in detail, chapter 2.5 with DNA extracted from the cultured cell lines as per 
the protocol described in chapter 2.3 
 
6.3  Results 
6.3.1  Correlation  between  MMR  protein  expression  and  chemotherapy 
sensitivity 
Figure  6.1  demonstrates  a  high  correlation  between  cisplatin  sensitivity  and  the 
mismatch repair proteins MLH1 (r
2 = 0.83) and MSH2 (r
2 = 0.87) but not PMS2 (r
2 = 
0.22).  Figure 6.2 demonstrates no such correlation between doxorubicin sensitivity and 
MLH1, MSH2 expression.  Drug sensitivities and protein expression levels are shown 
in table 6.3.  A clear correlation between etoposide sensitivity and MLH1 (r
2 = 0.66) 
and MSH2 (r
2 = 0.59) but not PMS2 was also identified (figure not shown). 
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Table 6.3:  MMR  and  chemosensitivity  levels  in  a  panel  of  SCLC  cell  lines 
(courtesy of Dr J Plumb) 
 
Cell 
line 
MLH1 
expression 
MSH2 
expression 
PMS2 
expression 
Cisplatin 
IC50 
(µM) 
Doxorubicin 
IC50 
(nM) 
Etoposide 
IC50 
(µM) 
LS106  0.53  0.77  0.22  7.16  33  5.69 
LS111  2.27  1.61  0.19  0.07  284  1.70 
LS112  0.88  0.58  0.08  5.73  64  3.61 
LS277  1.91  1.32  0.40  0.41  0.1  0.22 
LCPH3  1.42  1.13  0.08  0.87  60  0.79 
LS274  0.63  0.72  0.20  4.53  144  11.17 
LS310  0.30  0.25  0.06  10.6  172  10.71 
 
Levels  of  MMR  protein  expression  measured  by  Western  blot  and  quantified  by 
densitometry. 
 
Drug sensitivity does not relate to the proliferating cell population (Ki67) or to the 
population doubling times of the cell line 
 
 
Figure 6.1:  Assessment of possible correlation of MMR protein expression with 
cisplatin sensitivity (courtesy of Dr J Plumb) 
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Figure 6.2:  Assessment of possible correlation of MMR protein expression with 
doxorubicin sensitivity (courtesy of Dr J Plumb) 
 
 
 
 
 
 
 
 
 
 
6.3.2  Does methylation of the hMLH1 promoter play a role in cisplatin sensitivity 
in a panel of SCLC cell lines 
Figure 6.3 demonstrates that there is only methylation of the hMLH1 promoter in 1 of 
the cell lines examined, LS310 this is a post-chemotherapy cell line compared with 
LS274 that is a pre-chemotherapy cell line derived from the same patient .  There was 
no evidence of methylation of the p16, DAPK and MINT 25 loci in any of the cell lines 
studied. 
 
Table 6.1 demonstrates that LS310 is 2.3 fold more resistant to cisplatin and shows a 
50% reduction in MLH1 expression when compared to the LS274 cell line (p < 0.001). 
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Figure 6.4 demonstrates that treatment of the LS310 cell line with the demethylating 
agent 2-deoxy-5-azacytidine results in a 1.5 fold increase in sensitivity to cisplatin (p < 
0.01).  This was accompanied by a 1.4 increase in MLH1 expression. 
 
Figure 6.3:  Methylation of the hMLH1 promoter in a panel of SCLC cell lines 
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Ladder:  123bp 
Lane 1:  ivm DNA – positive control 
Lane 3:  dH2O – negative control 
Lane 5:  LCPH3 
Lane 6:  LS106 
Lane 7:  LS111 
Lane 8:  LS112 
Lane 9:  LS274 
Lane 10:  LS277 
Lane 11:  LS310 
Lane 12:  LS310 
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Figure 6.4:  The  effect  of  2-deoxy-5-azacytidine  on  cisplatin  sensitivity  of  the 
SCLC cell lines, LS274 and LS310 (courtesy of Dr J Plumb) 
 
 
6.4  Discussion 
In  this  study  we  have  demonstrated  that  in  paired  cell  lines  derived from  the  same 
patient pre and post chemotherapy that there is increased cellular drug resistance in the 
post-chemotherapy cell line (LS310).  We have also demonstrated methylation of the 
hMLH1 gene promoter in the cell line established post-chemotherapy (LS310). 
 
Although this finding has been demonstrated by Strathdee et al. in the A2780 ovarian 
cancer cell line where cisplatin resistance is associated with loss of MLH1 expression it 
has never previously been reported in small cell lung cancer studies.  In Strathdee’s 
study it was shown that the loss of MLH1 expression correlated with hypermethylation 
of  the  hMLH1  gene  promoter  and  that  treatment  of  the  resistant  cell  lines  with  5-
azacytidine led to both restoration of MLH1 expression and an increase in cisplatin 
sensitivity (Strathdee et al., 1999).  We have also demonstrated significantly increased   166 
sensitivity to cisplatin following treatment of the cell line with the demethylating agent 
decitabine. 
 
A recent study by Hansen et al examined the role of mismatch repair in a panel of small 
cell lines (Hansen et al., 2003) and evaluated the possible role methylation of hMLH1 
may play in any MMR deficiency demonstrated.  In this study 1 cell line (86MI) was 
found  to  be  deficient  in  MMR  and  this  cell  line  demonstrated  resistance  to  the 
alkylating  agent  methylnitronitrosoguanidine  (MNNG).    Although  this  cell  line  was 
found to be deficient in MMR using a heteroduplex repair assay that measures strand 
specific repair in M13mp2 DNA (Thomas DC, 1995) this was very much an unexpected 
result as all the MMR core proteins appeared to be expressed normally, as measured by 
both  Northern  and  Western  blotting  analyses  (Hansen  et  al.,  2003).    There  was  no 
evidence  of  MMR  protein  methylation  as  measured  by  MSP  in  this  study.    It  was 
concluded  that  the  phenotype  of  86MI  could  be  accounted  for  by  one  of  two 
possibilities, either a mutation in one of the four MMR genes (MLH1, MSH2, MSH6 
and PMS2) or inactivation of a secondary, known or as yet unknown MMR protein. 
 
A further study by Mackay et al. investigated the expression of the MLH1 protein in a 
cohort  of  patients  with  locally  advanced  breast  cancer  receiving  chemotherapy.  
Samples were obtained from the same patient pre and post chemotherapy.  This study 
demonstrated  that  the  level  of  MLH1  expression  pre-chemotherapy  did  not  predict 
response to chemotherapy or disease-free survival.  However primary chemotherapy did 
result in a significant reduction in the percentage of cells expressing MLH1 (p=0.010).  
This  reduction  in  MLH1  expression  after  chemotherapy  was  shown  to  be  strongly 
associated with poorer disease-free survival (p=0.0025) (Mackay et al., 2000).  It thus   167 
appears that in patients with locally advanced breast cancer, a decreased cellular MLH1 
expression is associated with a survival advantage in patients treated with combination 
chemotherapy.    This  further  supports  the  role  of  the  MMR  protein  hMLH1  in 
chemotherapy resistance. 
 
Due to the current process of managing lung cancer prospectively collected small cell 
lung cancer samples are not readily available for study and much of the published work 
has been performed using archived historical samples and cell lines (Chen et al., 1996, 
Mao  et  al.,  1994,  Merlo  et  al.,  1994,  Pylkkanen  et  al.,  1997).  This  has  particular 
relevance when investigating the possible impact of the methylation of specific gene 
promoters in studies of cultured cell lines.  There is evidence of high levels of de novo 
methylation at CpG islands in cell lines at sites that would, in the clinical setting be 
methylation free, however the reasons for this phenomenon remain unclear (Antequera 
et al., 1990).  Within our study only the cell line established post-chemotherapy, LS310, 
exhibited methylation at the MLH1 gene promoter and none of the cell lines studied 
demonstrated methylation of either the DAPK, p16 or MINT 25 loci suggesting that de 
novo  methylation  in  these  cell  lines  does  not  occur.  A  study  by  Toyooka  et  al 
demonstrated no methylation in a panel of small cancer cell lines of p16 and DAPK but 
did not study the hMLH1 locus (Toyooka et al., 2001). 
 
Despite the fact that fresh clinical SCLC samples are difficult to obtain the results of our 
study taken in conjunction with the studies by both Strathdee and Mackay highlight the 
importance of and need for future SCLC clinical studies to incorporate the collection of 
fresh tumour samples for study as an integral part of the protocol.     168 
Potential future studies include the study of any alterations in the methylation profile of 
a group of patients before and following chemotherapy and if this would need to be 
correlated  with  clinicopathological  variables.      Including  patients  with  SCLC  into 
studies examining the role of decitabine given along with chemotherapy is worthy of 
study in relation to our study results. 
 
The  possibility  of  a  clinical  study  in  patients  with  NSCLC  to  examine  the  role  of 
decitabine given in conjunction with chemotherapy might be another area of research. 
 
Thus the future holds the exciting prospect of well planned collaborative prospective 
combined clinical and translational research, which could yield important and fruitful 
interventions in the management of patients with lung cancer.   169 
7.  Conclusions 
The association between methylation of the MINT31 locus and an overall improved 
survival in NSCLC has never previously been reported and requires verification in a 
large  clinical  trial,  as  does  the  finding  that  only  patients  with  stage  II  disease 
demonstrated methylation of the HIC1 locus.  With regard to this an important success 
of this project was to establish cooperation between the Beatson Laboratories and the 
Cardiothoracic Unit at the Western Infirmary, Glasgow.   
 
Successful  multidisciplinary  collaboration  was  achieved  and  the  collection  of  fresh 
frozen  tumour  and  normal  adjacent  lung  samples  along  with  a  corresponding  blood 
sample was undertaken.  The aim was to enrol as many patients as possible undergoing 
resection of their primary lung cancer through the Unit.  Unfortunately our ability to do 
this  was  hindered  by  national  concerns  at  the  time  of  this  research  regarding  tissue 
collection  and  retention  for  use  in  clinical  trials.    As  a  result  of  these  concerns  all 
sample collections at the University of Glasgow were discontinued whilst a review of 
all projects involving tissue collection was undertaken.  At the end of the study period 
an additional 10 surgical samples with corresponding blood samples had been collected.  
These samples are stored and will be available for future research, although much larger 
trials  involving  appropriate  sample  collection  will  be  required  to  answer  all  of  the 
questions raised in this thesis. 
 
Other aspects of this research project were also limited by the availability of samples.  
In the case of our retrospective study of protein expression in bronchoscopic samples 
the number of samples available was disappointing.  Only 67 of a possible 110 samples 
were collected.  The major limiting factors were that a number of samples could not be   170 
located due to the laboratory moving as well as a significant number of samples being 
unusable secondary to damage by damp whilst in storage.  However in the case of the 
retrospectively  collected  surgical  samples  all  the  possible  available  samples  were 
identified, collected and studied. 
 
In addition to the sample collections described our local ethics approval in Glasgow 
allowed the prospective collection of pre-treatment blood samples and diagnostic tissue 
samples from patients as well as a post-treatment blood samples.  The aim of this study 
was  to  investigate  possible  molecular  changes  (allelic  imbalance/CpG  Island 
Methylation) that might predict response to chemotherapy and/or prognosis.  Moreover 
we intended to monitor these changes in the serum during/after treatment.  To date 
samples have been collected from 75 patients of whom 20 underwent surgery and 55 
received treatment with chemotherapy.  In addition 44 samples were collected from 
patients after treatment. All these samples have been stored and now that the technology 
and  methodology  for  reliable  assessment  of  methylation  of  serum  DNA  is  well 
established, these specimens will be available for study in the future. 
 
As a consequence of the above problems of sample collection the results in all of the 
studies  undertaken  are  based  on  small  study  numbers,  despite  significant  efforts  at 
sample collection during the study period.  Therefore their statistical significance cannot 
be established with confidence and in order to validate these results, and in particular to 
validate the positive findings of the relationship between methylation of the MINT 31 
promoter region and improved overall survival, further large-scale trials are needed. 
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It will be important to investigate further the question raised in the SCLC cell line study 
described in this thesis (chapter 6) as to whether resistance (acquired or intrinsic) to 
chemotherapy secondary to the methylation of the hMLH1 promoter is a phenomenon 
that  is  actually  seen  in  clinical  practice.    There  is  a  growing  body  of  literature 
investigating the use of the demethylating agent, decitabine, in the clinical arena and 
future translational studies of its effects are essential.  These studies will require the 
measurement of serum DNA changes, as this source of DNA presents a potentially very 
attractive non-invasive means of monitoring/assessing the DNA molecular profile of 
tumours. 
 
In order for these goals to be achieved it will be essential that future clinical trials in 
patients with lung cancer have a translational component incorporated into the protocol 
allowing  the  collection  and  study  of important clinical  samples  in  conjunction  with 
robustly collected clinical data.     172 
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9.  Appendix 
9.1  Patient Information Sheets – Collection of Blood samples 
As you know you have recently been told that you have lung cancer.  The doctors 
looking  after  you  will  have  discussed  your  treatment  options  with  you  and  your 
treatment will now go ahead as planned.  Although we hope that this treatment will help 
you, as you know there is no guarantee of cure.  This is because lung cancer may recur 
or prove resistant to the various treatments.  It is important to find out more about 
resistance  to  treatment  in  lung  cancer  and  previous  studies  have  suggested  that  this 
might be related to a specific marker in the tumour.  We would like to invite you to take 
part in a research study, which is looking at this. 
 
The aim of this study, is to look at blood samples from lung cancer patients in the 
laboratory to see if we can identify a genetic abnormality in the tumour which shows up 
in the blood.  If it is detected then this study may help us to plan treatment decisions in 
lung cancer patients in the future. 
 
If you agree to take part in the study then an extra blood sample will be taken (about 2 
teaspoonfuls) along with your routine blood samples, before, during and after the course 
of your treatment.  It is important for you to understand that the information obtained 
will not benefit yourself but may be of use in planning treatment for patients with lung 
cancer in the future. 
 
You can of course decide not to take part in the study and if this is so it will in no way 
affect your relationship with the medical and nursing staff looking after you.  If you 
agree to take part in the study then your GP will be informed.  You can also at any time 
change your mind and withdraw form the study.  As stated earlier your treatment will be 
unaffected by this study. 
 
If you would like further information please contact: 
 
Dr S Davidson       0141 201 3715 
Mr J McPhelim      0141 201 3718 
Dr R Milroy        0141 201 3715   200 
9.2  Patient Information Sheets – Collection of Tumour/Normal Lung Samples 
As it will have been explained to you, you are about to undergo an operation to remove 
all, or part of, your lung.  Doctors in the Pathology Department will perform a number 
of tests on the tissue that is removed during the operation.  This will allow your surgeon 
to give you a diagnosis and prognosis and guide you if any other treatment is required.  
Once they have completed their examination, the tissue is normally discarded. 
 
Because  we  are  constantly  engaged  in  research  ourselves  and  in  collaboration  with 
others,  we  are  seeking  your  permission  to  use  some  of  this  tissue  that  is  normally 
discarded.  This would be used in a number of ongoing projects designed to investigate 
cancer and in detailing the anatomy and physiology of the blood vessels within the lung. 
 
If you wish your resected tissue to be used in this way, the following guarantees will be 
given: 
•  No  tissue  will  be  removed  apart  from  what  is  deemed  necessary  for  your 
operation as decided by the surgeon. 
•  Sampling of tissue will not prejudice in any way the results of your operation or 
affect the ability of the pathologist to produce an accurate report. 
•  Samples used for research will be removed from tissue that would normally be 
discarded. 
•  In cases of cancer research, small samples may be frozen and stored to allow 
tests to be done at a future date. 
 
Should you not wish tissues to be removed, this will not affect your treatment in any 
way. 
 
The research projects have been approved by the Research and Ethics Committee for 
North Glasgow Hospitals University Trust.   201 
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